data_6iha_residue ############################ # Computer software used # ############################ save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 6iha _Structure_validation_residue.Date_analyzed 2019-09-27 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.558 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.6 p . . . . . 0 CA--C 1.515 -0.403 0 CA-C-O 121.102 0.477 . . . . 0.0 110.529 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.89 -26.16 67.99 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.948 172.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 21.4 m -91.68 6.65 45.04 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.417 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 13.8 mptt -113.99 9.05 17.31 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.16 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.619 ' O ' HG21 ' A' ' 24' ' ' VAL . 8.4 m -140.94 -37.16 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.282 -174.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.59 -48.13 65.82 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.669 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_exo -71.02 -23.59 24.91 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 121.625 1.55 . . . . 0.0 111.358 -178.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.619 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.1 m -78.86 -42.16 24.33 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.3 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.55 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.6 t -69.01 -25.27 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 121.842 0.829 . . . . 0.0 110.059 177.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.22 -8.74 48.57 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.402 173.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -106.83 -30.28 9.0 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.068 174.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 41.4 m-85 -77.59 -36.21 52.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.425 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.445 ' HB1' ' O ' ' A' ' 25' ' ' VAL . . . . . . . . 0 C--N 1.318 -0.783 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.806 -179.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.527 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 N--CA 1.45 -0.457 0 CA-C-O 121.06 0.457 . . . . 0.0 110.464 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.4 ' O ' HG21 ' A' ' 21' ' ' VAL . . . -63.93 -23.61 67.41 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.521 0.677 . . . . 0.0 109.92 171.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 23.5 m -93.23 6.59 47.5 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 13.2 mptt -113.04 6.6 17.73 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.883 -1.053 . . . . 0.0 108.935 178.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.63 ' O ' HG21 ' A' ' 24' ' ' VAL . 12.9 m -133.77 -37.81 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.359 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.16 -48.75 68.97 Favored Pre-proline 0 C--N 1.322 -0.611 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.223 178.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -70.24 -24.37 27.54 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 121.637 1.558 . . . . 0.0 111.424 -179.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.63 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.02 -42.0 27.62 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.467 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.437 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.492 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.5 t -67.42 -25.57 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.785 0 CA-C-O 121.755 0.788 . . . . 0.0 109.841 176.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.54 -5.88 32.26 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.668 174.027 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.2 -26.46 9.17 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.03 174.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.492 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.5 m-85 -82.29 -33.84 28.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.668 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' A' ' 25' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.639 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.01 -178.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.646 ' O ' HG11 ' A' ' 21' ' ' VAL . 2.3 p . . . . . 0 CA--C 1.514 -0.436 0 CA-C-O 121.311 0.577 . . . . 0.0 110.305 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.15 -22.85 65.08 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.518 173.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.4 m -95.08 3.14 55.14 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 177.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.471 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.5 mptp? -113.83 8.34 17.32 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.031 -0.986 . . . . 0.0 109.438 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.646 HG11 ' O ' ' A' ' 17' ' ' VAL . 12.0 m -135.64 -36.31 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.286 -175.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.73 -47.76 54.78 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.649 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.75 -21.74 21.25 Favored 'Trans proline' 0 C--N 1.353 0.804 0 C-N-CA 121.829 1.686 . . . . 0.0 111.339 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.637 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -78.7 -42.4 25.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.275 179.523 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.506 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.3 t -68.37 -24.89 30.17 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.879 0 CA-C-O 121.858 0.837 . . . . 0.0 109.963 177.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.68 -8.65 53.55 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.821 -1.082 . . . . 0.0 110.475 174.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 -24.16 11.2 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.166 175.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.506 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 42.3 m-85 -83.08 -40.81 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.433 178.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.305 179.879 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.554 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.515 -0.387 0 CA-C-O 121.205 0.526 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.23 -25.42 64.01 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.443 173.162 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -95.18 7.33 46.48 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-O 121.644 0.735 . . . . 0.0 109.124 178.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -112.36 7.04 19.08 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-N 115.104 -0.953 . . . . 0.0 108.975 179.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.623 ' O ' HG21 ' A' ' 24' ' ' VAL . 10.6 m -133.51 -36.28 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.272 -175.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.9 -47.82 52.82 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.49 178.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_exo -71.7 -23.11 23.17 Favored 'Trans proline' 0 C--N 1.353 0.806 0 C-N-CA 121.848 1.698 . . . . 0.0 111.494 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.623 HG21 ' O ' ' A' ' 21' ' ' VAL . 4.5 m -77.9 -42.22 28.27 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.483 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.503 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 87.5 t -68.12 -23.42 28.78 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.942 0 CA-C-O 121.872 0.844 . . . . 0.0 109.453 174.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.14 -5.74 41.11 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.557 173.566 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.11 -21.99 11.67 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.833 173.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.503 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.1 m-85 -86.12 -29.97 22.89 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.388 0.613 . . . . 0.0 110.01 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.766 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.03 176.149 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.449 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.514 -0.431 0 CA-C-O 121.627 0.727 . . . . 0.0 109.86 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.472 ' O ' HG21 ' A' ' 21' ' ' VAL . . . -62.47 -25.71 68.13 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.901 171.039 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.5 m -89.62 5.63 44.84 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -109.4 5.43 23.44 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.114 179.414 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.665 ' O ' HG21 ' A' ' 24' ' ' VAL . 10.2 m -135.99 -36.76 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.372 -173.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.33 -46.1 84.84 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.818 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -72.6 -22.19 21.23 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 121.795 1.663 . . . . 0.0 111.491 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.665 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -81.32 -41.6 19.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.494 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.499 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.7 t -67.3 -24.66 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.714 0 CA-C-O 121.911 0.862 . . . . 0.0 109.704 176.461 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.21 -3.45 20.3 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.646 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.24 -17.91 10.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.188 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.502 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 44.8 m-85 -90.11 -42.82 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.828 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.704 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.926 -176.788 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.542 ' O ' HG11 ' A' ' 21' ' ' VAL . 2.5 p . . . . . 0 CA--C 1.514 -0.44 0 CA-C-O 121.35 0.595 . . . . 0.0 110.037 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.429 ' O ' HG21 ' A' ' 21' ' ' VAL . . . -62.21 -25.4 67.78 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.51 171.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.1 t -90.41 3.4 53.91 Favored 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.401 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 13.6 mptt -111.44 7.05 20.66 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.166 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.642 ' O ' HG21 ' A' ' 24' ' ' VAL . 10.4 m -135.21 -37.83 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.341 -175.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.59 -48.78 80.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.392 179.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -71.71 -23.47 22.72 Favored 'Trans proline' 0 C--N 1.353 0.778 0 C-N-CA 121.61 1.54 . . . . 0.0 111.379 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.642 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -78.65 -41.81 24.98 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.272 -179.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.492 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 88.4 t -67.34 -24.57 31.87 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 CA-C-O 121.923 0.868 . . . . 0.0 109.798 176.516 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.48 0.78 9.41 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.52 174.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.73 -22.48 6.84 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.209 173.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.492 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.9 m-85 -86.82 -34.87 19.39 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.956 178.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.777 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.251 179.653 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.493 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.509 -0.634 0 CA-C-O 121.242 0.544 . . . . 0.0 110.049 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.409 ' O ' HG21 ' A' ' 21' ' ' VAL . . . -61.56 -24.29 66.55 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.784 170.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.7 m -93.27 8.29 40.91 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -114.91 7.52 15.68 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.771 -1.104 . . . . 0.0 108.888 178.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.657 ' O ' HG21 ' A' ' 24' ' ' VAL . 10.6 m -136.71 -35.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.788 -175.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.11 -47.16 79.97 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 177.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -72.25 -22.81 21.67 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.633 1.555 . . . . 0.0 111.325 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.657 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.98 -40.29 22.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.332 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.204 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.499 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.7 t -68.9 -25.25 29.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.947 0 CA-C-O 121.676 0.75 . . . . 0.0 109.566 174.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.03 -3.39 22.62 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.519 173.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.83 -28.57 8.71 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.701 172.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.499 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.5 m-85 -80.99 -31.05 34.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.661 179.199 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.47 ' HB1' ' O ' ' A' ' 25' ' ' VAL . . . . . . . . 0 C--N 1.318 -0.769 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.972 177.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.599 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.5 p . . . . . 0 CA--C 1.517 -0.296 0 CA-C-O 121.116 0.484 . . . . 0.0 111.017 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.27 -22.34 65.93 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.447 174.343 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.4 m -100.03 9.15 43.34 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.139 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.48 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.4 mptm? -114.48 9.06 16.66 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.122 178.161 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.599 HG11 ' O ' ' A' ' 17' ' ' VAL . 14.1 m -131.99 -35.93 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.113 -175.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.13 -47.84 20.79 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.351 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -73.73 -20.05 20.51 Favored 'Trans proline' 0 C--N 1.352 0.759 0 C-N-CA 121.868 1.712 . . . . 0.0 111.596 -179.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.554 HG21 ' O ' ' A' ' 21' ' ' VAL . 4.4 m -78.73 -42.86 25.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.383 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.185 178.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.493 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.4 t -66.93 -24.3 32.25 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.596 0 CA-C-O 121.972 0.891 . . . . 0.0 109.691 175.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.07 -0.62 14.52 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.504 174.2 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.68 -22.17 8.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.948 173.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.493 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.2 m-85 -87.38 -40.99 13.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.889 179.488 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.765 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.744 179.38 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.535 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.515 -0.384 0 CA-C-O 121.311 0.577 . . . . 0.0 110.442 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.53 -18.67 65.04 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.229 172.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.5 t -99.84 7.85 44.63 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 177.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.412 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 4.9 mptp? -114.08 11.59 17.69 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.089 -0.96 . . . . 0.0 108.97 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.627 ' O ' HG21 ' A' ' 24' ' ' VAL . 13.5 m -138.03 -37.37 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 114.713 -1.131 . . . . 0.0 109.969 -175.434 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.87 -48.08 52.49 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.551 178.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -70.51 -24.25 26.47 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 121.627 1.551 . . . . 0.0 111.412 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.627 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.8 m -75.85 -43.22 39.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.316 -0.554 . . . . 0.0 110.199 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.482 ' O ' ' HB1' ' A' ' 29' ' ' ALA . 94.8 t -69.2 -25.88 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 CA-C-O 121.477 0.656 . . . . 0.0 110.282 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.28 -16.57 64.35 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.279 173.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -98.46 -27.5 14.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.069 176.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.467 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 51.1 m-85 -83.24 -26.14 31.03 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.018 178.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.482 ' HB1' ' O ' ' A' ' 25' ' ' VAL . . . . . . . . 0 C--N 1.321 -0.66 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.542 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.528 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.2 p . . . . . 0 CA--C 1.512 -0.512 0 CA-C-O 121.258 0.551 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . 0.457 ' O ' HG21 ' A' ' 21' ' ' VAL . . . -61.02 -27.78 68.57 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.914 170.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.3 m -89.69 6.02 43.28 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -111.89 5.89 19.19 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.809 -1.087 . . . . 0.0 108.854 178.349 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.628 ' O ' HG21 ' A' ' 24' ' ' VAL . 7.5 m -135.98 -37.76 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.38 -175.352 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.2 -48.61 68.82 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.707 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.01 -22.09 23.4 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 121.554 1.503 . . . . 0.0 111.371 -179.023 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.628 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -79.57 -41.42 22.17 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.279 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.495 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.5 t -67.51 -24.11 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.779 0 CA-C-O 121.846 0.831 . . . . 0.0 109.674 176.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.57 2.6 9.36 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.519 174.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.98 -22.64 6.1 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.081 172.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.495 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -84.98 -41.6 15.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-O 121.297 0.57 . . . . 0.0 110.361 178.494 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.683 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.357 177.584 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.575 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.6 p . . . . . 0 CA--C 1.515 -0.366 0 CA-C-O 121.189 0.518 . . . . 0.0 110.721 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.12 -31.15 68.68 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.121 172.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -90.61 8.54 33.68 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -112.42 5.19 17.96 Favored 'General case' 0 N--CA 1.437 -1.076 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.854 178.046 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.659 ' O ' HG21 ' A' ' 24' ' ' VAL . 5.8 m -136.3 -36.96 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.596 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.8 -47.79 23.35 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.684 179.567 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_exo -70.14 -22.22 30.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.797 1.665 . . . . 0.0 111.419 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.659 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -76.79 -42.42 33.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.137 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.477 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 93.1 t -68.13 -25.14 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.715 0 CA-C-O 121.833 0.825 . . . . 0.0 109.682 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.05 0.51 11.22 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.664 174.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.63 -22.32 8.13 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.037 172.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.477 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.4 m-85 -85.95 -41.61 14.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.846 178.618 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.72 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.803 -178.695 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.603 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.8 p . . . . . 0 CA--C 1.514 -0.418 0 CA-C-O 121.332 0.587 . . . . 0.0 110.423 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.67 -28.13 67.0 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.433 173.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.6 m -93.08 5.96 49.65 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.287 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.41 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 0.9 OUTLIER -111.48 8.02 20.95 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.849 179.507 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.639 ' O ' HG21 ' A' ' 24' ' ' VAL . 5.4 m -136.56 -39.93 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.435 -175.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.1 -49.05 58.18 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.74 -178.435 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -72.28 -21.32 23.41 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 121.65 1.566 . . . . 0.0 111.396 -178.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.639 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.0 m -78.73 -43.19 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.374 -0.531 . . . . 0.0 110.027 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.502 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.6 t -68.34 -23.85 28.91 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.721 0 CA-C-O 121.922 0.868 . . . . 0.0 109.975 176.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.88 -5.15 28.45 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.205 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.18 -25.11 9.05 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.349 174.28 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.502 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.9 m-85 -85.39 -31.93 22.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.968 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.791 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.489 -179.504 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.631 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.4 p . . . . . 0 CA--C 1.514 -0.434 0 CA-C-O 120.923 0.392 . . . . 0.0 110.617 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.99 -28.99 68.15 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.267 0.556 . . . . 0.0 109.916 173.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.5 m -89.34 3.88 50.71 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.458 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.5 mptm? -112.29 4.58 17.8 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.078 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.631 HG11 ' O ' ' A' ' 17' ' ' VAL . 7.2 m -134.35 -36.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.754 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.25 -49.92 11.75 Favored Pre-proline 0 C--N 1.318 -0.764 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.406 -179.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -71.41 -22.41 25.01 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.652 1.568 . . . . 0.0 111.153 -178.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.501 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -77.67 -45.34 28.62 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.402 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.233 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.496 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 83.7 t -69.01 -22.99 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.635 0 CA-C-O 122.021 0.915 . . . . 0.0 109.848 177.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.36 1.47 7.81 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.361 172.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -125.11 -15.16 6.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.465 174.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.496 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 52.7 m-85 -94.1 -30.47 14.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.063 0.458 . . . . 0.0 111.15 177.327 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.651 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.073 -173.502 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.629 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.513 -0.449 0 CA-C-O 121.026 0.441 . . . . 0.0 110.77 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.67 -29.01 67.78 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.405 174.189 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.4 m -91.91 6.5 45.98 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.077 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.477 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.3 mptp? -114.86 7.17 15.65 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.18 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.632 ' O ' HG21 ' A' ' 24' ' ' VAL . 12.1 m -133.61 -37.36 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.986 -176.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.35 -47.1 70.84 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.476 179.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -74.52 -18.96 19.59 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 121.589 1.526 . . . . 0.0 111.654 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.632 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -81.81 -43.99 19.97 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.152 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.485 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.2 t -67.2 -22.63 29.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 CA-C-O 121.932 0.872 . . . . 0.0 109.993 176.35 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.31 -10.8 60.35 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.532 174.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.52 -19.47 13.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.989 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.485 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 53.9 m-85 -90.89 -46.27 8.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.971 178.393 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.69 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.156 178.828 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.603 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.4 p . . . . . 0 CA--C 1.513 -0.469 0 CA-C-O 121.254 0.55 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.33 68.05 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.973 172.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.7 m -89.31 4.94 47.18 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 13.9 mptt -112.69 4.02 16.91 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.271 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.625 ' O ' HG21 ' A' ' 24' ' ' VAL . 6.1 m -135.71 -35.82 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.608 -174.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.35 -49.12 12.31 Favored Pre-proline 0 C--N 1.316 -0.863 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.584 -179.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -71.46 -19.94 27.96 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 121.753 1.635 . . . . 0.0 111.28 -178.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.625 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -77.21 -44.44 30.83 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.322 0 C-N-CA 120.406 -0.517 . . . . 0.0 109.875 178.547 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.486 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 99.4 t -68.78 -24.06 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.763 0 CA-C-O 121.851 0.834 . . . . 0.0 110.048 177.242 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -75.18 0.61 15.78 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.432 174.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.54 -21.82 8.99 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.785 172.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.486 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -86.52 -48.07 8.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.522 178.419 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.641 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.602 178.087 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.671 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.3 p . . . . . 0 CA--C 1.512 -0.485 0 CA-C-O 121.124 0.488 . . . . 0.0 110.302 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.13 -28.03 64.3 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.39 173.68 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 m -93.39 5.87 50.08 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.423 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.0 OUTLIER -114.41 5.05 15.51 Favored 'General case' 0 N--CA 1.44 -0.967 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.229 178.712 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.671 HG11 ' O ' ' A' ' 17' ' ' VAL . 11.5 m -133.44 -32.03 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.063 -174.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.23 -46.39 1.65 Allowed Pre-proline 0 C--N 1.316 -0.871 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.79 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -72.19 -23.25 21.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 121.633 1.555 . . . . 0.0 111.174 179.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.49 HG21 ' O ' ' A' ' 21' ' ' VAL . 5.3 m -71.57 -45.06 69.42 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.918 179.088 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.487 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.3 t -68.27 -24.99 30.5 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.7 0.762 . . . . 0.0 109.943 176.596 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.62 -5.72 39.29 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.54 174.499 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.71 -27.25 9.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.94 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.487 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.7 m-85 -81.8 -36.95 27.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.447 179.197 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.457 ' HB1' ' O ' ' A' ' 25' ' ' VAL . . . . . . . . 0 C--N 1.318 -0.777 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.095 177.023 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.625 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.511 -0.555 0 CA-C-O 121.185 0.517 . . . . 0.0 110.573 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.24 -23.47 65.66 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.203 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.8 m -94.25 2.51 55.88 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.435 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 14.0 mptt -112.31 7.96 19.48 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.331 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.668 ' O ' HG21 ' A' ' 24' ' ' VAL . 12.6 m -135.37 -37.6 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.09 -175.092 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.77 -46.67 88.24 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.68 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -73.98 -21.55 18.22 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.639 1.56 . . . . 0.0 111.356 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.668 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.4 m -80.87 -40.05 18.44 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.302 -179.214 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.484 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 90.9 t -69.82 -23.12 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 CA-C-O 121.598 0.713 . . . . 0.0 109.84 175.435 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.08 -18.46 63.26 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.154 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -94.42 -20.7 19.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.386 -0.824 . . . . 0.0 109.707 176.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.484 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 41.3 m-85 -85.59 -39.9 16.84 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.8 176.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.743 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.329 -177.765 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.642 ' O ' HG11 ' A' ' 21' ' ' VAL . 2.1 p . . . . . 0 CA--C 1.512 -0.489 0 CA-C-O 120.902 0.382 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.0 -26.26 65.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.36 0.6 . . . . 0.0 110.178 174.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.49 1.75 56.91 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.426 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.8 mptp? -113.39 6.55 17.27 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.166 -0.924 . . . . 0.0 109.369 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.661 ' O ' HG21 ' A' ' 24' ' ' VAL . 12.7 m -133.52 -37.51 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.274 -175.859 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.54 -45.5 76.77 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.696 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -73.92 -20.78 19.21 Favored 'Trans proline' 0 N--CA 1.454 -0.853 0 C-N-CA 121.448 1.432 . . . . 0.0 111.46 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.661 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -82.96 -41.83 17.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.642 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.495 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.1 t -66.31 -24.73 33.96 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 CA-C-O 121.899 0.857 . . . . 0.0 109.814 176.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.03 -7.25 45.04 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.676 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.86 -23.88 10.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.008 174.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.497 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 44.0 m-85 -83.32 -43.7 15.7 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.256 178.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.707 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.951 178.642 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.625 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.509 -0.614 0 CA-C-O 120.911 0.386 . . . . 0.0 110.605 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.76 -32.83 69.64 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.329 0.585 . . . . 0.0 109.818 172.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 66.1 m -86.36 4.44 39.29 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.123 -179.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . 0.439 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.2 mptm? -113.76 3.43 15.54 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.223 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.625 HG11 ' O ' ' A' ' 17' ' ' VAL . 5.6 m -134.56 -38.42 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.326 -176.226 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.72 -50.04 36.42 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.397 -178.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_exo -71.04 -22.62 25.99 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.647 1.565 . . . . 0.0 111.153 -178.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.601 HG21 ' O ' ' A' ' 21' ' ' VAL . 2.8 m -78.47 -44.08 26.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.251 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 95.6 t -68.77 -24.2 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.802 0 CA-C-O 121.909 0.861 . . . . 0.0 110.07 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.77 -5.35 33.43 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.445 173.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.76 -19.16 11.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.285 174.301 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.53 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 44.9 m-85 -87.66 -43.06 12.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.602 177.64 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.322 -0.604 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.131 -177.825 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.585 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.514 -0.433 0 CA-C-O 121.168 0.508 . . . . 0.0 110.696 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.89 -29.06 62.64 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.527 172.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 57.7 m -90.32 4.19 51.49 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -112.24 6.65 19.08 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.128 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' VAL . . . . . 0.668 ' O ' HG21 ' A' ' 24' ' ' VAL . 9.3 m -134.81 -37.01 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.082 -175.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.23 -46.62 85.68 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.724 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -73.28 -21.55 19.94 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.691 1.594 . . . . 0.0 111.446 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . 0.668 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -82.06 -41.12 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.425 -178.751 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . 0.513 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.8 t -67.86 -24.15 30.22 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 CA-C-O 121.919 0.866 . . . . 0.0 109.646 176.097 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.64 -1.58 14.17 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.761 -1.109 . . . . 0.0 110.566 173.776 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.69 -22.18 8.15 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.208 173.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' PHE . . . . . 0.513 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.0 m-85 -85.68 -35.95 20.57 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-O 121.258 0.551 . . . . 0.0 110.591 178.289 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.721 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.849 177.512 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 21.8 pttp . . . . . 0 N--CA 1.479 1.021 0 CA-C-O 121.164 0.506 . . . . 0.0 110.98 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 65.7 mt -125.32 126.09 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 CA-C-O 120.988 0.423 . . . . 0.0 110.313 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.5 t30 -77.04 117.92 19.1 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.026 178.26 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.602 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 73.2 mmtt -92.43 -16.04 26.41 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.898 -174.022 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 7.1 tp60 -68.16 -37.33 80.89 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 174.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 51.5 tttp -48.92 -43.19 39.23 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.747 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.602 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 3.2 mp -60.81 -30.34 47.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 115.068 -0.969 . . . . 0.0 111.955 -175.982 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 6.5 mptt -81.56 -36.01 29.59 Favored 'General case' 0 CA--C 1.503 -0.832 0 C-N-CA 119.516 -0.874 . . . . 0.0 109.427 173.406 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 20.9 m-80 -55.96 -55.68 29.84 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.076 0.465 . . . . 0.0 110.397 -178.06 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.429 ' O ' ' HB2' ' A' ' 14' ' ' ALA . . . -67.22 -27.5 73.5 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.626 -0.716 . . . . 0.0 112.543 -179.375 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.97 -28.6 43.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.303 0.573 . . . . 0.0 110.649 178.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 8.8 tmtt? -81.86 -38.82 24.84 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.357 -178.274 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.557 ' O ' HG11 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -84.82 -8.67 58.71 Favored 'General case' 0 C--O 1.201 -1.453 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 177.008 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.494 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -65.5 -24.97 67.27 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 172.817 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.3 mt -93.62 -33.66 13.61 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.317 -1.31 . . . . 0.0 109.39 174.296 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.577 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -69.35 -49.35 39.41 Favored Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.14 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.558 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.6 p -77.31 -23.84 14.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.734 -0.733 . . . . 0.0 110.529 -177.039 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.494 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -61.89 -26.16 67.99 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.948 172.844 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 21.4 m -91.68 6.65 45.04 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.01 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.577 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.8 mptt -113.99 9.05 17.31 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.16 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.619 ' O ' HG21 ' A' ' 24' ' ' VAL . 8.4 m -140.94 -37.16 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.282 -174.258 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.59 -48.13 65.82 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.669 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_exo -71.02 -23.59 24.91 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 121.625 1.55 . . . . 0.0 111.358 -178.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.619 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.1 m -78.86 -42.16 24.33 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.3 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.55 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.6 t -69.01 -25.27 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 121.842 0.829 . . . . 0.0 110.059 177.669 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.22 -8.74 48.57 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.402 173.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -106.83 -30.28 9.0 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.068 174.165 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 41.4 m-85 -77.59 -36.21 52.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.425 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.445 ' HB1' ' O ' ' A' ' 25' ' ' VAL . . . -86.07 -57.53 2.99 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.806 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.503 ' HD3' ' N ' ' A' ' 30' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.248 0.99 0 C-N-CA 120.421 -0.511 . . . . 0.0 111.146 -179.033 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 39.6 ttpt . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 11.1 tt -79.3 149.69 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 175.994 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -70.64 122.79 20.44 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.771 0.32 . . . . 0.0 110.313 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.607 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 75.1 mmtt -90.66 -24.43 20.48 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.315 -175.928 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . 0.457 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 52.8 tp60 -61.84 -34.71 76.45 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 175.432 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.418 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 59.7 tttt -54.64 -35.85 63.92 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.71 175.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.607 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.4 mp -56.87 -34.32 43.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.939 176.935 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.457 ' HD3' ' HA ' ' A' ' 5' ' ' GLN . 0.0 OUTLIER -87.11 -13.48 44.05 Favored 'General case' 0 CA--C 1.509 -0.606 0 C-N-CA 120.638 -0.425 . . . . 0.0 109.89 178.661 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.464 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 1.0 OUTLIER -62.91 -64.3 0.96 Allowed 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 178.955 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.76 -34.36 88.4 Favored Glycine 0 N--CA 1.446 -0.667 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.767 177.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.41 -29.24 69.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.103 0.477 . . . . 0.0 111.379 179.156 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.424 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 6.6 tmtt? -87.12 -42.33 13.1 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.695 -177.392 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.6 ' O ' HG11 ' A' ' 17' ' ' VAL . 30.6 pttt -87.01 -1.67 58.05 Favored 'General case' 0 C--O 1.205 -1.252 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.997 -178.449 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -70.12 -15.87 63.03 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 122.091 0.948 . . . . 0.0 108.476 172.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 mt -100.24 -30.27 11.99 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.836 -1.529 . . . . 0.0 109.344 173.469 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.556 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -81.54 -53.96 3.65 Favored Glycine 0 N--CA 1.444 -0.771 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.972 -177.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.6 HG11 ' O ' ' A' ' 13' ' ' LYS . 1.1 p -76.17 -23.15 15.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.06 0.457 . . . . 0.0 110.464 -176.363 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.4 ' O ' HG21 ' A' ' 21' ' ' VAL . . . -63.93 -23.61 67.41 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.521 0.677 . . . . 0.0 109.92 171.964 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 23.5 m -93.23 6.59 47.5 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.564 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.556 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.2 mptt -113.04 6.6 17.73 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.883 -1.053 . . . . 0.0 108.935 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.63 ' O ' HG21 ' A' ' 24' ' ' VAL . 12.9 m -133.77 -37.81 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.359 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.16 -48.75 68.97 Favored Pre-proline 0 C--N 1.322 -0.611 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.223 178.622 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -70.24 -24.37 27.54 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 121.637 1.558 . . . . 0.0 111.424 -179.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.63 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.02 -42.0 27.62 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.467 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.437 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.492 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.5 t -67.42 -25.57 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.785 0 CA-C-O 121.755 0.788 . . . . 0.0 109.841 176.58 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.506 ' HB2' ' NH2' ' A' ' 30' ' ' ARG . . . -70.54 -5.88 32.26 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.668 174.027 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.2 -26.46 9.17 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.03 174.242 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.492 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.5 m-85 -82.29 -33.84 28.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.668 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.431 ' HB1' ' O ' ' A' ' 25' ' ' VAL . . . -87.83 -62.57 1.47 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.01 -178.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.506 ' NH2' ' HB2' ' A' ' 26' ' ' ALA . 1.7 ppt_? . . . . . 0 C--O 1.243 0.725 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.638 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 56.3 mtmt . . . . . 0 N--CA 1.48 1.062 0 CA-C-O 120.953 0.406 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.409 ' N ' HD11 ' A' ' 2' ' ' ILE . 3.2 mp -80.0 133.51 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.388 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 39.0 t30 -59.96 118.86 6.76 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.211 0.529 . . . . 0.0 110.977 -177.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.634 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 13.2 mptt -90.8 -20.24 22.57 Favored 'General case' 0 CA--C 1.512 -0.498 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.227 -176.547 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . 0.442 ' HA ' ' OE1' ' A' ' 5' ' ' GLN . 6.1 tp60 -66.42 -37.62 85.62 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.302 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.421 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 54.6 tttt -54.27 -32.88 57.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.874 -1.057 . . . . 0.0 112.103 177.004 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.634 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.3 mp -55.35 -38.51 48.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.073 175.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.485 ' O ' ' HB3' ' A' ' 12' ' ' LYS . 6.6 mptt -84.59 -18.37 35.77 Favored 'General case' 0 CA--C 1.505 -0.76 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.738 177.672 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.421 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 0.9 OUTLIER -59.38 -59.92 4.68 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 179.704 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.77 -34.23 86.67 Favored Glycine 0 N--CA 1.445 -0.738 0 CA-C-N 115.107 -0.952 . . . . 0.0 111.945 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -67.54 -26.62 66.4 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.973 0.416 . . . . 0.0 111.315 179.787 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.485 ' HB3' ' O ' ' A' ' 8' ' ' LYS . 0.8 OUTLIER -92.02 -37.52 12.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.98 -177.664 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.525 ' O ' HG11 ' A' ' 17' ' ' VAL . 4.9 pttt -84.97 -4.16 59.04 Favored 'General case' 0 C--O 1.202 -1.431 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 178.517 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -65.24 -24.12 67.25 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 171.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.9 mt -90.94 -33.82 15.43 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 113.889 -1.505 . . . . 0.0 109.4 175.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.28 -52.3 6.24 Favored Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 115.104 -0.953 . . . . 0.0 111.901 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.646 ' O ' HG11 ' A' ' 21' ' ' VAL . 2.3 p -68.05 -24.3 30.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-O 121.311 0.577 . . . . 0.0 110.305 -177.538 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.15 -22.85 65.08 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.518 173.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.4 m -95.08 3.14 55.14 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 177.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.471 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.5 mptp? -113.83 8.34 17.32 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.031 -0.986 . . . . 0.0 109.438 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.646 HG11 ' O ' ' A' ' 17' ' ' VAL . 12.0 m -135.64 -36.31 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.286 -175.803 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.73 -47.76 54.78 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.649 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -72.75 -21.74 21.25 Favored 'Trans proline' 0 C--N 1.353 0.804 0 C-N-CA 121.829 1.686 . . . . 0.0 111.339 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.637 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -78.7 -42.4 25.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.275 179.523 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.506 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.3 t -68.37 -24.89 30.17 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.879 0 CA-C-O 121.858 0.837 . . . . 0.0 109.963 177.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.68 -8.65 53.55 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.821 -1.082 . . . . 0.0 110.475 174.117 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 -24.16 11.2 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.166 175.153 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.506 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 42.3 m-85 -83.08 -40.81 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.433 178.699 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -83.36 -49.9 8.88 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.305 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.754 0 CA-C-O 118.585 -0.722 . . . . 0.0 110.205 177.814 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt . . . . . 0 N--CA 1.48 1.059 0 CA-C-O 120.699 0.285 . . . . 0.0 110.406 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 72.6 mt -89.47 137.32 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.758 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 176.434 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -138.7 125.51 20.98 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.953 0.406 . . . . 0.0 110.738 -177.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.615 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 46.4 mmtm -97.31 -17.45 19.76 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.6 -177.659 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -65.74 -36.94 84.99 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 175.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 28.8 ttpt -51.18 -35.09 34.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.949 -1.023 . . . . 0.0 111.571 175.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.615 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.3 mp -57.11 -40.96 76.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.292 177.64 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.11 -27.02 56.94 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.74 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 24.9 m-80 -63.8 -56.07 18.28 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.07 -28.5 72.93 Favored Glycine 0 N--CA 1.445 -0.762 0 CA-C-N 115.394 -0.821 . . . . 0.0 112.321 178.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.59 -32.4 60.31 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.081 0.467 . . . . 0.0 110.561 177.299 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.446 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 0.8 OUTLIER -76.4 -39.21 54.28 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.624 -179.635 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.549 ' O ' HG11 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -85.63 -8.7 58.09 Favored 'General case' 0 C--O 1.2 -1.522 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.442 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.44 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -65.65 -25.44 67.36 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 172.388 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.7 mt -89.34 -36.12 15.71 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 114.335 -1.302 . . . . 0.0 109.439 173.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.568 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -70.38 -50.88 24.43 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 114.892 -1.049 . . . . 0.0 111.813 -178.487 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.554 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.7 p -74.71 -19.91 16.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.626 -0.787 . . . . 0.0 110.61 -176.79 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.44 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -59.23 -25.42 64.01 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.443 173.162 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -95.18 7.33 46.48 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-O 121.644 0.735 . . . . 0.0 109.124 178.52 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.568 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.3 mptt -112.36 7.04 19.08 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-N 115.104 -0.953 . . . . 0.0 108.975 179.0 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.623 ' O ' HG21 ' A' ' 24' ' ' VAL . 10.6 m -133.51 -36.28 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.272 -175.244 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.9 -47.82 52.82 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.49 178.783 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_exo -71.7 -23.11 23.17 Favored 'Trans proline' 0 C--N 1.353 0.806 0 C-N-CA 121.848 1.698 . . . . 0.0 111.494 179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.623 HG21 ' O ' ' A' ' 21' ' ' VAL . 4.5 m -77.9 -42.22 28.27 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.483 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.503 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 87.5 t -68.12 -23.42 28.78 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.942 0 CA-C-O 121.872 0.844 . . . . 0.0 109.453 174.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.59 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -73.14 -5.74 41.11 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.557 173.566 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.11 -21.99 11.67 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.833 173.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.503 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.1 m-85 -86.12 -29.97 22.89 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.388 0.613 . . . . 0.0 110.01 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.72 -52.18 5.46 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.03 176.149 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.59 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 48.5 mtm180 . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.691 -0.671 . . . . 0.0 110.597 174.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 63.9 pttt . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 73.4 mt -121.19 136.18 58.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -110.65 123.39 49.92 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.602 -177.772 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.64 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 1.1 mptm? -91.45 -15.58 28.63 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.395 -177.919 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 39.1 tt0 -67.53 -36.6 81.32 Favored 'General case' 0 N--CA 1.445 -0.681 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 174.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 53.4 tttt -54.45 -33.13 59.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.865 177.249 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.64 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -56.28 -35.33 42.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.02 176.167 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.421 ' O ' ' HB3' ' A' ' 12' ' ' LYS . 0.3 OUTLIER -79.27 -27.48 42.3 Favored 'General case' 0 CA--C 1.507 -0.701 0 C-N-CA 120.551 -0.46 . . . . 0.0 109.789 175.774 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.413 HD21 ' N ' ' A' ' 9' ' ' ASN . 0.8 OUTLIER -59.26 -60.77 3.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.023 0.44 . . . . 0.0 109.929 -175.199 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.57 -26.46 73.68 Favored Glycine 0 CA--C 1.508 -0.387 0 CA-C-N 115.432 -0.803 . . . . 0.0 112.613 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.55 -31.81 60.18 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.156 0.503 . . . . 0.0 110.636 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.421 ' HB3' ' O ' ' A' ' 8' ' ' LYS . 6.1 tmtt? -83.14 -37.81 23.24 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.562 -177.692 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.577 ' O ' HG11 ' A' ' 17' ' ' VAL . 2.7 pttt -84.21 -5.53 59.27 Favored 'General case' 0 C--O 1.201 -1.448 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 177.275 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.469 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -68.41 -22.48 64.62 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 170.78 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.3 mt -96.08 -29.19 14.24 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 114.227 -1.352 . . . . 0.0 109.399 173.778 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.542 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -76.33 -48.54 9.29 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.702 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.577 HG11 ' O ' ' A' ' 13' ' ' LYS . 1.7 p -76.8 -20.25 14.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.627 0.727 . . . . 0.0 109.86 -178.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.472 ' O ' HG21 ' A' ' 21' ' ' VAL . . . -62.47 -25.71 68.13 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.901 171.039 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.5 m -89.62 5.63 44.84 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.542 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.1 mptm? -109.4 5.43 23.44 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.114 179.414 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.665 ' O ' HG21 ' A' ' 24' ' ' VAL . 10.2 m -135.99 -36.76 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.372 -173.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.33 -46.1 84.84 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.818 179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -72.6 -22.19 21.23 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 121.795 1.663 . . . . 0.0 111.491 179.584 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.665 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -81.32 -41.6 19.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.494 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.499 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.7 t -67.3 -24.66 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.714 0 CA-C-O 121.911 0.862 . . . . 0.0 109.704 176.461 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.21 -3.45 20.3 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.646 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.24 -17.91 10.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.188 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.502 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 44.8 m-85 -90.11 -42.82 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.828 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 -52.62 6.03 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.926 -176.788 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.246 0.869 0 C-N-CA 120.782 -0.367 . . . . 0.0 111.526 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp . . . . . 0 N--CA 1.479 1.007 0 CA-C-O 120.984 0.421 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 89.1 mt -110.25 134.51 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.027 178.697 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -159.1 106.85 1.81 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.336 0.589 . . . . 0.0 110.174 178.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.615 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 74.9 mmtt -88.76 -20.1 25.18 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.291 -174.555 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . 0.411 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 8.6 tp-100 -64.1 -32.85 74.56 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 175.884 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.439 ' HA ' ' HB2' ' A' ' 9' ' ' ASN . 4.0 ttpm? -59.01 -35.08 72.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.278 176.631 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.615 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.8 mp -58.54 -32.16 45.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 121.029 -0.268 . . . . 0.0 111.368 178.326 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.411 ' HD3' ' HA ' ' A' ' 5' ' ' GLN . 0.4 OUTLIER -85.72 -37.25 19.57 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 176.545 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.439 ' HB2' ' HA ' ' A' ' 6' ' ' LYS . 12.8 m-20 -65.6 -45.96 81.2 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.304 -176.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.47 -25.88 72.7 Favored Glycine 0 CA--C 1.506 -0.485 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 176.47 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -80.93 -25.16 37.66 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.268 0.556 . . . . 0.0 110.145 174.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.69 -34.12 27.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.447 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.598 ' O ' HG11 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -87.15 -7.95 57.46 Favored 'General case' 0 C--O 1.199 -1.571 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.103 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.475 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -66.3 -23.33 66.36 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 170.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.9 mt -94.57 -33.59 12.97 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 114.06 -1.427 . . . . 0.0 109.446 173.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.566 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -71.12 -46.81 41.03 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.212 -0.904 . . . . 0.0 111.401 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.598 HG11 ' O ' ' A' ' 13' ' ' LYS . 2.5 p -76.15 -24.6 16.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-O 121.35 0.595 . . . . 0.0 110.037 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.475 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -62.21 -25.4 67.78 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.51 171.874 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.1 t -90.41 3.4 53.91 Favored 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.566 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.6 mptt -111.44 7.05 20.66 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.166 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.642 ' O ' HG21 ' A' ' 24' ' ' VAL . 10.4 m -135.21 -37.83 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.341 -175.55 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.59 -48.78 80.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.392 179.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -71.71 -23.47 22.72 Favored 'Trans proline' 0 C--N 1.353 0.778 0 C-N-CA 121.61 1.54 . . . . 0.0 111.379 -179.183 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.642 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -78.65 -41.81 24.98 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.272 -179.132 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.492 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 88.4 t -67.34 -24.57 31.87 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 CA-C-O 121.923 0.868 . . . . 0.0 109.798 176.516 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.48 0.78 9.41 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.52 174.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.73 -22.48 6.84 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.209 173.031 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.492 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.9 m-85 -86.82 -34.87 19.39 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.956 178.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -88.92 -61.41 1.71 Allowed 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.251 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.94 0 CA-C-O 119.272 -0.394 . . . . 0.0 111.515 -178.529 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 64.8 pttt . . . . . 0 N--CA 1.48 1.053 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 39.6 mm -104.41 131.97 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.277 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 55.4 t-20 -114.34 122.49 46.86 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.158 177.505 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.494 ' HA ' HD13 ' A' ' 7' ' ' ILE . 34.4 mmtp -124.6 -17.39 5.99 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.974 172.308 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 24.4 tp60 -61.0 -37.17 81.59 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.149 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.5 tttt -64.5 -41.77 96.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.658 176.986 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.494 HD13 ' HA ' ' A' ' 4' ' ' LYS . 3.8 mp -60.31 -41.96 88.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 177.157 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.469 ' HD2' ' HA ' ' A' ' 8' ' ' LYS . 37.9 tptt -64.63 -42.83 95.21 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.272 175.475 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.642 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 75.8 m-20 -68.96 -44.48 72.88 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.748 -175.775 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 14' ' ' ALA . . . -64.21 -22.21 66.93 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.479 -0.867 . . . . 0.0 111.391 177.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.8 -28.02 20.72 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.043 0.449 . . . . 0.0 110.572 176.286 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.446 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 3.2 tmtm? -85.32 -49.53 8.08 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.959 -178.281 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.642 ' HG2' ' O ' ' A' ' 9' ' ' ASN . 50.4 pttt -81.47 -7.05 59.53 Favored 'General case' 0 C--O 1.205 -1.244 0 CA-C-O 120.726 0.298 . . . . 0.0 110.259 -175.494 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.521 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -66.18 -12.52 56.46 Favored 'General case' 0 C--N 1.314 -0.966 0 O-C-N 121.161 -0.962 . . . . 0.0 108.956 175.529 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.4 mt -102.75 -33.01 9.56 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 113.689 -1.596 . . . . 0.0 110.129 172.424 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.463 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -82.91 -53.96 3.36 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.573 -0.739 . . . . 0.0 112.122 -177.944 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.51 HG11 ' O ' ' A' ' 13' ' ' LYS . 1.1 p -76.74 -18.36 14.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-O 121.242 0.544 . . . . 0.0 110.049 -177.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.521 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -61.56 -24.29 66.55 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.784 170.617 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.7 m -93.27 8.29 40.91 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.276 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.463 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.8 mptt -114.91 7.52 15.68 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.771 -1.104 . . . . 0.0 108.888 178.279 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.657 ' O ' HG21 ' A' ' 24' ' ' VAL . 10.6 m -136.71 -35.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.788 -175.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.11 -47.16 79.97 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 177.881 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -72.25 -22.81 21.67 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.633 1.555 . . . . 0.0 111.325 -179.753 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.657 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.98 -40.29 22.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.332 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.204 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.499 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.7 t -68.9 -25.25 29.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.947 0 CA-C-O 121.676 0.75 . . . . 0.0 109.566 174.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.508 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -72.03 -3.39 22.62 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.519 173.419 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.83 -28.57 8.71 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.701 172.526 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.499 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.5 m-85 -80.99 -31.05 34.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.661 179.199 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.47 ' HB1' ' O ' ' A' ' 25' ' ' VAL . . . -87.3 -50.66 6.43 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.972 177.3 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.508 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 79.1 mtm180 . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.629 -0.701 . . . . 0.0 110.341 175.422 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt . . . . . 0 N--CA 1.481 1.079 0 CA-C-O 120.846 0.355 . . . . 0.0 110.396 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 11.6 tt -78.22 155.06 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.211 179.163 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 26.7 t30 -74.48 115.33 13.9 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.001 0.429 . . . . 0.0 109.948 176.802 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.52 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 34.4 mmtp -85.89 -19.92 29.83 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.289 -172.904 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 51.3 tp60 -65.24 -37.5 87.43 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.448 177.903 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.0 tttt -58.55 -40.86 84.22 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.944 175.342 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.52 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 1.7 mp -53.45 -41.19 44.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.276 178.069 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.503 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 2.9 mptt -77.83 -38.14 46.92 Favored 'General case' 0 CA--C 1.507 -0.688 0 C-N-CA 119.861 -0.736 . . . . 0.0 109.998 178.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -62.49 -49.14 76.54 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.847 -176.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.8 -29.41 75.03 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.842 -0.694 . . . . 0.0 111.945 178.011 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.23 59.92 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.107 0.479 . . . . 0.0 110.301 176.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.455 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 9.9 tmtt? -77.68 -40.14 42.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.301 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.522 ' O ' HG11 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -82.02 -11.05 59.03 Favored 'General case' 0 C--O 1.2 -1.522 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 177.86 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.9 -23.15 67.14 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.868 0.842 . . . . 0.0 108.782 173.127 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.9 mt -90.75 -38.76 12.82 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.121 172.843 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.697 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -69.42 -54.89 11.24 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.585 -177.249 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.599 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.5 p -68.7 -28.06 38.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-N 114.817 -0.691 . . . . 0.0 111.017 -175.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.27 -22.34 65.93 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.447 174.343 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.4 m -100.03 9.15 43.34 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.139 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.697 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.4 mptm? -114.48 9.06 16.66 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.122 178.161 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.599 HG11 ' O ' ' A' ' 17' ' ' VAL . 14.1 m -131.99 -35.93 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.113 -175.818 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -70.13 -47.84 20.79 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.351 179.808 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -73.73 -20.05 20.51 Favored 'Trans proline' 0 C--N 1.352 0.759 0 C-N-CA 121.868 1.712 . . . . 0.0 111.596 -179.631 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.554 HG21 ' O ' ' A' ' 21' ' ' VAL . 4.4 m -78.73 -42.86 25.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.383 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.185 178.926 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.493 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.4 t -66.93 -24.3 32.25 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.596 0 CA-C-O 121.972 0.891 . . . . 0.0 109.691 175.414 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.471 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -73.07 -0.62 14.52 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.504 174.2 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.68 -22.17 8.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.948 173.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.493 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.2 m-85 -87.38 -40.99 13.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.889 179.488 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.35 -46.41 9.69 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.744 179.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.471 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 8.7 mtm180 . . . . . 0 C--O 1.249 1.048 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.769 176.689 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . 0.501 ' HD3' ' H1 ' ' A' ' 1' ' ' LYS . 0.2 OUTLIER . . . . . 0 N--CA 1.48 1.057 0 CA-C-O 120.798 0.332 . . . . 0.0 110.439 . . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.7 mm -107.01 123.58 62.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.927 178.231 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -85.14 115.17 22.79 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.991 0.425 . . . . 0.0 111.041 -177.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.484 ' HA ' HD13 ' A' ' 7' ' ' ILE . 34.0 mmtp -109.51 -5.08 15.86 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.109 175.239 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -59.86 -51.26 70.48 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.638 179.448 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 57.8 tttt -58.19 -37.44 74.77 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.3 177.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.484 HD13 ' HA ' ' A' ' 4' ' ' LYS . 3.1 mp -61.33 -40.39 85.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 176.255 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.432 ' HD2' ' HA ' ' A' ' 8' ' ' LYS . 17.3 tptm -64.82 -41.28 95.89 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.734 174.252 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 20.9 m-80 -55.09 -57.03 13.38 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 178.146 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.31 -36.71 92.88 Favored Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.537 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.8 -34.79 72.11 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.032 0.444 . . . . 0.0 111.148 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -81.86 -36.17 28.53 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.686 -176.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.544 ' O ' HG11 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -83.54 -11.17 57.73 Favored 'General case' 0 C--O 1.202 -1.406 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 177.376 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.448 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -62.21 -23.85 66.88 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 172.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.2 mt -90.81 -38.3 13.06 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 114.229 -1.351 . . . . 0.0 109.756 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.522 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -70.21 -50.75 26.0 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.119 -0.946 . . . . 0.0 111.775 -178.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.544 HG11 ' O ' ' A' ' 13' ' ' LYS . 1.7 p -71.72 -24.46 23.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 114.899 -0.65 . . . . 0.0 110.442 -177.793 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.448 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -64.53 -18.67 65.04 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.229 172.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.5 t -99.84 7.85 44.63 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 177.077 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.522 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 4.9 mptp? -114.08 11.59 17.69 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.089 -0.96 . . . . 0.0 108.97 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.627 ' O ' HG21 ' A' ' 24' ' ' VAL . 13.5 m -138.03 -37.37 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 114.713 -1.131 . . . . 0.0 109.969 -175.434 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.87 -48.08 52.49 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.551 178.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 12.0 Cg_exo -70.51 -24.25 26.47 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 121.627 1.551 . . . . 0.0 111.412 -179.209 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.627 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.8 m -75.85 -43.22 39.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.316 -0.554 . . . . 0.0 110.199 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.482 ' O ' ' HB1' ' A' ' 29' ' ' ALA . 94.8 t -69.2 -25.88 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 CA-C-O 121.477 0.656 . . . . 0.0 110.282 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.28 -16.57 64.35 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.279 173.731 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -98.46 -27.5 14.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.069 176.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.467 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 51.1 m-85 -83.24 -26.14 31.03 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.018 178.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.482 ' HB1' ' O ' ' A' ' 25' ' ' VAL . . . -90.91 -64.84 1.07 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.542 179.339 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.111 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.863 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 63.1 tttm . . . . . 0 N--CA 1.479 0.994 0 CA-C-O 121.038 0.447 . . . . 0.0 110.332 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 79.0 mt -106.62 125.95 62.47 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 40.0 t30 -67.67 112.8 4.99 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.286 0.565 . . . . 0.0 110.371 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.615 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 34.8 mmtp -95.35 -17.69 21.39 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.008 -176.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -61.4 -40.07 93.03 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 175.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.41 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 4.5 ttpm? -55.38 -33.44 63.45 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.83 178.063 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.615 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -56.91 -40.79 74.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.085 176.646 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.37 -32.45 60.84 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 120.176 -0.609 . . . . 0.0 109.384 177.305 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.471 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 17.0 m-80 -55.9 -57.39 12.27 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 123.526 0.516 . . . . 0.0 109.643 178.234 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.81 -36.37 93.02 Favored Glycine 0 N--CA 1.444 -0.768 0 CA-C-N 115.289 -0.869 . . . . 0.0 112.143 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.35 -27.45 66.27 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.016 0.436 . . . . 0.0 111.066 177.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.424 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 9.1 tmtt? -82.81 -43.31 16.83 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.759 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.6 ' O ' HG11 ' A' ' 17' ' ' VAL . 25.0 pttt -86.75 -3.6 59.07 Favored 'General case' 0 C--O 1.202 -1.396 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.857 -179.18 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.507 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -68.87 -17.09 63.93 Favored 'General case' 0 C--N 1.314 -0.952 0 O-C-N 121.24 -0.913 . . . . 0.0 108.56 173.145 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.1 mt -98.61 -32.98 11.15 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 113.754 -1.567 . . . . 0.0 109.403 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.48 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -77.89 -52.22 5.48 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.12 -0.946 . . . . 0.0 112.062 -177.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.6 HG11 ' O ' ' A' ' 13' ' ' LYS . 1.2 p -76.13 -21.65 15.53 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.258 0.551 . . . . 0.0 110.127 -177.702 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.507 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -61.02 -27.78 68.57 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.914 170.847 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.3 m -89.69 6.02 43.28 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.48 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -111.89 5.89 19.19 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.809 -1.087 . . . . 0.0 108.854 178.349 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.628 ' O ' HG21 ' A' ' 24' ' ' VAL . 7.5 m -135.98 -37.76 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.38 -175.352 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.2 -48.61 68.82 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.707 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -72.01 -22.09 23.4 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 121.554 1.503 . . . . 0.0 111.371 -179.023 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.628 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -79.57 -41.42 22.17 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.279 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.495 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.5 t -67.51 -24.11 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.779 0 CA-C-O 121.846 0.831 . . . . 0.0 109.674 176.558 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.469 ' HB2' ' NH2' ' A' ' 30' ' ' ARG . . . -74.57 2.6 9.36 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.519 174.705 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.98 -22.64 6.1 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.081 172.516 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.495 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -84.98 -41.6 15.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-O 121.297 0.57 . . . . 0.0 110.361 178.494 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.07 -51.46 7.99 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.357 177.584 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.469 ' NH2' ' HB2' ' A' ' 26' ' ' ALA . 44.7 mtm180 . . . . . 0 C--O 1.247 0.953 0 CA-C-O 118.479 -0.772 . . . . 0.0 111.125 175.605 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 96.8 mttt . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.439 HG21 ' N ' ' A' ' 3' ' ' ASN . 48.2 mm -79.09 147.05 7.03 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.604 -176.028 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . 0.439 ' N ' HG21 ' A' ' 2' ' ' ILE . 54.1 t30 78.34 104.41 0.07 Allowed 'General case' 0 CA--C 1.51 -0.578 0 O-C-N 124.327 1.017 . . . . 0.0 110.773 -179.129 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.596 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 75.2 mmtt -94.18 -12.7 27.76 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 114.421 -1.263 . . . . 0.0 110.195 -178.486 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . 0.433 ' HA ' ' CD ' ' A' ' 8' ' ' LYS . 49.8 tp60 -65.15 -33.78 76.83 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 174.471 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -55.47 -42.12 73.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.92 174.972 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.596 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 3.6 mp -58.18 -39.06 71.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.555 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.487 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 2.8 mptt -79.51 -26.95 41.43 Favored 'General case' 0 CA--C 1.506 -0.714 0 C-N-CA 119.592 -0.843 . . . . 0.0 109.853 177.858 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.0 m-20 -72.03 -46.14 58.19 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.709 -177.791 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -63.84 -31.1 79.66 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 174.157 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.85 -27.3 57.77 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.966 0.413 . . . . 0.0 110.697 176.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.491 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 0.9 OUTLIER -78.87 -42.04 28.36 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.143 -179.905 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.545 ' O ' HG11 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -83.38 -10.13 58.62 Favored 'General case' 0 C--O 1.199 -1.57 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 178.346 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.12 -24.89 67.86 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 172.611 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.7 mt -87.24 -40.69 14.31 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 114.149 -1.387 . . . . 0.0 109.333 172.907 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.584 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -68.77 -52.38 25.07 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.89 -177.342 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.575 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.6 p -71.03 -22.92 23.06 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-N 114.743 -0.729 . . . . 0.0 110.721 -176.175 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.12 -31.15 68.68 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.121 172.763 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -90.61 8.54 33.68 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.584 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.1 mptm? -112.42 5.19 17.96 Favored 'General case' 0 N--CA 1.437 -1.076 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.854 178.046 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.659 ' O ' HG21 ' A' ' 24' ' ' VAL . 5.8 m -136.3 -36.96 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.596 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -69.8 -47.79 23.35 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.684 179.567 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_exo -70.14 -22.22 30.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.797 1.665 . . . . 0.0 111.419 -179.512 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.659 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -76.79 -42.42 33.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.137 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.477 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 93.1 t -68.13 -25.14 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.715 0 CA-C-O 121.833 0.825 . . . . 0.0 109.682 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.05 0.51 11.22 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.664 174.057 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.63 -22.32 8.13 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.037 172.764 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.477 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.4 m-85 -85.95 -41.61 14.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.846 178.618 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.56 -56.5 3.83 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.803 -178.695 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.241 0.626 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.454 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 67.1 mttm . . . . . 0 N--CA 1.477 0.924 0 CA-C-O 120.745 0.307 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 72.4 mt -117.39 132.59 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.869 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.4 t30 -68.18 109.0 3.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.029 0.442 . . . . 0.0 110.296 177.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.542 ' C ' ' HD3' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -96.94 -7.94 31.91 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.018 -176.233 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -64.74 -43.65 92.66 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 176.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 16.4 ttpp -56.97 -35.38 69.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.539 173.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.496 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 1.8 mp -64.07 -42.82 96.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.8 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 177.038 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.451 ' HA ' ' HD2' ' A' ' 8' ' ' LYS . 22.5 tptp -58.54 -42.01 86.85 Favored 'General case' 0 CA--C 1.51 -0.586 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.908 172.993 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 24.2 m-80 -55.83 -57.52 11.7 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.474 179.666 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.77 -20.8 70.67 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.606 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -84.08 -25.94 29.39 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.223 0.535 . . . . 0.0 110.672 177.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 2.1 tmtm? -88.25 -40.19 13.84 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.382 -178.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.526 ' O ' HG11 ' A' ' 17' ' ' VAL . 3.5 pttt -80.82 -6.65 58.83 Favored 'General case' 0 C--O 1.202 -1.395 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 177.016 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -66.2 -21.27 66.3 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.945 0.879 . . . . 0.0 108.7 172.721 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.1 mt -93.26 -35.87 12.87 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 114.038 -1.437 . . . . 0.0 109.532 173.48 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.617 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -72.83 -52.25 9.75 Favored Glycine 0 CA--C 1.502 -0.745 0 CA-C-N 115.008 -0.996 . . . . 0.0 111.797 -178.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.603 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.8 p -69.37 -25.11 28.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 114.999 -0.6 . . . . 0.0 110.423 -176.574 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.67 -28.13 67.0 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.433 173.524 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.6 m -93.08 5.96 49.65 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.287 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.617 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -111.48 8.02 20.95 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.849 179.507 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.639 ' O ' HG21 ' A' ' 24' ' ' VAL . 5.4 m -136.56 -39.93 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.435 -175.966 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.1 -49.05 58.18 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.74 -178.435 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 6.9 Cg_exo -72.28 -21.32 23.41 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 121.65 1.566 . . . . 0.0 111.396 -178.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.639 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.0 m -78.73 -43.19 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.374 -0.531 . . . . 0.0 110.027 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.502 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.6 t -68.34 -23.85 28.91 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.721 0 CA-C-O 121.922 0.868 . . . . 0.0 109.975 176.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.88 -5.15 28.45 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.205 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.18 -25.11 9.05 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.349 174.28 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.502 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.9 m-85 -85.39 -31.93 22.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.968 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -96.26 -55.39 2.96 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.489 -179.504 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.46 -0.781 . . . . 0.0 110.158 -179.019 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 46.7 mmtm . . . . . 0 N--CA 1.481 1.103 0 CA-C-O 120.774 0.321 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . 0.416 ' N ' HD11 ' A' ' 2' ' ' ILE . 3.1 mp -92.75 125.94 45.27 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.959 -178.852 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 40.4 t30 -121.9 106.45 11.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.423 0.63 . . . . 0.0 110.485 177.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.613 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 34.6 mmtp -88.37 -17.44 30.54 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.843 -1.071 . . . . 0.0 109.723 -177.478 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . 0.407 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 54.9 tp60 -64.29 -37.56 87.92 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 174.732 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.439 ' HB3' ' HZ2' ' A' ' 6' ' ' LYS . 5.0 ttpm? -50.01 -37.48 32.99 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.301 175.346 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.613 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -56.66 -39.95 66.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.222 178.373 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.407 ' HD3' ' HA ' ' A' ' 5' ' ' GLN . 0.0 OUTLIER -80.96 -22.59 39.43 Favored 'General case' 0 CA--C 1.508 -0.664 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.855 179.746 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 25.7 m-80 -64.42 -57.57 8.91 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 177.77 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -60.66 -39.4 96.53 Favored Glycine 0 N--CA 1.444 -0.784 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.633 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.36 -29.38 70.1 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.817 0.341 . . . . 0.0 111.423 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.401 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 1.0 OUTLIER -83.6 -43.14 15.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.041 0.448 . . . . 0.0 110.763 -177.936 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.577 ' O ' HG11 ' A' ' 17' ' ' VAL . 2.6 pttm -88.42 -3.16 58.88 Favored 'General case' 0 C--O 1.202 -1.442 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.748 -177.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.31 -22.18 64.72 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 171.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.8 mt -94.54 -29.88 14.67 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.059 -1.428 . . . . 0.0 109.454 174.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.577 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -79.27 -53.23 4.51 Favored Glycine 0 N--CA 1.444 -0.824 0 CA-C-N 114.977 -1.011 . . . . 0.0 111.98 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.631 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.4 p -72.6 -25.59 22.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.317 -0.442 . . . . 0.0 110.617 -175.716 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.99 -28.99 68.15 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.267 0.556 . . . . 0.0 109.916 173.008 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.5 m -89.34 3.88 50.71 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.577 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.5 mptm? -112.29 4.58 17.8 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.078 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.631 HG11 ' O ' ' A' ' 17' ' ' VAL . 7.2 m -134.35 -36.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.754 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.25 -49.92 11.75 Favored Pre-proline 0 C--N 1.318 -0.764 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.406 -179.478 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -71.41 -22.41 25.01 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.652 1.568 . . . . 0.0 111.153 -178.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.501 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -77.67 -45.34 28.62 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.402 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.233 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.496 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 83.7 t -69.01 -22.99 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.635 0 CA-C-O 122.021 0.915 . . . . 0.0 109.848 177.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.36 1.47 7.81 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.361 172.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -125.11 -15.16 6.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.465 174.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.496 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 52.7 m-85 -94.1 -30.47 14.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.063 0.458 . . . . 0.0 111.15 177.327 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -112.78 -47.1 3.08 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.073 -173.502 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.246 0.909 0 CA-C-O 119.075 -0.488 . . . . 0.0 112.073 -174.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 120.652 0.263 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 81.2 mt -98.17 129.28 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 CA-C-O 120.94 0.4 . . . . 0.0 110.505 -178.624 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 54.3 t-20 -113.68 131.74 56.04 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 176.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.589 ' O ' ' HB ' ' A' ' 7' ' ' ILE . 32.7 mmtp -112.37 -33.35 6.22 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.032 177.078 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 24.5 tp60 -59.49 -45.93 90.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.957 0.408 . . . . 0.0 110.667 -178.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.8 tttt -53.2 -34.16 55.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.832 0.825 . . . . 0.0 110.832 178.502 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.589 ' HB ' ' O ' ' A' ' 4' ' ' LYS . 1.2 mp -62.27 -31.17 50.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.423 -176.598 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.471 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -87.71 -25.08 23.64 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 177.076 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -60.81 -59.06 5.98 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.585 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.465 ' O ' ' HB2' ' A' ' 14' ' ' ALA . . . -65.81 -26.14 72.06 Favored Glycine 0 N--CA 1.443 -0.866 0 CA-C-N 115.157 -0.929 . . . . 0.0 112.229 179.778 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -76.77 -27.79 55.44 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.08 0.467 . . . . 0.0 110.653 177.437 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.91 -40.44 18.57 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.677 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.546 ' O ' HG11 ' A' ' 17' ' ' VAL . 10.2 pttt -85.57 -4.03 59.04 Favored 'General case' 0 C--O 1.201 -1.492 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.215 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.465 ' HB2' ' O ' ' A' ' 10' ' ' GLY . . . -66.16 -21.81 66.35 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 171.766 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.9 mt -91.42 -34.82 14.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 113.978 -1.464 . . . . 0.0 109.475 175.03 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.498 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -75.84 -54.45 5.35 Favored Glycine 0 N--CA 1.446 -0.699 0 CA-C-N 115.122 -0.945 . . . . 0.0 111.93 -179.262 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.629 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.7 p -70.01 -24.11 26.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.052 -0.574 . . . . 0.0 110.77 -175.827 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.445 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -59.67 -29.01 67.78 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.405 174.189 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.4 m -91.91 6.5 45.98 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.077 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.498 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 5.3 mptp? -114.86 7.17 15.65 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.18 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.632 ' O ' HG21 ' A' ' 24' ' ' VAL . 12.1 m -133.61 -37.36 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.986 -176.837 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.35 -47.1 70.84 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.476 179.365 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -74.52 -18.96 19.59 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 121.589 1.526 . . . . 0.0 111.654 -179.813 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.632 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -81.81 -43.99 19.97 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.152 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.485 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.2 t -67.2 -22.63 29.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 CA-C-O 121.932 0.872 . . . . 0.0 109.993 176.35 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.31 -10.8 60.35 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.532 174.25 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.52 -19.47 13.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.989 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.485 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 53.9 m-85 -90.89 -46.27 8.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.971 178.393 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -75.37 -48.97 20.51 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.156 178.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.405 HH11 ' HD2' ' A' ' 30' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.227 178.084 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 71.2 mmtt . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 121.006 0.432 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 82.3 mt -135.24 119.11 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.267 177.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.7 t30 -164.47 119.29 1.43 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.434 178.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.608 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 47.9 mmtm -93.3 -17.64 23.37 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.884 -175.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 46.9 tp60 -61.99 -42.74 99.48 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 176.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 29.2 ttpt -51.8 -35.5 44.39 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.767 176.711 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.608 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -57.32 -38.05 60.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.495 177.873 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.92 -32.82 59.77 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.764 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 25.8 m-80 -59.52 -56.34 23.25 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.719 179.638 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -62.78 -36.68 93.68 Favored Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.19 -0.914 . . . . 0.0 112.275 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.72 -30.73 67.35 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.876 0.37 . . . . 0.0 111.203 179.123 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 8.8 tmtt? -80.5 -38.45 29.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.004 0.43 . . . . 0.0 110.967 -178.793 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.504 ' O ' HG11 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -87.3 -7.04 58.27 Favored 'General case' 0 C--O 1.2 -1.54 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 178.576 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.92 -22.61 67.03 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 172.042 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 mt -91.79 -35.21 14.24 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.553 174.186 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.517 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -75.65 -51.57 7.11 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.105 -0.952 . . . . 0.0 112.468 -178.485 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.603 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.4 p -71.39 -23.27 22.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.254 0.55 . . . . 0.0 110.332 -177.06 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.33 68.05 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.973 172.85 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.7 m -89.31 4.94 47.18 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.517 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.9 mptt -112.69 4.02 16.91 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.271 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.625 ' O ' HG21 ' A' ' 24' ' ' VAL . 6.1 m -135.71 -35.82 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.608 -174.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -71.35 -49.12 12.31 Favored Pre-proline 0 C--N 1.316 -0.863 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.584 -179.509 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 7.3 Cg_exo -71.46 -19.94 27.96 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 121.753 1.635 . . . . 0.0 111.28 -178.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.625 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -77.21 -44.44 30.83 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.322 0 C-N-CA 120.406 -0.517 . . . . 0.0 109.875 178.547 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.486 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 99.4 t -68.78 -24.06 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.763 0 CA-C-O 121.851 0.834 . . . . 0.0 110.048 177.242 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -75.18 0.61 15.78 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.432 174.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.54 -21.82 8.99 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.785 172.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.486 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -86.52 -48.07 8.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.522 178.419 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -75.14 -48.23 24.71 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.602 178.087 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 34.2 mtm180 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.502 -0.761 . . . . 0.0 111.016 176.041 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 14.6 mmmm . . . . . 0 N--CA 1.479 1.0 0 CA-C-O 120.825 0.345 . . . . 0.0 110.975 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 80.4 mt -122.74 129.82 74.91 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.596 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 178.998 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -119.43 119.01 32.66 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.067 0.461 . . . . 0.0 110.585 177.279 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.563 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 33.7 mmtp -100.81 -20.75 15.39 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.663 179.616 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . 0.515 ' HG3' ' ND2' ' A' ' 9' ' ' ASN . 24.5 tp60 -60.03 -38.18 81.95 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.928 -179.665 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -56.91 -42.31 79.7 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.421 176.452 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.563 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.9 mp -54.69 -38.42 43.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.47 ' HD3' ' NE2' ' A' ' 5' ' ' GLN . 0.0 OUTLIER -81.99 -35.94 28.39 Favored 'General case' 0 CA--C 1.507 -0.7 0 C-N-CA 119.43 -0.908 . . . . 0.0 109.578 178.532 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.515 ' ND2' ' HG3' ' A' ' 5' ' ' GLN . 12.6 m-80 -60.77 -51.15 70.55 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.659 -0.416 . . . . 0.0 111.177 -176.715 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.44 -30.41 77.5 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.078 179.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.69 -22.84 42.9 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.16 0.505 . . . . 0.0 110.833 178.437 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.486 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 4.8 tmtm? -88.5 -43.44 11.43 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.102 -178.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.541 ' O ' HG11 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -77.32 -11.26 59.81 Favored 'General case' 0 C--O 1.199 -1.564 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.584 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.448 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -63.89 -22.11 66.77 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 172.667 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.9 mt -97.12 -32.16 12.1 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.631 174.348 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.543 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -72.97 -52.29 9.3 Favored Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.034 -0.985 . . . . 0.0 111.664 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.671 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.3 p -72.82 -24.12 21.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.909 -0.646 . . . . 0.0 110.302 -177.329 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.448 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -58.13 -28.03 64.3 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.39 173.68 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 m -93.39 5.87 50.08 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.543 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.0 OUTLIER -114.41 5.05 15.51 Favored 'General case' 0 N--CA 1.44 -0.967 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.229 178.712 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.671 HG11 ' O ' ' A' ' 17' ' ' VAL . 11.5 m -133.44 -32.03 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.063 -174.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -79.23 -46.39 1.65 Allowed Pre-proline 0 C--N 1.316 -0.871 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.79 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 8.4 Cg_exo -72.19 -23.25 21.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 121.633 1.555 . . . . 0.0 111.174 179.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.49 HG21 ' O ' ' A' ' 21' ' ' VAL . 5.3 m -71.57 -45.06 69.42 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.918 179.088 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.487 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.3 t -68.27 -24.99 30.5 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.7 0.762 . . . . 0.0 109.943 176.596 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.484 ' HB2' ' NH2' ' A' ' 30' ' ' ARG . . . -72.62 -5.72 39.29 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.54 174.499 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.71 -27.25 9.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.94 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.487 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.7 m-85 -81.8 -36.95 27.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.447 179.197 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.457 ' HB1' ' O ' ' A' ' 25' ' ' VAL . . . -82.48 -49.49 9.87 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.095 177.023 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.484 ' NH2' ' HB2' ' A' ' 26' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.814 -0.612 . . . . 0.0 110.648 177.275 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 30.5 ttpt . . . . . 0 N--CA 1.48 1.037 0 CA-C-O 121.119 0.485 . . . . 0.0 110.263 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 41.0 mm -128.83 133.51 66.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.451 -178.737 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -146.44 112.84 5.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.227 0.536 . . . . 0.0 109.732 173.97 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.603 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 74.5 mmtt -86.28 -22.63 26.69 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.222 -174.487 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 24.7 tp60 -60.86 -38.61 86.17 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 174.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.404 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 36.7 tttp -52.9 -37.51 60.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.734 177.164 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.603 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 3.1 mp -57.78 -35.51 51.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.317 178.813 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.4 mptt -82.95 -23.42 33.45 Favored 'General case' 0 CA--C 1.504 -0.806 0 C-N-CA 120.081 -0.648 . . . . 0.0 109.578 176.57 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.404 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 11.7 m-80 -60.92 -59.99 4.5 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.375 -0.53 . . . . 0.0 109.726 -178.219 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.29 -26.36 71.61 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.29 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -77.06 -29.17 54.96 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.196 0.522 . . . . 0.0 110.855 178.928 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.453 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 7.1 tmtt? -85.3 -41.82 15.18 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.82 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.539 ' O ' HG11 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -80.63 -9.88 59.76 Favored 'General case' 0 C--O 1.203 -1.392 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.628 -177.817 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -67.44 -20.84 65.55 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.323 -0.951 . . . . 0.0 108.762 173.93 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.8 mt -97.71 -32.02 11.96 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.104 -1.407 . . . . 0.0 109.073 172.785 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.595 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -74.38 -55.23 5.71 Favored Glycine 0 N--CA 1.443 -0.881 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.797 -177.687 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.625 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.1 p -71.22 -25.93 26.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 114.983 -0.609 . . . . 0.0 110.573 -175.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.24 -23.47 65.66 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.203 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.8 m -94.25 2.51 55.88 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.595 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 14.0 mptt -112.31 7.96 19.48 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.331 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.668 ' O ' HG21 ' A' ' 24' ' ' VAL . 12.6 m -135.37 -37.6 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.09 -175.092 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -62.77 -46.67 88.24 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.68 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 3.7 Cg_exo -73.98 -21.55 18.22 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.639 1.56 . . . . 0.0 111.356 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.668 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.4 m -80.87 -40.05 18.44 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.302 -179.214 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.484 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 90.9 t -69.82 -23.12 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 CA-C-O 121.598 0.713 . . . . 0.0 109.84 175.435 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.08 -18.46 63.26 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.154 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -94.42 -20.7 19.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.386 -0.824 . . . . 0.0 109.707 176.106 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.484 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 41.3 m-85 -85.59 -39.9 16.84 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.8 176.514 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.452 ' HB3' ' HD3' ' A' ' 30' ' ' ARG . . . -73.02 -59.74 2.56 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.329 -177.765 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.452 ' HD3' ' HB3' ' A' ' 29' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.001 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.596 176.012 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 10.1 ptpp? . . . . . 0 N--CA 1.48 1.03 0 CA-C-O 120.806 0.336 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.85 125.84 74.42 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.18 179.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -150.01 116.71 5.85 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.845 177.722 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.62 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 5.0 mptp? -88.15 -24.65 23.29 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.932 -174.852 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . 0.406 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 8.5 tp-100 -61.04 -36.96 80.97 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.581 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.408 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 37.2 tttp -52.58 -35.74 54.61 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.791 176.43 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.62 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.4 mp -56.44 -37.9 53.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.733 176.908 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.406 ' HD3' ' HA ' ' A' ' 5' ' ' GLN . 7.9 mptt -79.04 -22.66 45.08 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 177.269 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.408 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -60.6 -57.15 13.92 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.949 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.16 -35.78 90.93 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-N 114.775 -1.102 . . . . 0.0 112.058 178.238 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.22 -35.42 81.0 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.07 0.462 . . . . 0.0 111.077 179.5 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -80.06 -38.48 31.76 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.034 -178.341 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.545 ' O ' HG11 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -81.32 -11.02 59.45 Favored 'General case' 0 C--O 1.2 -1.502 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 178.706 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.56 -22.56 67.0 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.915 0.864 . . . . 0.0 108.713 172.775 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 mt -92.76 -36.37 12.93 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 114.07 -1.423 . . . . 0.0 109.246 173.479 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.541 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -70.08 -53.66 13.87 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.484 -178.888 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.642 ' O ' HG11 ' A' ' 21' ' ' VAL . 2.1 p -68.93 -28.48 39.75 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 CA-C-N 114.908 -0.646 . . . . 0.0 110.779 -178.01 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.0 -26.26 65.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.36 0.6 . . . . 0.0 110.178 174.279 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.49 1.75 56.91 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.541 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 5.8 mptp? -113.39 6.55 17.27 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.166 -0.924 . . . . 0.0 109.369 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.661 ' O ' HG21 ' A' ' 24' ' ' VAL . 12.7 m -133.52 -37.51 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.274 -175.859 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.54 -45.5 76.77 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.696 -179.955 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -73.92 -20.78 19.21 Favored 'Trans proline' 0 N--CA 1.454 -0.853 0 C-N-CA 121.448 1.432 . . . . 0.0 111.46 179.669 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.661 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -82.96 -41.83 17.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.642 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.495 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.1 t -66.31 -24.73 33.96 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 CA-C-O 121.899 0.857 . . . . 0.0 109.814 176.308 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.03 -7.25 45.04 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.676 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.86 -23.88 10.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.008 174.952 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.497 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 44.0 m-85 -83.32 -43.7 15.7 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.256 178.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.36 -50.76 10.35 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.951 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.458 -0.782 . . . . 0.0 110.129 178.004 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 49.1 mmtm . . . . . 0 N--CA 1.48 1.039 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.1 mp -82.61 125.55 39.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.095 0.474 . . . . 0.0 110.962 -177.509 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -169.17 125.36 0.91 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.618 178.782 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.626 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 47.6 mmtm -92.2 -21.8 20.17 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-O 120.894 0.378 . . . . 0.0 110.394 -175.299 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . 0.406 ' C ' HD21 ' A' ' 9' ' ' ASN . 52.6 tt0 -65.74 -35.11 79.81 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 174.363 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.459 ' HA ' ' HB2' ' A' ' 9' ' ' ASN . 29.6 ttpt -51.11 -35.75 36.95 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.646 176.37 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.626 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.4 mp -55.28 -40.76 58.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.329 177.209 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -80.32 -29.7 38.08 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 177.487 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.482 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 24.0 m-80 -58.94 -57.79 11.53 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.649 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.82 -34.59 89.26 Favored Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.846 178.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.53 -22.69 61.74 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.097 0.475 . . . . 0.0 110.739 178.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.432 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 1.0 OUTLIER -90.75 -45.4 8.86 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.753 178.701 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.595 ' O ' HG11 ' A' ' 17' ' ' VAL . 24.0 pttt -81.06 -2.9 49.99 Favored 'General case' 0 C--O 1.206 -1.232 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.996 -177.534 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -71.06 -17.85 62.58 Favored 'General case' 0 C--N 1.312 -1.04 0 O-C-N 121.043 -1.035 . . . . 0.0 108.506 173.034 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 mt -101.85 -24.92 13.97 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 113.874 -1.512 . . . . 0.0 109.264 173.837 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.584 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -82.83 -55.42 2.98 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.722 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.625 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.1 p -75.03 -24.37 17.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.27 -0.465 . . . . 0.0 110.605 -175.251 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.76 -32.83 69.64 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.329 0.585 . . . . 0.0 109.818 172.999 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 66.1 m -86.36 4.44 39.29 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.123 -179.383 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . 0.584 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.2 mptm? -113.76 3.43 15.54 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.223 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.625 HG11 ' O ' ' A' ' 17' ' ' VAL . 5.6 m -134.56 -38.42 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.326 -176.226 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -67.72 -50.04 36.42 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.397 -178.501 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 8.3 Cg_exo -71.04 -22.62 25.99 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.647 1.565 . . . . 0.0 111.153 -178.038 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.601 HG21 ' O ' ' A' ' 21' ' ' VAL . 2.8 m -78.47 -44.08 26.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.251 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 95.6 t -68.77 -24.2 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.802 0 CA-C-O 121.909 0.861 . . . . 0.0 110.07 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.77 -5.35 33.43 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.445 173.969 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.76 -19.16 11.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.285 174.301 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.53 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 44.9 m-85 -87.66 -43.06 12.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.602 177.64 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.31 -55.5 4.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.131 -177.825 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.448 ' HD3' ' N ' ' A' ' 30' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.038 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.946 -178.614 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm . . . . . 0 N--CA 1.481 1.086 0 CA-C-O 120.957 0.408 . . . . 0.0 110.794 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 41.1 mm -95.37 132.14 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.92 177.736 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 20.5 t30 -162.92 117.17 1.7 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.41 -179.297 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' LYS . . . . . 0.581 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 34.7 mmtp -79.69 -22.14 43.81 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.458 -171.193 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 26.2 tp60 -64.6 -39.68 94.16 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 173.903 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.746 ' HA ' ' OD1' ' A' ' 9' ' ' ASN . 29.6 ttpt -61.09 -32.67 72.33 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.853 179.234 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.581 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 1.7 mp -55.25 -35.6 36.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.586 175.372 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' LYS . . . . . 0.431 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 0.1 OUTLIER -82.45 -22.85 35.06 Favored 'General case' 0 CA--C 1.511 -0.525 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.204 177.035 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ASN . . . . . 0.746 ' OD1' ' HA ' ' A' ' 6' ' ' LYS . 4.6 m120 -62.49 -56.06 21.67 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.149 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.418 ' O ' ' HB2' ' A' ' 14' ' ' ALA . . . -67.84 -28.23 73.5 Favored Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 114.653 -1.158 . . . . 0.0 112.385 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.46 -30.23 63.04 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.013 0.435 . . . . 0.0 110.778 178.556 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -83.27 -37.58 23.31 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.935 -178.509 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.52 ' O ' HG11 ' A' ' 17' ' ' VAL . 12.3 pttt -87.78 -3.99 58.91 Favored 'General case' 0 C--O 1.2 -1.502 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 177.378 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' ALA . . . . . 0.526 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -64.55 -21.34 66.66 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 172.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 mt -90.77 -37.41 13.68 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 113.694 -1.594 . . . . 0.0 109.673 175.317 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.71 -53.91 5.67 Favored Glycine 0 CA--C 1.509 -0.338 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.298 -179.528 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.585 ' O ' HG11 ' A' ' 21' ' ' VAL . 1.1 p -70.83 -16.97 20.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.118 -0.541 . . . . 0.0 110.696 -176.886 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ALA . . . . . 0.526 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -56.89 -29.06 62.64 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.527 172.717 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 57.7 m -90.32 4.19 51.49 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.794 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -112.24 6.65 19.08 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.128 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' VAL . . . . . 0.668 ' O ' HG21 ' A' ' 24' ' ' VAL . 9.3 m -134.81 -37.01 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.082 -175.653 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -63.23 -46.62 85.68 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.724 179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -73.28 -21.55 19.94 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.691 1.594 . . . . 0.0 111.446 -179.822 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . 0.668 HG21 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -82.06 -41.12 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.425 -178.751 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . 0.513 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.8 t -67.86 -24.15 30.22 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 CA-C-O 121.919 0.866 . . . . 0.0 109.646 176.097 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' ALA . . . . . 0.491 ' HB2' ' NH2' ' A' ' 30' ' ' ARG . . . -71.64 -1.58 14.17 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.761 -1.109 . . . . 0.0 110.566 173.776 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.69 -22.18 8.15 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.208 173.833 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' PHE . . . . . 0.513 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.0 m-85 -85.68 -35.95 20.57 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-O 121.258 0.551 . . . . 0.0 110.591 178.289 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.79 -50.62 6.35 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.849 177.512 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' ARG . . . . . 0.491 ' NH2' ' HB2' ' A' ' 26' ' ' ALA . 42.9 mtm180 . . . . . 0 C--O 1.248 0.991 0 CA-C-O 118.886 -0.578 . . . . 0.0 111.491 177.651 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.528 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.6 p . . . . . 0 CA--C 1.515 -0.403 0 CA-C-O 121.102 0.477 . . . . 0.0 110.529 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.89 -26.16 67.99 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.948 172.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 21.4 m -91.68 6.65 45.04 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.01 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.424 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 13.8 mptt -113.99 9.05 17.31 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.16 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.599 ' O ' HG22 ' A' ' 24' ' ' VAL . 8.4 m -140.94 -37.16 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.282 -174.258 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.479 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.59 -48.13 65.82 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.669 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.479 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.7 Cg_exo -71.02 -23.59 24.91 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 121.625 1.55 . . . . 0.0 111.358 -178.641 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.599 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.1 m -78.86 -42.16 24.33 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.3 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.55 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.517 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.6 t -69.01 -25.27 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 121.842 0.829 . . . . 0.0 110.059 177.669 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.22 -8.74 48.57 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.402 173.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -106.83 -30.28 9.0 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.068 174.165 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.517 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 41.4 m-85 -77.59 -36.21 52.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.425 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.783 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.806 -179.148 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.523 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 N--CA 1.45 -0.457 0 CA-C-O 121.06 0.457 . . . . 0.0 110.464 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.93 -23.61 67.41 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.521 0.677 . . . . 0.0 109.92 171.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 23.5 m -93.23 6.59 47.5 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.564 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.416 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 13.2 mptt -113.04 6.6 17.73 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.883 -1.053 . . . . 0.0 108.935 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.588 ' O ' HG22 ' A' ' 24' ' ' VAL . 12.9 m -133.77 -37.81 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.359 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.519 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.16 -48.75 68.97 Favored Pre-proline 0 C--N 1.322 -0.611 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.223 178.622 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.519 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 11.8 Cg_exo -70.24 -24.37 27.54 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 121.637 1.558 . . . . 0.0 111.424 -179.359 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.588 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.02 -42.0 27.62 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.467 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.437 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.491 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.5 t -67.42 -25.57 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.785 0 CA-C-O 121.755 0.788 . . . . 0.0 109.841 176.58 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.54 -5.88 32.26 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.668 174.027 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.2 -26.46 9.17 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.03 174.242 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.491 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.5 m-85 -82.29 -33.84 28.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.668 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.639 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.01 -178.983 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.619 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.3 p . . . . . 0 CA--C 1.514 -0.436 0 CA-C-O 121.311 0.577 . . . . 0.0 110.305 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.15 -22.85 65.08 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.518 173.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.4 m -95.08 3.14 55.14 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 177.704 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.476 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.5 mptp? -113.83 8.34 17.32 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.031 -0.986 . . . . 0.0 109.438 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.619 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.0 m -135.64 -36.31 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.286 -175.803 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.473 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.73 -47.76 54.78 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.649 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.473 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.8 Cg_exo -72.75 -21.74 21.25 Favored 'Trans proline' 0 C--N 1.353 0.804 0 C-N-CA 121.829 1.686 . . . . 0.0 111.339 -179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -78.7 -42.4 25.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.275 179.523 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.52 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.3 t -68.37 -24.89 30.17 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.879 0 CA-C-O 121.858 0.837 . . . . 0.0 109.963 177.085 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.68 -8.65 53.55 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.821 -1.082 . . . . 0.0 110.475 174.117 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 -24.16 11.2 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.166 175.153 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.52 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 42.3 m-85 -83.08 -40.81 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.433 178.699 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.305 179.879 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.515 -0.387 0 CA-C-O 121.205 0.526 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.23 -25.42 64.01 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.443 173.162 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -95.18 7.33 46.48 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-O 121.644 0.735 . . . . 0.0 109.124 178.52 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -112.36 7.04 19.08 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-N 115.104 -0.953 . . . . 0.0 108.975 179.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.566 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.6 m -133.51 -36.28 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.272 -175.244 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.489 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.9 -47.82 52.82 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.49 178.783 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.489 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 9.3 Cg_exo -71.7 -23.11 23.17 Favored 'Trans proline' 0 C--N 1.353 0.806 0 C-N-CA 121.848 1.698 . . . . 0.0 111.494 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 21' ' ' VAL . 4.5 m -77.9 -42.22 28.27 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.483 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.508 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 87.5 t -68.12 -23.42 28.78 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.942 0 CA-C-O 121.872 0.844 . . . . 0.0 109.453 174.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.14 -5.74 41.11 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.557 173.566 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.11 -21.99 11.67 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.833 173.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.508 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.1 m-85 -86.12 -29.97 22.89 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.388 0.613 . . . . 0.0 110.01 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.766 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.03 176.149 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.443 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.514 -0.431 0 CA-C-O 121.627 0.727 . . . . 0.0 109.86 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.47 -25.71 68.13 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.901 171.039 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.5 m -89.62 5.63 44.84 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -109.4 5.43 23.44 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.114 179.414 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.629 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.2 m -135.99 -36.76 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.372 -173.417 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.441 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.33 -46.1 84.84 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.818 179.008 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.441 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.6 -22.19 21.23 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 121.795 1.663 . . . . 0.0 111.491 179.584 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.629 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -81.32 -41.6 19.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.494 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 21' ' ' VAL . 89.7 t -67.3 -24.66 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.714 0 CA-C-O 121.911 0.862 . . . . 0.0 109.704 176.461 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.21 -3.45 20.3 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.646 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.24 -17.91 10.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.188 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.8 m-85 -90.11 -42.82 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.828 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.704 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.926 -176.788 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.538 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.5 p . . . . . 0 CA--C 1.514 -0.44 0 CA-C-O 121.35 0.595 . . . . 0.0 110.037 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.21 -25.4 67.78 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.51 171.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.1 t -90.41 3.4 53.91 Favored 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.408 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 13.6 mptt -111.44 7.05 20.66 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.166 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.612 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.4 m -135.21 -37.83 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.341 -175.55 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.501 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.59 -48.78 80.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.392 179.169 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.501 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.2 Cg_exo -71.71 -23.47 22.72 Favored 'Trans proline' 0 C--N 1.353 0.778 0 C-N-CA 121.61 1.54 . . . . 0.0 111.379 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -78.65 -41.81 24.98 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.272 -179.132 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.509 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 88.4 t -67.34 -24.57 31.87 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 CA-C-O 121.923 0.868 . . . . 0.0 109.798 176.516 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.48 0.78 9.41 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.52 174.173 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.73 -22.48 6.84 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.209 173.031 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.509 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.9 m-85 -86.82 -34.87 19.39 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.956 178.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.777 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.251 179.653 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.477 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.509 -0.634 0 CA-C-O 121.242 0.544 . . . . 0.0 110.049 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.56 -24.29 66.55 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.784 170.617 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.7 m -93.27 8.29 40.91 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.276 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -114.91 7.52 15.68 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.771 -1.104 . . . . 0.0 108.888 178.279 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.623 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.6 m -136.71 -35.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.788 -175.878 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.467 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -64.11 -47.16 79.97 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 177.881 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.467 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.25 -22.81 21.67 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.633 1.555 . . . . 0.0 111.325 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.98 -40.29 22.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.332 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.204 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.502 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.7 t -68.9 -25.25 29.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.947 0 CA-C-O 121.676 0.75 . . . . 0.0 109.566 174.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.03 -3.39 22.62 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.519 173.419 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.83 -28.57 8.71 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.701 172.526 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.502 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.5 m-85 -80.99 -31.05 34.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.661 179.199 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.769 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.972 177.3 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.582 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.5 p . . . . . 0 CA--C 1.517 -0.296 0 CA-C-O 121.116 0.484 . . . . 0.0 111.017 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.27 -22.34 65.93 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.447 174.343 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.4 m -100.03 9.15 43.34 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.139 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.4 mptm? -114.48 9.06 16.66 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.122 178.161 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 17' ' ' VAL . 14.1 m -131.99 -35.93 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.113 -175.818 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.485 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -70.13 -47.84 20.79 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.351 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 5.0 Cg_exo -73.73 -20.05 20.51 Favored 'Trans proline' 0 C--N 1.352 0.759 0 C-N-CA 121.868 1.712 . . . . 0.0 111.596 -179.631 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 21' ' ' VAL . 4.4 m -78.73 -42.86 25.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.383 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.185 178.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.49 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.4 t -66.93 -24.3 32.25 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.596 0 CA-C-O 121.972 0.891 . . . . 0.0 109.691 175.414 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.07 -0.62 14.52 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.504 174.2 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.68 -22.17 8.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.948 173.375 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.49 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.2 m-85 -87.38 -40.99 13.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.889 179.488 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.765 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.744 179.38 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.503 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.515 -0.384 0 CA-C-O 121.311 0.577 . . . . 0.0 110.442 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.53 -18.67 65.04 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.229 172.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.5 t -99.84 7.85 44.63 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 177.077 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.431 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 4.9 mptp? -114.08 11.59 17.69 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.089 -0.96 . . . . 0.0 108.97 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.609 ' O ' HG22 ' A' ' 24' ' ' VAL . 13.5 m -138.03 -37.37 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 114.713 -1.131 . . . . 0.0 109.969 -175.434 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.487 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.87 -48.08 52.49 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.551 178.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.487 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 12.0 Cg_exo -70.51 -24.25 26.47 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 121.627 1.551 . . . . 0.0 111.412 -179.209 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.609 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.8 m -75.85 -43.22 39.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.316 -0.554 . . . . 0.0 110.199 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 21' ' ' VAL . 94.8 t -69.2 -25.88 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 CA-C-O 121.477 0.656 . . . . 0.0 110.282 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.28 -16.57 64.35 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.279 173.731 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -98.46 -27.5 14.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.069 176.292 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.475 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 51.1 m-85 -83.24 -26.14 31.03 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.018 178.566 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.66 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.542 179.339 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.521 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.2 p . . . . . 0 CA--C 1.512 -0.512 0 CA-C-O 121.258 0.551 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.02 -27.78 68.57 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.914 170.847 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.3 m -89.69 6.02 43.28 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -111.89 5.89 19.19 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.809 -1.087 . . . . 0.0 108.854 178.349 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.604 ' O ' HG22 ' A' ' 24' ' ' VAL . 7.5 m -135.98 -37.76 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.38 -175.352 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.494 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.2 -48.61 68.82 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.707 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.494 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.7 Cg_exo -72.01 -22.09 23.4 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 121.554 1.503 . . . . 0.0 111.371 -179.023 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -79.57 -41.42 22.17 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.279 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.5 t -67.51 -24.11 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.779 0 CA-C-O 121.846 0.831 . . . . 0.0 109.674 176.558 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.57 2.6 9.36 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.519 174.705 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.98 -22.64 6.1 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.081 172.516 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -84.98 -41.6 15.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-O 121.297 0.57 . . . . 0.0 110.361 178.494 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.683 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.357 177.584 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.6 p . . . . . 0 CA--C 1.515 -0.366 0 CA-C-O 121.189 0.518 . . . . 0.0 110.721 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.12 -31.15 68.68 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.121 172.763 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -90.61 8.54 33.68 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.408 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.1 mptm? -112.42 5.19 17.96 Favored 'General case' 0 N--CA 1.437 -1.076 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.854 178.046 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.658 ' O ' HG22 ' A' ' 24' ' ' VAL . 5.8 m -136.3 -36.96 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.596 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.516 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -69.8 -47.79 23.35 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.684 179.567 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.516 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 11.0 Cg_exo -70.14 -22.22 30.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.797 1.665 . . . . 0.0 111.419 -179.512 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.658 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -76.79 -42.42 33.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.137 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.479 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 93.1 t -68.13 -25.14 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.715 0 CA-C-O 121.833 0.825 . . . . 0.0 109.682 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.05 0.51 11.22 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.664 174.057 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.63 -22.32 8.13 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.037 172.764 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.479 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.4 m-85 -85.95 -41.61 14.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.846 178.618 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.72 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.803 -178.695 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.581 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.8 p . . . . . 0 CA--C 1.514 -0.418 0 CA-C-O 121.332 0.587 . . . . 0.0 110.423 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.67 -28.13 67.0 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.433 173.524 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.6 m -93.08 5.96 49.65 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.287 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.421 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 0.9 OUTLIER -111.48 8.02 20.95 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.849 179.507 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.621 ' O ' HG22 ' A' ' 24' ' ' VAL . 5.4 m -136.56 -39.93 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.435 -175.966 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.52 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.1 -49.05 58.18 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.74 -178.435 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.52 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.28 -21.32 23.41 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 121.65 1.566 . . . . 0.0 111.396 -178.806 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.0 m -78.73 -43.19 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.374 -0.531 . . . . 0.0 110.027 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.6 t -68.34 -23.85 28.91 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.721 0 CA-C-O 121.922 0.868 . . . . 0.0 109.975 176.89 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.88 -5.15 28.45 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.205 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.18 -25.11 9.05 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.349 174.28 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.9 m-85 -85.39 -31.93 22.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.968 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.791 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.489 -179.504 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.612 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.4 p . . . . . 0 CA--C 1.514 -0.434 0 CA-C-O 120.923 0.392 . . . . 0.0 110.617 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.99 -28.99 68.15 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.267 0.556 . . . . 0.0 109.916 173.008 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.5 m -89.34 3.88 50.71 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.464 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.5 mptm? -112.29 4.58 17.8 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.078 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.612 HG13 ' O ' ' A' ' 17' ' ' VAL . 7.2 m -134.35 -36.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.754 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.518 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -71.25 -49.92 11.75 Favored Pre-proline 0 C--N 1.318 -0.764 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.406 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.518 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.8 Cg_exo -71.41 -22.41 25.01 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.652 1.568 . . . . 0.0 111.153 -178.261 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.481 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -77.67 -45.34 28.62 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.402 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.233 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 83.7 t -69.01 -22.99 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.635 0 CA-C-O 122.021 0.915 . . . . 0.0 109.848 177.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.36 1.47 7.81 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.361 172.977 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -125.11 -15.16 6.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.465 174.27 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 52.7 m-85 -94.1 -30.47 14.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.063 0.458 . . . . 0.0 111.15 177.327 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.651 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.073 -173.502 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.608 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.513 -0.449 0 CA-C-O 121.026 0.441 . . . . 0.0 110.77 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.67 -29.01 67.78 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.405 174.189 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.4 m -91.91 6.5 45.98 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.077 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.487 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.3 mptp? -114.86 7.17 15.65 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.18 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.608 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.1 m -133.61 -37.36 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.986 -176.837 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.451 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.35 -47.1 70.84 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.476 179.365 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.451 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 4.0 Cg_exo -74.52 -18.96 19.59 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 121.589 1.526 . . . . 0.0 111.654 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.582 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -81.81 -43.99 19.97 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.152 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.495 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.2 t -67.2 -22.63 29.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 CA-C-O 121.932 0.872 . . . . 0.0 109.993 176.35 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.31 -10.8 60.35 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.532 174.25 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.52 -19.47 13.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.989 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.495 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 53.9 m-85 -90.89 -46.27 8.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.971 178.393 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.69 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.156 178.828 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.583 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.4 p . . . . . 0 CA--C 1.513 -0.469 0 CA-C-O 121.254 0.55 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.33 68.05 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.973 172.85 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.7 m -89.31 4.94 47.18 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.759 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.401 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 13.9 mptt -112.69 4.02 16.91 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.271 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.612 ' O ' HG22 ' A' ' 24' ' ' VAL . 6.1 m -135.71 -35.82 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.608 -174.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.503 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -71.35 -49.12 12.31 Favored Pre-proline 0 C--N 1.316 -0.863 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.584 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.503 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.3 Cg_exo -71.46 -19.94 27.96 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 121.753 1.635 . . . . 0.0 111.28 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -77.21 -44.44 30.83 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.322 0 C-N-CA 120.406 -0.517 . . . . 0.0 109.875 178.547 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.477 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 99.4 t -68.78 -24.06 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.763 0 CA-C-O 121.851 0.834 . . . . 0.0 110.048 177.242 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -75.18 0.61 15.78 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.432 174.694 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.54 -21.82 8.99 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.785 172.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.477 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -86.52 -48.07 8.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.522 178.419 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.641 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.602 178.087 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.3 p . . . . . 0 CA--C 1.512 -0.485 0 CA-C-O 121.124 0.488 . . . . 0.0 110.302 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.13 -28.03 64.3 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.39 173.68 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 m -93.39 5.87 50.08 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.439 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.0 OUTLIER -114.41 5.05 15.51 Favored 'General case' 0 N--CA 1.44 -0.967 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.229 178.712 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 17' ' ' VAL . 11.5 m -133.44 -32.03 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.063 -174.744 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.48 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -79.23 -46.39 1.65 Allowed Pre-proline 0 C--N 1.316 -0.871 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.79 -179.626 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.4 Cg_exo -72.19 -23.25 21.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 121.633 1.555 . . . . 0.0 111.174 179.453 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 21' ' ' VAL . 5.3 m -71.57 -45.06 69.42 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.918 179.088 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.487 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.3 t -68.27 -24.99 30.5 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.7 0.762 . . . . 0.0 109.943 176.596 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.62 -5.72 39.29 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.54 174.499 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.71 -27.25 9.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.94 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.487 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.7 m-85 -81.8 -36.95 27.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.447 179.197 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.777 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.095 177.023 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.586 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.511 -0.555 0 CA-C-O 121.185 0.517 . . . . 0.0 110.573 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.24 -23.47 65.66 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.203 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.8 m -94.25 2.51 55.88 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.448 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 14.0 mptt -112.31 7.96 19.48 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.331 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.611 ' O ' HG22 ' A' ' 24' ' ' VAL . 12.6 m -135.37 -37.6 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.09 -175.092 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.44 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -62.77 -46.67 88.24 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.68 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 3.7 Cg_exo -73.98 -21.55 18.22 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.639 1.56 . . . . 0.0 111.356 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.4 m -80.87 -40.05 18.44 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.302 -179.214 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 21' ' ' VAL . 90.9 t -69.82 -23.12 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 CA-C-O 121.598 0.713 . . . . 0.0 109.84 175.435 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.08 -18.46 63.26 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.154 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -94.42 -20.7 19.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.386 -0.824 . . . . 0.0 109.707 176.106 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.479 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 41.3 m-85 -85.59 -39.9 16.84 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.8 176.514 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.743 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.329 -177.765 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.61 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.1 p . . . . . 0 CA--C 1.512 -0.489 0 CA-C-O 120.902 0.382 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 21' ' ' VAL . . . -60.0 -26.26 65.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.36 0.6 . . . . 0.0 110.178 174.279 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.49 1.75 56.91 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.438 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.8 mptp? -113.39 6.55 17.27 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.166 -0.924 . . . . 0.0 109.369 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.61 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.7 m -133.52 -37.51 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.274 -175.859 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.42 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -64.54 -45.5 76.77 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.696 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.42 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 3.1 Cg_exo -73.92 -20.78 19.21 Favored 'Trans proline' 0 N--CA 1.454 -0.853 0 C-N-CA 121.448 1.432 . . . . 0.0 111.46 179.669 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -82.96 -41.83 17.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.642 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.506 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.1 t -66.31 -24.73 33.96 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 CA-C-O 121.899 0.857 . . . . 0.0 109.814 176.308 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.03 -7.25 45.04 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.676 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.86 -23.88 10.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.008 174.952 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.506 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.0 m-85 -83.32 -43.7 15.7 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.256 178.798 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.707 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.951 178.642 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.588 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.509 -0.614 0 CA-C-O 120.911 0.386 . . . . 0.0 110.605 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.76 -32.83 69.64 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.329 0.585 . . . . 0.0 109.818 172.999 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 66.1 m -86.36 4.44 39.29 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.123 -179.383 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' LYS . . . . . 0.447 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.2 mptm? -113.76 3.43 15.54 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.223 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 17' ' ' VAL . 5.6 m -134.56 -38.42 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.326 -176.226 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.513 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -67.72 -50.04 36.42 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.397 -178.501 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.513 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.3 Cg_exo -71.04 -22.62 25.99 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.647 1.565 . . . . 0.0 111.153 -178.038 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.583 HG22 ' O ' ' A' ' 21' ' ' VAL . 2.8 m -78.47 -44.08 26.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.251 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 95.6 t -68.77 -24.2 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.802 0 CA-C-O 121.909 0.861 . . . . 0.0 110.07 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.77 -5.35 33.43 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.445 173.969 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.76 -19.16 11.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.285 174.301 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.53 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 44.9 m-85 -87.66 -43.06 12.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.602 177.64 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.322 -0.604 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.131 -177.825 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 0.56 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.514 -0.433 0 CA-C-O 121.168 0.508 . . . . 0.0 110.696 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.89 -29.06 62.64 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.527 172.717 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 57.7 m -90.32 4.19 51.49 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.794 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -112.24 6.65 19.08 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.128 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' VAL . . . . . 0.62 ' O ' HG22 ' A' ' 24' ' ' VAL . 9.3 m -134.81 -37.01 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.082 -175.653 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . 0.445 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.23 -46.62 85.68 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.724 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' PRO . . . . . 0.445 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.1 Cg_exo -73.28 -21.55 19.94 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.691 1.594 . . . . 0.0 111.446 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.62 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -82.06 -41.12 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.425 -178.751 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . 0.516 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.8 t -67.86 -24.15 30.22 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 CA-C-O 121.919 0.866 . . . . 0.0 109.646 176.097 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.64 -1.58 14.17 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.761 -1.109 . . . . 0.0 110.566 173.776 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.69 -22.18 8.15 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.208 173.833 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' PHE . . . . . 0.516 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.0 m-85 -85.68 -35.95 20.57 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-O 121.258 0.551 . . . . 0.0 110.591 178.289 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.721 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.849 177.512 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 21.8 pttp . . . . . 0 N--CA 1.479 1.021 0 CA-C-O 121.164 0.506 . . . . 0.0 110.98 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 65.7 mt -125.32 126.09 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 CA-C-O 120.988 0.423 . . . . 0.0 110.313 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.5 t30 -77.04 117.92 19.1 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.026 178.26 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.61 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 73.2 mmtt -92.43 -16.04 26.41 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.898 -174.022 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' GLN . . . . . 0.4 ' HA ' ' OE1' ' A' ' 5' ' ' GLN . 7.1 tp60 -68.16 -37.33 80.89 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 174.182 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 51.5 tttp -48.92 -43.19 39.23 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.747 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.61 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 3.2 mp -60.81 -30.34 47.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 115.068 -0.969 . . . . 0.0 111.955 -175.982 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 6.5 mptt -81.56 -36.01 29.59 Favored 'General case' 0 CA--C 1.503 -0.832 0 C-N-CA 119.516 -0.874 . . . . 0.0 109.427 173.406 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 8.2 m120 -55.96 -55.68 29.84 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.076 0.465 . . . . 0.0 110.397 -178.06 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 14' ' ' ALA . . . -67.22 -27.5 73.5 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.626 -0.716 . . . . 0.0 112.543 -179.375 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.97 -28.6 43.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.303 0.573 . . . . 0.0 110.649 178.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 8.8 tmtt? -81.86 -38.82 24.84 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.357 -178.274 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.502 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -84.82 -8.67 58.71 Favored 'General case' 0 C--O 1.201 -1.453 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 177.008 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.443 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -65.5 -24.97 67.27 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 172.817 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.3 mt -93.62 -33.66 13.61 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.317 -1.31 . . . . 0.0 109.39 174.296 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.589 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -69.35 -49.35 39.41 Favored Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.14 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.528 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.6 p -77.31 -23.84 14.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.734 -0.733 . . . . 0.0 110.529 -177.039 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.443 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -61.89 -26.16 67.99 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.948 172.844 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 21.4 m -91.68 6.65 45.04 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.01 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.589 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.8 mptt -113.99 9.05 17.31 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.16 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.599 ' O ' HG22 ' A' ' 24' ' ' VAL . 8.4 m -140.94 -37.16 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.282 -174.258 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.479 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.59 -48.13 65.82 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.669 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.479 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.7 Cg_exo -71.02 -23.59 24.91 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 121.625 1.55 . . . . 0.0 111.358 -178.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.599 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.1 m -78.86 -42.16 24.33 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.3 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.55 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.517 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.6 t -69.01 -25.27 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 121.842 0.829 . . . . 0.0 110.059 177.669 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.22 -8.74 48.57 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.402 173.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -106.83 -30.28 9.0 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.068 174.165 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.517 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 41.4 m-85 -77.59 -36.21 52.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.425 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.415 ' HB3' ' HD3' ' A' ' 30' ' ' ARG . . . -86.07 -57.53 2.99 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.806 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.504 ' HD3' ' N ' ' A' ' 30' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.248 0.99 0 C-N-CA 120.421 -0.511 . . . . 0.0 111.146 -179.033 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 39.6 ttpt . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 11.1 tt -79.3 149.69 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 175.994 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -70.64 122.79 20.44 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.771 0.32 . . . . 0.0 110.313 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.609 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 75.1 mmtt -90.66 -24.43 20.48 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.315 -175.928 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' GLN . . . . . 0.469 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 52.8 tp60 -61.84 -34.71 76.45 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 175.432 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.424 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 59.7 tttt -54.64 -35.85 63.92 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.71 175.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.609 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.4 mp -56.87 -34.32 43.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.939 176.935 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.535 ' HA ' ' HB3' ' A' ' 11' ' ' ALA . 0.0 OUTLIER -87.11 -13.48 44.05 Favored 'General case' 0 CA--C 1.509 -0.606 0 C-N-CA 120.638 -0.425 . . . . 0.0 109.89 178.661 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.478 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 4.1 m-20 -62.91 -64.3 0.96 Allowed 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 178.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.76 -34.36 88.4 Favored Glycine 0 N--CA 1.446 -0.667 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.767 177.256 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.535 ' HB3' ' HA ' ' A' ' 8' ' ' LYS . . . -65.41 -29.24 69.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.103 0.477 . . . . 0.0 111.379 179.156 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.431 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 6.6 tmtt? -87.12 -42.33 13.1 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.695 -177.392 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.605 ' O ' HG12 ' A' ' 17' ' ' VAL . 30.6 pttt -87.01 -1.67 58.05 Favored 'General case' 0 C--O 1.205 -1.252 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.997 -178.449 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -70.12 -15.87 63.03 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 122.091 0.948 . . . . 0.0 108.476 172.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 mt -100.24 -30.27 11.99 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.836 -1.529 . . . . 0.0 109.344 173.469 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.568 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -81.54 -53.96 3.65 Favored Glycine 0 N--CA 1.444 -0.771 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.972 -177.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.605 HG12 ' O ' ' A' ' 13' ' ' LYS . 1.1 p -76.17 -23.15 15.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.06 0.457 . . . . 0.0 110.464 -176.363 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.93 -23.61 67.41 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.521 0.677 . . . . 0.0 109.92 171.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 23.5 m -93.23 6.59 47.5 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.564 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.568 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.2 mptt -113.04 6.6 17.73 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.883 -1.053 . . . . 0.0 108.935 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.588 ' O ' HG22 ' A' ' 24' ' ' VAL . 12.9 m -133.77 -37.81 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.359 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.519 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.16 -48.75 68.97 Favored Pre-proline 0 C--N 1.322 -0.611 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.223 178.622 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.519 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 11.8 Cg_exo -70.24 -24.37 27.54 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 121.637 1.558 . . . . 0.0 111.424 -179.359 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.588 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.02 -42.0 27.62 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.467 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.437 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.491 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.5 t -67.42 -25.57 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.785 0 CA-C-O 121.755 0.788 . . . . 0.0 109.841 176.58 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.401 ' HB1' ' CZ ' ' A' ' 30' ' ' ARG . . . -70.54 -5.88 32.26 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.668 174.027 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.2 -26.46 9.17 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.03 174.242 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.491 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.5 m-85 -82.29 -33.84 28.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.668 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.83 -62.57 1.47 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.01 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.401 ' CZ ' ' HB1' ' A' ' 26' ' ' ALA . 1.7 ppt_? . . . . . 0 C--O 1.243 0.725 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.638 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 56.3 mtmt . . . . . 0 N--CA 1.48 1.062 0 CA-C-O 120.953 0.406 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.407 HD12 ' N ' ' A' ' 2' ' ' ILE . 3.2 mp -80.0 133.51 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.388 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 39.0 t30 -59.96 118.86 6.76 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.211 0.529 . . . . 0.0 110.977 -177.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.641 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 13.2 mptt -90.8 -20.24 22.57 Favored 'General case' 0 CA--C 1.512 -0.498 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.227 -176.547 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' GLN . . . . . 0.472 ' HA ' ' OE1' ' A' ' 5' ' ' GLN . 6.1 tp60 -66.42 -37.62 85.62 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.302 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.426 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 54.6 tttt -54.27 -32.88 57.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.874 -1.057 . . . . 0.0 112.103 177.004 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.641 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.3 mp -55.35 -38.51 48.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.073 175.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.498 ' O ' ' HB3' ' A' ' 12' ' ' LYS . 6.6 mptt -84.59 -18.37 35.77 Favored 'General case' 0 CA--C 1.505 -0.76 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.738 177.672 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.426 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 5.4 m-20 -59.38 -59.92 4.68 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 179.704 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.77 -34.23 86.67 Favored Glycine 0 N--CA 1.445 -0.738 0 CA-C-N 115.107 -0.952 . . . . 0.0 111.945 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.422 ' HB3' ' HA ' ' A' ' 8' ' ' LYS . . . -67.54 -26.62 66.4 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.973 0.416 . . . . 0.0 111.315 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.498 ' HB3' ' O ' ' A' ' 8' ' ' LYS . 0.8 OUTLIER -92.02 -37.52 12.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.98 -177.664 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.477 ' O ' HG12 ' A' ' 17' ' ' VAL . 4.9 pttt -84.97 -4.16 59.04 Favored 'General case' 0 C--O 1.202 -1.431 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 178.517 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -65.24 -24.12 67.25 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 171.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.9 mt -90.94 -33.82 15.43 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 113.889 -1.505 . . . . 0.0 109.4 175.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.28 -52.3 6.24 Favored Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 115.104 -0.953 . . . . 0.0 111.901 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.619 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.3 p -68.05 -24.3 30.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-O 121.311 0.577 . . . . 0.0 110.305 -177.538 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.15 -22.85 65.08 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.518 173.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.4 m -95.08 3.14 55.14 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 177.704 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.476 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.5 mptp? -113.83 8.34 17.32 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.031 -0.986 . . . . 0.0 109.438 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.619 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.0 m -135.64 -36.31 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.286 -175.803 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.473 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.73 -47.76 54.78 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.649 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.473 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.8 Cg_exo -72.75 -21.74 21.25 Favored 'Trans proline' 0 C--N 1.353 0.804 0 C-N-CA 121.829 1.686 . . . . 0.0 111.339 -179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -78.7 -42.4 25.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.275 179.523 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.52 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.3 t -68.37 -24.89 30.17 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.879 0 CA-C-O 121.858 0.837 . . . . 0.0 109.963 177.085 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.68 -8.65 53.55 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.821 -1.082 . . . . 0.0 110.475 174.117 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 -24.16 11.2 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.166 175.153 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.52 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 42.3 m-85 -83.08 -40.81 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.433 178.699 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -83.36 -49.9 8.88 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.305 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.754 0 CA-C-O 118.585 -0.722 . . . . 0.0 110.205 177.814 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt . . . . . 0 N--CA 1.48 1.059 0 CA-C-O 120.699 0.285 . . . . 0.0 110.406 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 72.6 mt -89.47 137.32 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.758 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 176.434 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -138.7 125.51 20.98 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.953 0.406 . . . . 0.0 110.738 -177.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.62 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 46.4 mmtm -97.31 -17.45 19.76 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.6 -177.659 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -65.74 -36.94 84.99 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 175.942 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 28.8 ttpt -51.18 -35.09 34.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.949 -1.023 . . . . 0.0 111.571 175.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.62 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.3 mp -57.11 -40.96 76.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.292 177.64 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.11 -27.02 56.94 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 10.3 m120 -63.8 -56.07 18.28 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.07 -28.5 72.93 Favored Glycine 0 N--CA 1.445 -0.762 0 CA-C-N 115.394 -0.821 . . . . 0.0 112.321 178.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.59 -32.4 60.31 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.081 0.467 . . . . 0.0 110.561 177.299 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.442 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 0.8 OUTLIER -76.4 -39.21 54.28 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.624 -179.635 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.494 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -85.63 -8.7 58.09 Favored 'General case' 0 C--O 1.2 -1.522 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.442 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.422 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -65.65 -25.44 67.36 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 172.388 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.7 mt -89.34 -36.12 15.71 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 114.335 -1.302 . . . . 0.0 109.439 173.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.577 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -70.38 -50.88 24.43 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 114.892 -1.049 . . . . 0.0 111.813 -178.487 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p -74.71 -19.91 16.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.626 -0.787 . . . . 0.0 110.61 -176.79 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.422 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -59.23 -25.42 64.01 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.443 173.162 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -95.18 7.33 46.48 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-O 121.644 0.735 . . . . 0.0 109.124 178.52 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.577 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.3 mptt -112.36 7.04 19.08 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-N 115.104 -0.953 . . . . 0.0 108.975 179.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.566 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.6 m -133.51 -36.28 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.272 -175.244 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.489 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.9 -47.82 52.82 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.49 178.783 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.489 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 9.3 Cg_exo -71.7 -23.11 23.17 Favored 'Trans proline' 0 C--N 1.353 0.806 0 C-N-CA 121.848 1.698 . . . . 0.0 111.494 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 21' ' ' VAL . 4.5 m -77.9 -42.22 28.27 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.483 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.508 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 87.5 t -68.12 -23.42 28.78 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.942 0 CA-C-O 121.872 0.844 . . . . 0.0 109.453 174.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.599 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -73.14 -5.74 41.11 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.557 173.566 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.11 -21.99 11.67 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.833 173.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.508 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.1 m-85 -86.12 -29.97 22.89 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.388 0.613 . . . . 0.0 110.01 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.72 -52.18 5.46 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.03 176.149 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.599 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 48.5 mtm180 . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.691 -0.671 . . . . 0.0 110.597 174.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 63.9 pttt . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 73.4 mt -121.19 136.18 58.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -110.65 123.39 49.92 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.602 -177.772 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.645 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 1.1 mptm? -91.45 -15.58 28.63 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.395 -177.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 39.1 tt0 -67.53 -36.6 81.32 Favored 'General case' 0 N--CA 1.445 -0.681 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 174.453 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 53.4 tttt -54.45 -33.13 59.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.865 177.249 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.645 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -56.28 -35.33 42.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.02 176.167 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.433 ' O ' ' HB3' ' A' ' 12' ' ' LYS . 0.3 OUTLIER -79.27 -27.48 42.3 Favored 'General case' 0 CA--C 1.507 -0.701 0 C-N-CA 120.551 -0.46 . . . . 0.0 109.789 175.774 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 3.8 m-20 -59.26 -60.77 3.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.023 0.44 . . . . 0.0 109.929 -175.199 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.57 -26.46 73.68 Favored Glycine 0 CA--C 1.508 -0.387 0 CA-C-N 115.432 -0.803 . . . . 0.0 112.613 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.55 -31.81 60.18 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.156 0.503 . . . . 0.0 110.636 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.433 ' HB3' ' O ' ' A' ' 8' ' ' LYS . 6.1 tmtt? -83.14 -37.81 23.24 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.562 -177.692 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.524 ' O ' HG12 ' A' ' 17' ' ' VAL . 2.7 pttt -84.21 -5.53 59.27 Favored 'General case' 0 C--O 1.201 -1.448 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 177.275 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.452 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -68.41 -22.48 64.62 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 170.78 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.3 mt -96.08 -29.19 14.24 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 114.227 -1.352 . . . . 0.0 109.399 173.778 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.555 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -76.33 -48.54 9.29 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.702 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.524 HG12 ' O ' ' A' ' 13' ' ' LYS . 1.7 p -76.8 -20.25 14.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.627 0.727 . . . . 0.0 109.86 -178.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.452 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -62.47 -25.71 68.13 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.901 171.039 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.5 m -89.62 5.63 44.84 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.555 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.1 mptm? -109.4 5.43 23.44 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.114 179.414 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.629 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.2 m -135.99 -36.76 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.372 -173.417 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.441 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.33 -46.1 84.84 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.818 179.008 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.441 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.6 -22.19 21.23 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 121.795 1.663 . . . . 0.0 111.491 179.584 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.629 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -81.32 -41.6 19.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.494 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 21' ' ' VAL . 89.7 t -67.3 -24.66 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.714 0 CA-C-O 121.911 0.862 . . . . 0.0 109.704 176.461 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.21 -3.45 20.3 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.646 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.24 -17.91 10.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.188 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.8 m-85 -90.11 -42.82 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.828 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 -52.62 6.03 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.926 -176.788 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.246 0.869 0 C-N-CA 120.782 -0.367 . . . . 0.0 111.526 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp . . . . . 0 N--CA 1.479 1.007 0 CA-C-O 120.984 0.421 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 89.1 mt -110.25 134.51 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.027 178.697 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -159.1 106.85 1.81 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.336 0.589 . . . . 0.0 110.174 178.453 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.62 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 74.9 mmtt -88.76 -20.1 25.18 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.291 -174.555 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' GLN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 59.9 tp60 -64.1 -32.85 74.56 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 175.884 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.474 ' HA ' ' HB2' ' A' ' 9' ' ' ASN . 4.0 ttpm? -59.01 -35.08 72.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.278 176.631 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.62 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.8 mp -58.54 -32.16 45.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 121.029 -0.268 . . . . 0.0 111.368 178.326 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.434 ' HD3' ' HA ' ' A' ' 5' ' ' GLN . 0.4 OUTLIER -85.72 -37.25 19.57 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 176.545 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.474 ' HB2' ' HA ' ' A' ' 6' ' ' LYS . 12.8 m-20 -65.6 -45.96 81.2 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.304 -176.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.47 -25.88 72.7 Favored Glycine 0 CA--C 1.506 -0.485 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 176.47 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -80.93 -25.16 37.66 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.268 0.556 . . . . 0.0 110.145 174.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.69 -34.12 27.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.447 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.541 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -87.15 -7.95 57.46 Favored 'General case' 0 C--O 1.199 -1.571 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.103 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.447 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -66.3 -23.33 66.36 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 170.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.9 mt -94.57 -33.59 12.97 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 114.06 -1.427 . . . . 0.0 109.446 173.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.577 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -71.12 -46.81 41.03 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.212 -0.904 . . . . 0.0 111.401 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 13' ' ' LYS . 2.5 p -76.15 -24.6 16.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-O 121.35 0.595 . . . . 0.0 110.037 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.447 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -62.21 -25.4 67.78 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.51 171.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.1 t -90.41 3.4 53.91 Favored 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.577 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.6 mptt -111.44 7.05 20.66 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.166 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.612 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.4 m -135.21 -37.83 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.341 -175.55 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.501 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.59 -48.78 80.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.392 179.169 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.501 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.2 Cg_exo -71.71 -23.47 22.72 Favored 'Trans proline' 0 C--N 1.353 0.778 0 C-N-CA 121.61 1.54 . . . . 0.0 111.379 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -78.65 -41.81 24.98 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.272 -179.132 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.509 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 88.4 t -67.34 -24.57 31.87 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 CA-C-O 121.923 0.868 . . . . 0.0 109.798 176.516 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.48 0.78 9.41 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.52 174.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.73 -22.48 6.84 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.209 173.031 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.509 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.9 m-85 -86.82 -34.87 19.39 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.956 178.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -88.92 -61.41 1.71 Allowed 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.251 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.94 0 CA-C-O 119.272 -0.394 . . . . 0.0 111.515 -178.529 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 64.8 pttt . . . . . 0 N--CA 1.48 1.053 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 39.6 mm -104.41 131.97 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.277 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 55.4 t-20 -114.34 122.49 46.86 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.158 177.505 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.612 ' HA ' HD13 ' A' ' 7' ' ' ILE . 34.4 mmtp -124.6 -17.39 5.99 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.974 172.308 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 24.4 tp60 -61.0 -37.17 81.59 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.149 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.5 tttt -64.5 -41.77 96.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.658 176.986 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.612 HD13 ' HA ' ' A' ' 4' ' ' LYS . 3.8 mp -60.31 -41.96 88.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 177.157 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.476 ' HA ' ' HD2' ' A' ' 8' ' ' LYS . 37.9 tptt -64.63 -42.83 95.21 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.272 175.475 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.649 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 75.8 m-20 -68.96 -44.48 72.88 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.748 -175.775 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.47 ' O ' ' HB2' ' A' ' 14' ' ' ALA . . . -64.21 -22.21 66.93 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.479 -0.867 . . . . 0.0 111.391 177.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.8 -28.02 20.72 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.043 0.449 . . . . 0.0 110.572 176.286 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.457 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 3.2 tmtm? -85.32 -49.53 8.08 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.959 -178.281 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.649 ' HG2' ' O ' ' A' ' 9' ' ' ASN . 50.4 pttt -81.47 -7.05 59.53 Favored 'General case' 0 C--O 1.205 -1.244 0 CA-C-O 120.726 0.298 . . . . 0.0 110.259 -175.494 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.488 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -66.18 -12.52 56.46 Favored 'General case' 0 C--N 1.314 -0.966 0 O-C-N 121.161 -0.962 . . . . 0.0 108.956 175.529 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.4 mt -102.75 -33.01 9.56 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 113.689 -1.596 . . . . 0.0 110.129 172.424 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.475 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -82.91 -53.96 3.36 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.573 -0.739 . . . . 0.0 112.122 -177.944 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.604 HG12 ' O ' ' A' ' 13' ' ' LYS . 1.1 p -76.74 -18.36 14.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-O 121.242 0.544 . . . . 0.0 110.049 -177.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.488 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -61.56 -24.29 66.55 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.784 170.617 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.7 m -93.27 8.29 40.91 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.276 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.475 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.8 mptt -114.91 7.52 15.68 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.771 -1.104 . . . . 0.0 108.888 178.279 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.623 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.6 m -136.71 -35.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.788 -175.878 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.467 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -64.11 -47.16 79.97 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 177.881 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.467 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.25 -22.81 21.67 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.633 1.555 . . . . 0.0 111.325 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.98 -40.29 22.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.332 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.204 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.502 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.7 t -68.9 -25.25 29.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.947 0 CA-C-O 121.676 0.75 . . . . 0.0 109.566 174.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.502 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -72.03 -3.39 22.62 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.519 173.419 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.83 -28.57 8.71 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.701 172.526 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.502 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.5 m-85 -80.99 -31.05 34.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.661 179.199 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.3 -50.66 6.43 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.972 177.3 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.502 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 79.1 mtm180 . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.629 -0.701 . . . . 0.0 110.341 175.422 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt . . . . . 0 N--CA 1.481 1.079 0 CA-C-O 120.846 0.355 . . . . 0.0 110.396 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 11.6 tt -78.22 155.06 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.211 179.163 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 26.7 t30 -74.48 115.33 13.9 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.001 0.429 . . . . 0.0 109.948 176.802 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.627 ' HA ' HD13 ' A' ' 7' ' ' ILE . 34.4 mmtp -85.89 -19.92 29.83 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.289 -172.904 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 51.3 tp60 -65.24 -37.5 87.43 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.448 177.903 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.0 tttt -58.55 -40.86 84.22 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.944 175.342 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.627 HD13 ' HA ' ' A' ' 4' ' ' LYS . 1.7 mp -53.45 -41.19 44.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.276 178.069 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.505 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 2.9 mptt -77.83 -38.14 46.92 Favored 'General case' 0 CA--C 1.507 -0.688 0 C-N-CA 119.861 -0.736 . . . . 0.0 109.998 178.599 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -62.49 -49.14 76.54 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.847 -176.808 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.8 -29.41 75.03 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.842 -0.694 . . . . 0.0 111.945 178.011 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.23 59.92 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.107 0.479 . . . . 0.0 110.301 176.568 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.449 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 9.9 tmtt? -77.68 -40.14 42.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.301 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.493 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -82.02 -11.05 59.03 Favored 'General case' 0 C--O 1.2 -1.522 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 177.86 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.9 -23.15 67.14 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.868 0.842 . . . . 0.0 108.782 173.127 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.9 mt -90.75 -38.76 12.82 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.121 172.843 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.707 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -69.42 -54.89 11.24 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.585 -177.249 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.582 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.5 p -68.7 -28.06 38.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-N 114.817 -0.691 . . . . 0.0 111.017 -175.434 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.27 -22.34 65.93 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.447 174.343 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.4 m -100.03 9.15 43.34 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.139 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.707 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.4 mptm? -114.48 9.06 16.66 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.122 178.161 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 17' ' ' VAL . 14.1 m -131.99 -35.93 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.113 -175.818 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.485 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -70.13 -47.84 20.79 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.351 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 5.0 Cg_exo -73.73 -20.05 20.51 Favored 'Trans proline' 0 C--N 1.352 0.759 0 C-N-CA 121.868 1.712 . . . . 0.0 111.596 -179.631 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 21' ' ' VAL . 4.4 m -78.73 -42.86 25.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.383 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.185 178.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.49 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.4 t -66.93 -24.3 32.25 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.596 0 CA-C-O 121.972 0.891 . . . . 0.0 109.691 175.414 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.485 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -73.07 -0.62 14.52 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.504 174.2 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.68 -22.17 8.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.948 173.375 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.49 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.2 m-85 -87.38 -40.99 13.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.889 179.488 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.35 -46.41 9.69 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.744 179.38 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.485 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 8.7 mtm180 . . . . . 0 C--O 1.249 1.048 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.769 176.689 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.48 1.057 0 CA-C-O 120.798 0.332 . . . . 0.0 110.439 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.7 mm -107.01 123.58 62.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.927 178.231 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -85.14 115.17 22.79 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.991 0.425 . . . . 0.0 111.041 -177.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.668 ' HA ' HD13 ' A' ' 7' ' ' ILE . 34.0 mmtp -109.51 -5.08 15.86 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.109 175.239 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -59.86 -51.26 70.48 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.638 179.448 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 57.8 tttt -58.19 -37.44 74.77 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.3 177.296 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.668 HD13 ' HA ' ' A' ' 4' ' ' LYS . 3.1 mp -61.33 -40.39 85.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 176.255 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.437 ' HA ' ' HD2' ' A' ' 8' ' ' LYS . 17.3 tptm -64.82 -41.28 95.89 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.734 174.252 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.0 m120 -55.09 -57.03 13.38 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 178.146 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.31 -36.71 92.88 Favored Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.537 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.8 -34.79 72.11 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.032 0.444 . . . . 0.0 111.148 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -81.86 -36.17 28.53 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.686 -176.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.49 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -83.54 -11.17 57.73 Favored 'General case' 0 C--O 1.202 -1.406 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 177.376 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.411 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -62.21 -23.85 66.88 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 172.68 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.2 mt -90.81 -38.3 13.06 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 114.229 -1.351 . . . . 0.0 109.756 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.533 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -70.21 -50.75 26.0 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.119 -0.946 . . . . 0.0 111.775 -178.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.503 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p -71.72 -24.46 23.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 114.899 -0.65 . . . . 0.0 110.442 -177.793 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.411 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -64.53 -18.67 65.04 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.229 172.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.5 t -99.84 7.85 44.63 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 177.077 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.533 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 4.9 mptp? -114.08 11.59 17.69 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.089 -0.96 . . . . 0.0 108.97 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.609 ' O ' HG22 ' A' ' 24' ' ' VAL . 13.5 m -138.03 -37.37 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 114.713 -1.131 . . . . 0.0 109.969 -175.434 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.487 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.87 -48.08 52.49 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.551 178.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.487 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 12.0 Cg_exo -70.51 -24.25 26.47 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 121.627 1.551 . . . . 0.0 111.412 -179.209 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.609 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.8 m -75.85 -43.22 39.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.316 -0.554 . . . . 0.0 110.199 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 21' ' ' VAL . 94.8 t -69.2 -25.88 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 CA-C-O 121.477 0.656 . . . . 0.0 110.282 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.28 -16.57 64.35 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.279 173.731 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -98.46 -27.5 14.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.069 176.292 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.475 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 51.1 m-85 -83.24 -26.14 31.03 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.018 178.566 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -90.91 -64.84 1.07 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.542 179.339 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.111 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.863 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 63.1 tttm . . . . . 0 N--CA 1.479 0.994 0 CA-C-O 121.038 0.447 . . . . 0.0 110.332 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 79.0 mt -106.62 125.95 62.47 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 40.0 t30 -67.67 112.8 4.99 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.286 0.565 . . . . 0.0 110.371 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.62 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 34.8 mmtp -95.35 -17.69 21.39 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.008 -176.633 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -61.4 -40.07 93.03 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 175.341 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.42 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 4.5 ttpm? -55.38 -33.44 63.45 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.83 178.063 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.62 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -56.91 -40.79 74.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.085 176.646 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.37 -32.45 60.84 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 120.176 -0.609 . . . . 0.0 109.384 177.305 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.491 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 7.5 m120 -55.9 -57.39 12.27 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 123.526 0.516 . . . . 0.0 109.643 178.234 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.81 -36.37 93.02 Favored Glycine 0 N--CA 1.444 -0.768 0 CA-C-N 115.289 -0.869 . . . . 0.0 112.143 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.35 -27.45 66.27 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.016 0.436 . . . . 0.0 111.066 177.995 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.434 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 9.1 tmtt? -82.81 -43.31 16.83 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.759 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.589 ' O ' HG12 ' A' ' 17' ' ' VAL . 25.0 pttt -86.75 -3.6 59.07 Favored 'General case' 0 C--O 1.202 -1.396 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.857 -179.18 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -68.87 -17.09 63.93 Favored 'General case' 0 C--N 1.314 -0.952 0 O-C-N 121.24 -0.913 . . . . 0.0 108.56 173.145 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.1 mt -98.61 -32.98 11.15 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 113.754 -1.567 . . . . 0.0 109.403 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.489 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -77.89 -52.22 5.48 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.12 -0.946 . . . . 0.0 112.062 -177.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.589 HG12 ' O ' ' A' ' 13' ' ' LYS . 1.2 p -76.13 -21.65 15.53 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.258 0.551 . . . . 0.0 110.127 -177.702 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.48 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -61.02 -27.78 68.57 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.914 170.847 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.3 m -89.69 6.02 43.28 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.489 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -111.89 5.89 19.19 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.809 -1.087 . . . . 0.0 108.854 178.349 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.604 ' O ' HG22 ' A' ' 24' ' ' VAL . 7.5 m -135.98 -37.76 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.38 -175.352 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.494 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.2 -48.61 68.82 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.707 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.494 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.7 Cg_exo -72.01 -22.09 23.4 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 121.554 1.503 . . . . 0.0 111.371 -179.023 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -79.57 -41.42 22.17 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.279 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.5 t -67.51 -24.11 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.779 0 CA-C-O 121.846 0.831 . . . . 0.0 109.674 176.558 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.57 2.6 9.36 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.519 174.705 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.98 -22.64 6.1 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.081 172.516 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -84.98 -41.6 15.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-O 121.297 0.57 . . . . 0.0 110.361 178.494 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.07 -51.46 7.99 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.357 177.584 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 44.7 mtm180 . . . . . 0 C--O 1.247 0.953 0 CA-C-O 118.479 -0.772 . . . . 0.0 111.125 175.605 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 96.8 mttt . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 48.2 mm -79.09 147.05 7.03 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.604 -176.028 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 54.1 t30 78.34 104.41 0.07 Allowed 'General case' 0 CA--C 1.51 -0.578 0 O-C-N 124.327 1.017 . . . . 0.0 110.773 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.605 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 75.2 mmtt -94.18 -12.7 27.76 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 114.421 -1.263 . . . . 0.0 110.195 -178.486 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' GLN . . . . . 0.436 ' HA ' ' CD ' ' A' ' 8' ' ' LYS . 49.8 tp60 -65.15 -33.78 76.83 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 174.471 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -55.47 -42.12 73.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.92 174.972 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.605 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 3.6 mp -58.18 -39.06 71.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.555 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.493 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 2.8 mptt -79.51 -26.95 41.43 Favored 'General case' 0 CA--C 1.506 -0.714 0 C-N-CA 119.592 -0.843 . . . . 0.0 109.853 177.858 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.0 m-20 -72.03 -46.14 58.19 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.709 -177.791 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -63.84 -31.1 79.66 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 174.157 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.85 -27.3 57.77 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.966 0.413 . . . . 0.0 110.697 176.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.483 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 0.9 OUTLIER -78.87 -42.04 28.36 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.143 -179.905 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.494 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -83.38 -10.13 58.62 Favored 'General case' 0 C--O 1.199 -1.57 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 178.346 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.12 -24.89 67.86 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 172.611 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.7 mt -87.24 -40.69 14.31 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 114.149 -1.387 . . . . 0.0 109.333 172.907 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.594 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -68.77 -52.38 25.07 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.89 -177.342 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.6 p -71.03 -22.92 23.06 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-N 114.743 -0.729 . . . . 0.0 110.721 -176.175 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.12 -31.15 68.68 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.121 172.763 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -90.61 8.54 33.68 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.594 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.1 mptm? -112.42 5.19 17.96 Favored 'General case' 0 N--CA 1.437 -1.076 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.854 178.046 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.658 ' O ' HG22 ' A' ' 24' ' ' VAL . 5.8 m -136.3 -36.96 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.596 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.516 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -69.8 -47.79 23.35 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.684 179.567 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.516 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 11.0 Cg_exo -70.14 -22.22 30.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.797 1.665 . . . . 0.0 111.419 -179.512 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.658 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -76.79 -42.42 33.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.137 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.479 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 93.1 t -68.13 -25.14 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.715 0 CA-C-O 121.833 0.825 . . . . 0.0 109.682 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.05 0.51 11.22 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.664 174.057 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.63 -22.32 8.13 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.037 172.764 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.479 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.4 m-85 -85.95 -41.61 14.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.846 178.618 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.56 -56.5 3.83 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.803 -178.695 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.241 0.626 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.454 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 67.1 mttm . . . . . 0 N--CA 1.477 0.924 0 CA-C-O 120.745 0.307 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 72.4 mt -117.39 132.59 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.869 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.4 t30 -68.18 109.0 3.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.029 0.442 . . . . 0.0 110.296 177.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.637 ' HA ' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -96.94 -7.94 31.91 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.018 -176.233 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -64.74 -43.65 92.66 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 176.376 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 16.4 ttpp -56.97 -35.38 69.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.539 173.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.637 HD13 ' HA ' ' A' ' 4' ' ' LYS . 1.8 mp -64.07 -42.82 96.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.8 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 177.038 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.471 ' HA ' ' HD2' ' A' ' 8' ' ' LYS . 22.5 tptp -58.54 -42.01 86.85 Favored 'General case' 0 CA--C 1.51 -0.586 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.908 172.993 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.2 m120 -55.83 -57.52 11.7 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.474 179.666 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.77 -20.8 70.67 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.606 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -84.08 -25.94 29.39 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.223 0.535 . . . . 0.0 110.672 177.551 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 2.1 tmtm? -88.25 -40.19 13.84 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.382 -178.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.477 ' O ' HG12 ' A' ' 17' ' ' VAL . 3.5 pttt -80.82 -6.65 58.83 Favored 'General case' 0 C--O 1.202 -1.395 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 177.016 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -66.2 -21.27 66.3 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.945 0.879 . . . . 0.0 108.7 172.721 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.1 mt -93.26 -35.87 12.87 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 114.038 -1.437 . . . . 0.0 109.532 173.48 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.631 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -72.83 -52.25 9.75 Favored Glycine 0 CA--C 1.502 -0.745 0 CA-C-N 115.008 -0.996 . . . . 0.0 111.797 -178.604 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.581 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.8 p -69.37 -25.11 28.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 114.999 -0.6 . . . . 0.0 110.423 -176.574 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.67 -28.13 67.0 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.433 173.524 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.6 m -93.08 5.96 49.65 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.287 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.631 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -111.48 8.02 20.95 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.849 179.507 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.621 ' O ' HG22 ' A' ' 24' ' ' VAL . 5.4 m -136.56 -39.93 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.435 -175.966 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.52 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.1 -49.05 58.18 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.74 -178.435 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.52 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.28 -21.32 23.41 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 121.65 1.566 . . . . 0.0 111.396 -178.806 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.0 m -78.73 -43.19 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.374 -0.531 . . . . 0.0 110.027 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.6 t -68.34 -23.85 28.91 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.721 0 CA-C-O 121.922 0.868 . . . . 0.0 109.975 176.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.88 -5.15 28.45 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.205 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.18 -25.11 9.05 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.349 174.28 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.9 m-85 -85.39 -31.93 22.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.968 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -96.26 -55.39 2.96 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.489 -179.504 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.46 -0.781 . . . . 0.0 110.158 -179.019 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 46.7 mmtm . . . . . 0 N--CA 1.481 1.103 0 CA-C-O 120.774 0.321 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.423 ' N ' HD12 ' A' ' 2' ' ' ILE . 3.1 mp -92.75 125.94 45.27 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.959 -178.852 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 40.4 t30 -121.9 106.45 11.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.423 0.63 . . . . 0.0 110.485 177.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.619 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 34.6 mmtp -88.37 -17.44 30.54 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.843 -1.071 . . . . 0.0 109.723 -177.478 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' GLN . . . . . 0.442 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 54.9 tp60 -64.29 -37.56 87.92 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 174.732 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 5.0 ttpm? -50.01 -37.48 32.99 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.301 175.346 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.619 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -56.66 -39.95 66.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.222 178.373 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.442 ' HD3' ' HA ' ' A' ' 5' ' ' GLN . 0.0 OUTLIER -80.96 -22.59 39.43 Favored 'General case' 0 CA--C 1.508 -0.664 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.855 179.746 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.7 m120 -64.42 -57.57 8.91 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 177.77 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -60.66 -39.4 96.53 Favored Glycine 0 N--CA 1.444 -0.784 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.633 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.36 -29.38 70.1 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.817 0.341 . . . . 0.0 111.423 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.405 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 1.0 OUTLIER -83.6 -43.14 15.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.041 0.448 . . . . 0.0 110.763 -177.936 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.536 ' O ' HG12 ' A' ' 17' ' ' VAL . 2.6 pttm -88.42 -3.16 58.88 Favored 'General case' 0 C--O 1.202 -1.442 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.748 -177.612 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.31 -22.18 64.72 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 171.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.8 mt -94.54 -29.88 14.67 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.059 -1.428 . . . . 0.0 109.454 174.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.591 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -79.27 -53.23 4.51 Favored Glycine 0 N--CA 1.444 -0.824 0 CA-C-N 114.977 -1.011 . . . . 0.0 111.98 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.612 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.4 p -72.6 -25.59 22.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.317 -0.442 . . . . 0.0 110.617 -175.716 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.99 -28.99 68.15 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.267 0.556 . . . . 0.0 109.916 173.008 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.5 m -89.34 3.88 50.71 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.591 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.5 mptm? -112.29 4.58 17.8 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.078 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.612 HG13 ' O ' ' A' ' 17' ' ' VAL . 7.2 m -134.35 -36.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.754 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.518 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -71.25 -49.92 11.75 Favored Pre-proline 0 C--N 1.318 -0.764 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.406 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.518 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.8 Cg_exo -71.41 -22.41 25.01 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.652 1.568 . . . . 0.0 111.153 -178.261 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.481 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -77.67 -45.34 28.62 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.402 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.233 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 83.7 t -69.01 -22.99 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.635 0 CA-C-O 122.021 0.915 . . . . 0.0 109.848 177.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.417 ' HA ' ' HD2' ' A' ' 30' ' ' ARG . . . -72.36 1.47 7.81 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.361 172.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -125.11 -15.16 6.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.465 174.27 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 52.7 m-85 -94.1 -30.47 14.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.063 0.458 . . . . 0.0 111.15 177.327 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -112.78 -47.1 3.08 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.073 -173.502 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.417 ' HD2' ' HA ' ' A' ' 26' ' ' ALA . 0.6 OUTLIER . . . . . 0 C--O 1.246 0.909 0 CA-C-O 119.075 -0.488 . . . . 0.0 112.073 -174.569 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 120.652 0.263 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 81.2 mt -98.17 129.28 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 CA-C-O 120.94 0.4 . . . . 0.0 110.505 -178.624 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 54.3 t-20 -113.68 131.74 56.04 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 176.402 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.596 ' O ' ' HB ' ' A' ' 7' ' ' ILE . 32.7 mmtp -112.37 -33.35 6.22 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.032 177.078 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 7.2 tp-100 -59.49 -45.93 90.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.957 0.408 . . . . 0.0 110.667 -178.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.8 tttt -53.2 -34.16 55.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.832 0.825 . . . . 0.0 110.832 178.502 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.596 ' HB ' ' O ' ' A' ' 4' ' ' LYS . 1.2 mp -62.27 -31.17 50.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.423 -176.598 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.476 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -87.71 -25.08 23.64 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 177.076 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 9.1 m120 -60.81 -59.06 5.98 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.585 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.455 ' O ' ' HB2' ' A' ' 14' ' ' ALA . . . -65.81 -26.14 72.06 Favored Glycine 0 N--CA 1.443 -0.866 0 CA-C-N 115.157 -0.929 . . . . 0.0 112.229 179.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -76.77 -27.79 55.44 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.08 0.467 . . . . 0.0 110.653 177.437 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.91 -40.44 18.57 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.677 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.509 ' O ' HG12 ' A' ' 17' ' ' VAL . 10.2 pttt -85.57 -4.03 59.04 Favored 'General case' 0 C--O 1.201 -1.492 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.215 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.455 ' HB2' ' O ' ' A' ' 10' ' ' GLY . . . -66.16 -21.81 66.35 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 171.766 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.9 mt -91.42 -34.82 14.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 113.978 -1.464 . . . . 0.0 109.475 175.03 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.511 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -75.84 -54.45 5.35 Favored Glycine 0 N--CA 1.446 -0.699 0 CA-C-N 115.122 -0.945 . . . . 0.0 111.93 -179.262 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.608 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p -70.01 -24.11 26.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.052 -0.574 . . . . 0.0 110.77 -175.827 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.406 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -59.67 -29.01 67.78 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.405 174.189 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.4 m -91.91 6.5 45.98 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.077 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.511 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 5.3 mptp? -114.86 7.17 15.65 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.18 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.608 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.1 m -133.61 -37.36 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.986 -176.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.451 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.35 -47.1 70.84 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.476 179.365 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.451 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 4.0 Cg_exo -74.52 -18.96 19.59 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 121.589 1.526 . . . . 0.0 111.654 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.582 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -81.81 -43.99 19.97 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.152 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.495 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.2 t -67.2 -22.63 29.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 CA-C-O 121.932 0.872 . . . . 0.0 109.993 176.35 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.31 -10.8 60.35 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.532 174.25 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.52 -19.47 13.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.989 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.495 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 53.9 m-85 -90.89 -46.27 8.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.971 178.393 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -75.37 -48.97 20.51 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.156 178.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.421 HH11 ' HD2' ' A' ' 30' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.227 178.084 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 71.2 mmtt . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 121.006 0.432 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 82.3 mt -135.24 119.11 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.267 177.553 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.7 t30 -164.47 119.29 1.43 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.434 178.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.615 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 47.9 mmtm -93.3 -17.64 23.37 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.884 -175.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 46.9 tp60 -61.99 -42.74 99.48 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 176.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 29.2 ttpt -51.8 -35.5 44.39 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.767 176.711 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.615 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -57.32 -38.05 60.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.495 177.873 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.92 -32.82 59.77 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.764 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 11.2 m120 -59.52 -56.34 23.25 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.719 179.638 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -62.78 -36.68 93.68 Favored Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.19 -0.914 . . . . 0.0 112.275 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.72 -30.73 67.35 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.876 0.37 . . . . 0.0 111.203 179.123 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 8.8 tmtt? -80.5 -38.45 29.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.004 0.43 . . . . 0.0 110.967 -178.793 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.465 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -87.3 -7.04 58.27 Favored 'General case' 0 C--O 1.2 -1.54 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 178.576 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.92 -22.61 67.03 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 172.042 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 mt -91.79 -35.21 14.24 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.553 174.186 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.532 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -75.65 -51.57 7.11 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.105 -0.952 . . . . 0.0 112.468 -178.485 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.583 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.4 p -71.39 -23.27 22.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.254 0.55 . . . . 0.0 110.332 -177.06 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.33 68.05 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.973 172.85 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.7 m -89.31 4.94 47.18 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.532 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.9 mptt -112.69 4.02 16.91 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.271 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.612 ' O ' HG22 ' A' ' 24' ' ' VAL . 6.1 m -135.71 -35.82 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.608 -174.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.503 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -71.35 -49.12 12.31 Favored Pre-proline 0 C--N 1.316 -0.863 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.584 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.503 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.3 Cg_exo -71.46 -19.94 27.96 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 121.753 1.635 . . . . 0.0 111.28 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -77.21 -44.44 30.83 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.322 0 C-N-CA 120.406 -0.517 . . . . 0.0 109.875 178.547 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.477 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 99.4 t -68.78 -24.06 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.763 0 CA-C-O 121.851 0.834 . . . . 0.0 110.048 177.242 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.413 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -75.18 0.61 15.78 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.432 174.694 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.54 -21.82 8.99 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.785 172.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.477 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -86.52 -48.07 8.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.522 178.419 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -75.14 -48.23 24.71 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.602 178.087 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.413 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 34.2 mtm180 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.502 -0.761 . . . . 0.0 111.016 176.041 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 14.6 mmmm . . . . . 0 N--CA 1.479 1.0 0 CA-C-O 120.825 0.345 . . . . 0.0 110.975 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 80.4 mt -122.74 129.82 74.91 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.596 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 178.998 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -119.43 119.01 32.66 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.067 0.461 . . . . 0.0 110.585 177.279 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.568 ' HA ' HD13 ' A' ' 7' ' ' ILE . 33.7 mmtp -100.81 -20.75 15.39 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.663 179.616 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' GLN . . . . . 0.526 ' HG3' ' ND2' ' A' ' 9' ' ' ASN . 6.9 tp-100 -60.03 -38.18 81.95 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.928 -179.665 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -56.91 -42.31 79.7 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.421 176.452 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.568 HD13 ' HA ' ' A' ' 4' ' ' LYS . 2.9 mp -54.69 -38.42 43.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.455 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -81.99 -35.94 28.39 Favored 'General case' 0 CA--C 1.507 -0.7 0 C-N-CA 119.43 -0.908 . . . . 0.0 109.578 178.532 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.526 ' ND2' ' HG3' ' A' ' 5' ' ' GLN . 12.6 m-80 -60.77 -51.15 70.55 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.659 -0.416 . . . . 0.0 111.177 -176.715 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.44 -30.41 77.5 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.078 179.478 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.69 -22.84 42.9 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.16 0.505 . . . . 0.0 110.833 178.437 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.481 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 4.8 tmtm? -88.5 -43.44 11.43 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.102 -178.864 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.503 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -77.32 -11.26 59.81 Favored 'General case' 0 C--O 1.199 -1.564 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.584 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.437 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -63.89 -22.11 66.77 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 172.667 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.9 mt -97.12 -32.16 12.1 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.631 174.348 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.555 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -72.97 -52.29 9.3 Favored Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.034 -0.985 . . . . 0.0 111.664 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.3 p -72.82 -24.12 21.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.909 -0.646 . . . . 0.0 110.302 -177.329 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.437 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -58.13 -28.03 64.3 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.39 173.68 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 m -93.39 5.87 50.08 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.555 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.0 OUTLIER -114.41 5.05 15.51 Favored 'General case' 0 N--CA 1.44 -0.967 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.229 178.712 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 17' ' ' VAL . 11.5 m -133.44 -32.03 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.063 -174.744 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.48 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -79.23 -46.39 1.65 Allowed Pre-proline 0 C--N 1.316 -0.871 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.79 -179.626 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.4 Cg_exo -72.19 -23.25 21.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 121.633 1.555 . . . . 0.0 111.174 179.453 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 21' ' ' VAL . 5.3 m -71.57 -45.06 69.42 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.918 179.088 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.487 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.3 t -68.27 -24.99 30.5 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.7 0.762 . . . . 0.0 109.943 176.596 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.45 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -72.62 -5.72 39.29 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.54 174.499 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.71 -27.25 9.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.94 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.487 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.7 m-85 -81.8 -36.95 27.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.447 179.197 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.48 -49.49 9.87 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.095 177.023 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.45 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.814 -0.612 . . . . 0.0 110.648 177.275 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 30.5 ttpt . . . . . 0 N--CA 1.48 1.037 0 CA-C-O 121.119 0.485 . . . . 0.0 110.263 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 41.0 mm -128.83 133.51 66.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.451 -178.737 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -146.44 112.84 5.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.227 0.536 . . . . 0.0 109.732 173.97 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.609 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 74.5 mmtt -86.28 -22.63 26.69 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.222 -174.487 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 24.7 tp60 -60.86 -38.61 86.17 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 174.369 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 36.7 tttp -52.9 -37.51 60.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.734 177.164 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.609 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 3.1 mp -57.78 -35.51 51.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.317 178.813 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.4 mptt -82.95 -23.42 33.45 Favored 'General case' 0 CA--C 1.504 -0.806 0 C-N-CA 120.081 -0.648 . . . . 0.0 109.578 176.57 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.416 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 5.1 m120 -60.92 -59.99 4.5 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.375 -0.53 . . . . 0.0 109.726 -178.219 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.29 -26.36 71.61 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.29 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -77.06 -29.17 54.96 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.196 0.522 . . . . 0.0 110.855 178.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.464 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 7.1 tmtt? -85.3 -41.82 15.18 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.82 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.51 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -80.63 -9.88 59.76 Favored 'General case' 0 C--O 1.203 -1.392 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.628 -177.817 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -67.44 -20.84 65.55 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.323 -0.951 . . . . 0.0 108.762 173.93 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.8 mt -97.71 -32.02 11.96 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.104 -1.407 . . . . 0.0 109.073 172.785 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.61 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -74.38 -55.23 5.71 Favored Glycine 0 N--CA 1.443 -0.881 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.797 -177.687 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.586 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p -71.22 -25.93 26.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 114.983 -0.609 . . . . 0.0 110.573 -175.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.24 -23.47 65.66 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.203 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.8 m -94.25 2.51 55.88 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.61 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 14.0 mptt -112.31 7.96 19.48 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.331 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.611 ' O ' HG22 ' A' ' 24' ' ' VAL . 12.6 m -135.37 -37.6 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.09 -175.092 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.44 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -62.77 -46.67 88.24 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.68 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 3.7 Cg_exo -73.98 -21.55 18.22 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.639 1.56 . . . . 0.0 111.356 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.4 m -80.87 -40.05 18.44 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.302 -179.214 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 21' ' ' VAL . 90.9 t -69.82 -23.12 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 CA-C-O 121.598 0.713 . . . . 0.0 109.84 175.435 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.08 -18.46 63.26 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.154 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -94.42 -20.7 19.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.386 -0.824 . . . . 0.0 109.707 176.106 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.479 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 41.3 m-85 -85.59 -39.9 16.84 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.8 176.514 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.02 -59.74 2.56 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.329 -177.765 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.001 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.596 176.012 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 10.1 ptpp? . . . . . 0 N--CA 1.48 1.03 0 CA-C-O 120.806 0.336 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.85 125.84 74.42 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.18 179.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -150.01 116.71 5.85 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.845 177.722 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.628 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 5.0 mptp? -88.15 -24.65 23.29 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.932 -174.852 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' GLN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 61.4 tp60 -61.04 -36.96 80.97 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.581 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.413 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 37.2 tttp -52.58 -35.74 54.61 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.791 176.43 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.628 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.4 mp -56.44 -37.9 53.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.733 176.908 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.434 ' HD3' ' HA ' ' A' ' 5' ' ' GLN . 7.9 mptt -79.04 -22.66 45.08 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 177.269 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.413 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 3.8 m-20 -60.6 -57.15 13.92 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.16 -35.78 90.93 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-N 114.775 -1.102 . . . . 0.0 112.058 178.238 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ALA . . . . . 0.427 ' HB3' ' HA ' ' A' ' 8' ' ' LYS . . . -65.22 -35.42 81.0 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.07 0.462 . . . . 0.0 111.077 179.5 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -80.06 -38.48 31.76 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.034 -178.341 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.508 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -81.32 -11.02 59.45 Favored 'General case' 0 C--O 1.2 -1.502 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 178.706 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.56 -22.56 67.0 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.915 0.864 . . . . 0.0 108.713 172.775 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 mt -92.76 -36.37 12.93 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 114.07 -1.423 . . . . 0.0 109.246 173.479 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.555 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -70.08 -53.66 13.87 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.484 -178.888 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.61 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.1 p -68.93 -28.48 39.75 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 CA-C-N 114.908 -0.646 . . . . 0.0 110.779 -178.01 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 21' ' ' VAL . . . -60.0 -26.26 65.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.36 0.6 . . . . 0.0 110.178 174.279 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.49 1.75 56.91 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.555 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 5.8 mptp? -113.39 6.55 17.27 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.166 -0.924 . . . . 0.0 109.369 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.61 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.7 m -133.52 -37.51 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.274 -175.859 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.42 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -64.54 -45.5 76.77 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.696 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.42 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 3.1 Cg_exo -73.92 -20.78 19.21 Favored 'Trans proline' 0 N--CA 1.454 -0.853 0 C-N-CA 121.448 1.432 . . . . 0.0 111.46 179.669 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -82.96 -41.83 17.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.642 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.506 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.1 t -66.31 -24.73 33.96 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 CA-C-O 121.899 0.857 . . . . 0.0 109.814 176.308 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.03 -7.25 45.04 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.676 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.86 -23.88 10.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.008 174.952 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.506 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.0 m-85 -83.32 -43.7 15.7 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.256 178.798 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.36 -50.76 10.35 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.951 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.458 -0.782 . . . . 0.0 110.129 178.004 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 49.1 mmtm . . . . . 0 N--CA 1.48 1.039 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.1 mp -82.61 125.55 39.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.095 0.474 . . . . 0.0 110.962 -177.509 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -169.17 125.36 0.91 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.618 178.782 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.627 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 47.6 mmtm -92.2 -21.8 20.17 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-O 120.894 0.378 . . . . 0.0 110.394 -175.299 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 52.6 tt0 -65.74 -35.11 79.81 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 174.363 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.484 ' HA ' ' HB2' ' A' ' 9' ' ' ASN . 29.6 ttpt -51.11 -35.75 36.95 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.646 176.37 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.627 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.4 mp -55.28 -40.76 58.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.329 177.209 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -80.32 -29.7 38.08 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 177.487 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.499 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 8.6 m120 -58.94 -57.79 11.53 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.649 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.82 -34.59 89.26 Favored Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.846 178.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.53 -22.69 61.74 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.097 0.475 . . . . 0.0 110.739 178.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.434 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 1.0 OUTLIER -90.75 -45.4 8.86 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.753 178.701 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.575 ' O ' HG12 ' A' ' 17' ' ' VAL . 24.0 pttt -81.06 -2.9 49.99 Favored 'General case' 0 C--O 1.206 -1.232 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.996 -177.534 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -71.06 -17.85 62.58 Favored 'General case' 0 C--N 1.312 -1.04 0 O-C-N 121.043 -1.035 . . . . 0.0 108.506 173.034 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 mt -101.85 -24.92 13.97 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 113.874 -1.512 . . . . 0.0 109.264 173.837 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.596 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -82.83 -55.42 2.98 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.722 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.588 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p -75.03 -24.37 17.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.27 -0.465 . . . . 0.0 110.605 -175.251 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.76 -32.83 69.64 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.329 0.585 . . . . 0.0 109.818 172.999 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 66.1 m -86.36 4.44 39.29 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.123 -179.383 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' LYS . . . . . 0.596 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.2 mptm? -113.76 3.43 15.54 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.223 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 17' ' ' VAL . 5.6 m -134.56 -38.42 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.326 -176.226 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.513 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -67.72 -50.04 36.42 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.397 -178.501 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.513 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.3 Cg_exo -71.04 -22.62 25.99 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.647 1.565 . . . . 0.0 111.153 -178.038 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.583 HG22 ' O ' ' A' ' 21' ' ' VAL . 2.8 m -78.47 -44.08 26.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.251 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 95.6 t -68.77 -24.2 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.802 0 CA-C-O 121.909 0.861 . . . . 0.0 110.07 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.77 -5.35 33.43 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.445 173.969 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.76 -19.16 11.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.285 174.301 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.53 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 44.9 m-85 -87.66 -43.06 12.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.602 177.64 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.31 -55.5 4.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.131 -177.825 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.454 ' HD3' ' N ' ' A' ' 30' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.038 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.946 -178.614 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm . . . . . 0 N--CA 1.481 1.086 0 CA-C-O 120.957 0.408 . . . . 0.0 110.794 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 41.1 mm -95.37 132.14 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.92 177.736 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 20.5 t30 -162.92 117.17 1.7 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.41 -179.297 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' LYS . . . . . 0.591 ' HA ' HD13 ' A' ' 7' ' ' ILE . 34.7 mmtp -79.69 -22.14 43.81 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.458 -171.193 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 26.2 tp60 -64.6 -39.68 94.16 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 173.903 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.897 ' HA ' ' ND2' ' A' ' 9' ' ' ASN . 29.6 ttpt -61.09 -32.67 72.33 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.853 179.234 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.591 HD13 ' HA ' ' A' ' 4' ' ' LYS . 1.7 mp -55.25 -35.6 36.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.586 175.372 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' LYS . . . . . 0.447 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 0.1 OUTLIER -82.45 -22.85 35.06 Favored 'General case' 0 CA--C 1.511 -0.525 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.204 177.035 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ASN . . . . . 0.897 ' ND2' ' HA ' ' A' ' 6' ' ' LYS . 16.4 m-20 -62.49 -56.06 21.67 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.149 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.426 ' HA2' ' HE3' ' A' ' 13' ' ' LYS . . . -67.84 -28.23 73.5 Favored Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 114.653 -1.158 . . . . 0.0 112.385 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.46 -30.23 63.04 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.013 0.435 . . . . 0.0 110.778 178.556 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -83.27 -37.58 23.31 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.935 -178.509 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.493 ' O ' HG12 ' A' ' 17' ' ' VAL . 12.3 pttt -87.78 -3.99 58.91 Favored 'General case' 0 C--O 1.2 -1.502 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 177.378 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' ALA . . . . . 0.511 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -64.55 -21.34 66.66 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 172.576 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 mt -90.77 -37.41 13.68 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 113.694 -1.594 . . . . 0.0 109.673 175.317 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.71 -53.91 5.67 Favored Glycine 0 CA--C 1.509 -0.338 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.298 -179.528 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 0.56 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p -70.83 -16.97 20.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.118 -0.541 . . . . 0.0 110.696 -176.886 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ALA . . . . . 0.511 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -56.89 -29.06 62.64 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.527 172.717 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 57.7 m -90.32 4.19 51.49 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.794 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -112.24 6.65 19.08 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.128 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' VAL . . . . . 0.62 ' O ' HG22 ' A' ' 24' ' ' VAL . 9.3 m -134.81 -37.01 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.082 -175.653 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . 0.445 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.23 -46.62 85.68 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.724 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' PRO . . . . . 0.445 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.1 Cg_exo -73.28 -21.55 19.94 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.691 1.594 . . . . 0.0 111.446 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.62 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -82.06 -41.12 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.425 -178.751 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . 0.516 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.8 t -67.86 -24.15 30.22 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 CA-C-O 121.919 0.866 . . . . 0.0 109.646 176.097 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' ALA . . . . . 0.499 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -71.64 -1.58 14.17 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.761 -1.109 . . . . 0.0 110.566 173.776 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.69 -22.18 8.15 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.208 173.833 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' PHE . . . . . 0.516 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.0 m-85 -85.68 -35.95 20.57 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-O 121.258 0.551 . . . . 0.0 110.591 178.289 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.79 -50.62 6.35 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.849 177.512 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' ARG . . . . . 0.499 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 42.9 mtm180 . . . . . 0 C--O 1.248 0.991 0 CA-C-O 118.886 -0.578 . . . . 0.0 111.491 177.651 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.528 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.6 p . . . . . 0 CA--C 1.515 -0.403 0 CA-C-O 121.102 0.477 . . . . 0.0 110.529 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.89 -26.16 67.99 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.948 172.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 21.4 m -91.68 6.65 45.04 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.424 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 13.8 mptt -113.99 9.05 17.31 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.16 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.599 ' O ' HG22 ' A' ' 24' ' ' VAL . 8.4 m -140.94 -37.16 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.282 -174.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.479 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.59 -48.13 65.82 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.669 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.479 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.7 Cg_exo -71.02 -23.59 24.91 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 121.625 1.55 . . . . 0.0 111.358 -178.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.599 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.1 m -78.86 -42.16 24.33 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.3 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.55 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.517 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.6 t -69.01 -25.27 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 121.842 0.829 . . . . 0.0 110.059 177.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.22 -8.74 48.57 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.402 173.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -106.83 -30.28 9.0 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.068 174.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.517 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 41.4 m-85 -77.59 -36.21 52.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.425 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.783 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.806 -179.148 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.523 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 N--CA 1.45 -0.457 0 CA-C-O 121.06 0.457 . . . . 0.0 110.464 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.93 -23.61 67.41 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.521 0.677 . . . . 0.0 109.92 171.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 23.5 m -93.23 6.59 47.5 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.416 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 13.2 mptt -113.04 6.6 17.73 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.883 -1.053 . . . . 0.0 108.935 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.588 ' O ' HG22 ' A' ' 24' ' ' VAL . 12.9 m -133.77 -37.81 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.359 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.519 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.16 -48.75 68.97 Favored Pre-proline 0 C--N 1.322 -0.611 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.223 178.622 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.519 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 11.8 Cg_exo -70.24 -24.37 27.54 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 121.637 1.558 . . . . 0.0 111.424 -179.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.588 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.02 -42.0 27.62 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.467 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.437 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.491 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.5 t -67.42 -25.57 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.785 0 CA-C-O 121.755 0.788 . . . . 0.0 109.841 176.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.54 -5.88 32.26 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.668 174.027 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.2 -26.46 9.17 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.03 174.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.491 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.5 m-85 -82.29 -33.84 28.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.668 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.639 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.01 -178.983 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.619 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.3 p . . . . . 0 CA--C 1.514 -0.436 0 CA-C-O 121.311 0.577 . . . . 0.0 110.305 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.15 -22.85 65.08 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.518 173.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.4 m -95.08 3.14 55.14 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 177.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.476 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.5 mptp? -113.83 8.34 17.32 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.031 -0.986 . . . . 0.0 109.438 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.619 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.0 m -135.64 -36.31 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.286 -175.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.473 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.73 -47.76 54.78 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.649 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.473 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.8 Cg_exo -72.75 -21.74 21.25 Favored 'Trans proline' 0 C--N 1.353 0.804 0 C-N-CA 121.829 1.686 . . . . 0.0 111.339 -179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -78.7 -42.4 25.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.275 179.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.52 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.3 t -68.37 -24.89 30.17 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.879 0 CA-C-O 121.858 0.837 . . . . 0.0 109.963 177.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.68 -8.65 53.55 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.821 -1.082 . . . . 0.0 110.475 174.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 -24.16 11.2 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.166 175.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.52 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 42.3 m-85 -83.08 -40.81 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.433 178.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.305 179.879 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.515 -0.387 0 CA-C-O 121.205 0.526 . . . . 0.0 110.61 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.23 -25.42 64.01 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.443 173.162 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -95.18 7.33 46.48 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-O 121.644 0.735 . . . . 0.0 109.124 178.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 13.3 mptt -112.36 7.04 19.08 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-N 115.104 -0.953 . . . . 0.0 108.975 179.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.566 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.6 m -133.51 -36.28 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.272 -175.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.489 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.9 -47.82 52.82 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.49 178.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.489 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 9.3 Cg_exo -71.7 -23.11 23.17 Favored 'Trans proline' 0 C--N 1.353 0.806 0 C-N-CA 121.848 1.698 . . . . 0.0 111.494 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 21' ' ' VAL . 4.5 m -77.9 -42.22 28.27 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.483 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.508 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 87.5 t -68.12 -23.42 28.78 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.942 0 CA-C-O 121.872 0.844 . . . . 0.0 109.453 174.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.14 -5.74 41.11 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.557 173.566 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.11 -21.99 11.67 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.833 173.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.508 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.1 m-85 -86.12 -29.97 22.89 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.388 0.613 . . . . 0.0 110.01 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.444 -0.766 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.03 176.149 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.443 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.514 -0.431 0 CA-C-O 121.627 0.727 . . . . 0.0 109.86 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.47 -25.71 68.13 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.901 171.039 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.5 m -89.62 5.63 44.84 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 1.1 mptm? -109.4 5.43 23.44 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.114 179.414 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.629 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.2 m -135.99 -36.76 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.372 -173.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.441 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.33 -46.1 84.84 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.818 179.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.441 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.6 -22.19 21.23 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 121.795 1.663 . . . . 0.0 111.491 179.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.629 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -81.32 -41.6 19.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.494 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 21' ' ' VAL . 89.7 t -67.3 -24.66 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.714 0 CA-C-O 121.911 0.862 . . . . 0.0 109.704 176.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.21 -3.45 20.3 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.646 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.24 -17.91 10.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.188 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.8 m-85 -90.11 -42.82 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.828 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.704 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.926 -176.788 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.538 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.5 p . . . . . 0 CA--C 1.514 -0.44 0 CA-C-O 121.35 0.595 . . . . 0.0 110.037 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.21 -25.4 67.78 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.51 171.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.1 t -90.41 3.4 53.91 Favored 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.408 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 13.6 mptt -111.44 7.05 20.66 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.166 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.612 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.4 m -135.21 -37.83 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.341 -175.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.501 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.59 -48.78 80.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.392 179.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.501 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.2 Cg_exo -71.71 -23.47 22.72 Favored 'Trans proline' 0 C--N 1.353 0.778 0 C-N-CA 121.61 1.54 . . . . 0.0 111.379 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -78.65 -41.81 24.98 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.272 -179.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.509 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 88.4 t -67.34 -24.57 31.87 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 CA-C-O 121.923 0.868 . . . . 0.0 109.798 176.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.48 0.78 9.41 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.52 174.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.73 -22.48 6.84 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.209 173.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.509 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.9 m-85 -86.82 -34.87 19.39 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.956 178.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.777 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.251 179.653 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.477 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.509 -0.634 0 CA-C-O 121.242 0.544 . . . . 0.0 110.049 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.56 -24.29 66.55 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.784 170.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.7 m -93.27 8.29 40.91 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.276 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 13.8 mptt -114.91 7.52 15.68 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.771 -1.104 . . . . 0.0 108.888 178.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.623 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.6 m -136.71 -35.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.788 -175.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.467 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -64.11 -47.16 79.97 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 177.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.467 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.25 -22.81 21.67 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.633 1.555 . . . . 0.0 111.325 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.98 -40.29 22.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.332 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.204 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.502 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.7 t -68.9 -25.25 29.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.947 0 CA-C-O 121.676 0.75 . . . . 0.0 109.566 174.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.03 -3.39 22.62 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.519 173.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.83 -28.57 8.71 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.701 172.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.502 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.5 m-85 -80.99 -31.05 34.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.661 179.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.769 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.972 177.3 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.582 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.5 p . . . . . 0 CA--C 1.517 -0.296 0 CA-C-O 121.116 0.484 . . . . 0.0 111.017 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.27 -22.34 65.93 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.447 174.343 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.4 m -100.03 9.15 43.34 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.139 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.502 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.4 mptm? -114.48 9.06 16.66 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.122 178.161 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 17' ' ' VAL . 14.1 m -131.99 -35.93 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.113 -175.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.485 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -70.13 -47.84 20.79 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.351 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 5.0 Cg_exo -73.73 -20.05 20.51 Favored 'Trans proline' 0 C--N 1.352 0.759 0 C-N-CA 121.868 1.712 . . . . 0.0 111.596 -179.631 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 21' ' ' VAL . 4.4 m -78.73 -42.86 25.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.383 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.185 178.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.49 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.4 t -66.93 -24.3 32.25 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.596 0 CA-C-O 121.972 0.891 . . . . 0.0 109.691 175.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.07 -0.62 14.52 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.504 174.2 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.68 -22.17 8.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.948 173.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.49 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.2 m-85 -87.38 -40.99 13.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.889 179.488 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.765 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.744 179.38 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.503 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.515 -0.384 0 CA-C-O 121.311 0.577 . . . . 0.0 110.442 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -64.53 -18.67 65.04 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.229 172.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.5 t -99.84 7.85 44.63 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 177.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.431 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 4.9 mptp? -114.08 11.59 17.69 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.089 -0.96 . . . . 0.0 108.97 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.609 ' O ' HG22 ' A' ' 24' ' ' VAL . 13.5 m -138.03 -37.37 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 114.713 -1.131 . . . . 0.0 109.969 -175.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.487 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.87 -48.08 52.49 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.551 178.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.487 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 12.0 Cg_exo -70.51 -24.25 26.47 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 121.627 1.551 . . . . 0.0 111.412 -179.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.609 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.8 m -75.85 -43.22 39.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.316 -0.554 . . . . 0.0 110.199 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 21' ' ' VAL . 94.8 t -69.2 -25.88 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 CA-C-O 121.477 0.656 . . . . 0.0 110.282 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.28 -16.57 64.35 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.279 173.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -98.46 -27.5 14.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.069 176.292 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.475 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 51.1 m-85 -83.24 -26.14 31.03 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.018 178.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.66 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.542 179.339 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.521 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.2 p . . . . . 0 CA--C 1.512 -0.512 0 CA-C-O 121.258 0.551 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.02 -27.78 68.57 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.914 170.847 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.3 m -89.69 6.02 43.28 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 0.9 OUTLIER -111.89 5.89 19.19 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.809 -1.087 . . . . 0.0 108.854 178.349 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.604 ' O ' HG22 ' A' ' 24' ' ' VAL . 7.5 m -135.98 -37.76 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.38 -175.352 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.494 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.2 -48.61 68.82 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.707 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.494 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.7 Cg_exo -72.01 -22.09 23.4 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 121.554 1.503 . . . . 0.0 111.371 -179.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -79.57 -41.42 22.17 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.279 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.5 t -67.51 -24.11 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.779 0 CA-C-O 121.846 0.831 . . . . 0.0 109.674 176.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.57 2.6 9.36 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.519 174.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.98 -22.64 6.1 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.081 172.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -84.98 -41.6 15.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-O 121.297 0.57 . . . . 0.0 110.361 178.494 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.683 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.357 177.584 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.6 p . . . . . 0 CA--C 1.515 -0.366 0 CA-C-O 121.189 0.518 . . . . 0.0 110.721 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.12 -31.15 68.68 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.121 172.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -90.61 8.54 33.68 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.408 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.1 mptm? -112.42 5.19 17.96 Favored 'General case' 0 N--CA 1.437 -1.076 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.854 178.046 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.658 ' O ' HG22 ' A' ' 24' ' ' VAL . 5.8 m -136.3 -36.96 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.596 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.516 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -69.8 -47.79 23.35 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.684 179.567 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.516 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 11.0 Cg_exo -70.14 -22.22 30.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.797 1.665 . . . . 0.0 111.419 -179.512 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.658 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -76.79 -42.42 33.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.137 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.479 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 93.1 t -68.13 -25.14 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.715 0 CA-C-O 121.833 0.825 . . . . 0.0 109.682 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.05 0.51 11.22 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.664 174.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.63 -22.32 8.13 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.037 172.764 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.479 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.4 m-85 -85.95 -41.61 14.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.846 178.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.72 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.803 -178.695 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.581 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.8 p . . . . . 0 CA--C 1.514 -0.418 0 CA-C-O 121.332 0.587 . . . . 0.0 110.423 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.67 -28.13 67.0 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.433 173.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.6 m -93.08 5.96 49.65 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.287 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.421 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 0.9 OUTLIER -111.48 8.02 20.95 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.849 179.507 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.621 ' O ' HG22 ' A' ' 24' ' ' VAL . 5.4 m -136.56 -39.93 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.435 -175.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.52 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.1 -49.05 58.18 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.74 -178.435 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.52 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.28 -21.32 23.41 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 121.65 1.566 . . . . 0.0 111.396 -178.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.0 m -78.73 -43.19 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.374 -0.531 . . . . 0.0 110.027 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.6 t -68.34 -23.85 28.91 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.721 0 CA-C-O 121.922 0.868 . . . . 0.0 109.975 176.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.88 -5.15 28.45 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.205 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.18 -25.11 9.05 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.349 174.28 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.9 m-85 -85.39 -31.93 22.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.968 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.791 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.489 -179.504 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.612 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.4 p . . . . . 0 CA--C 1.514 -0.434 0 CA-C-O 120.923 0.392 . . . . 0.0 110.617 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.99 -28.99 68.15 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.267 0.556 . . . . 0.0 109.916 173.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.5 m -89.34 3.88 50.71 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.464 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.5 mptm? -112.29 4.58 17.8 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.078 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.612 HG13 ' O ' ' A' ' 17' ' ' VAL . 7.2 m -134.35 -36.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.754 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.518 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -71.25 -49.92 11.75 Favored Pre-proline 0 C--N 1.318 -0.764 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.406 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.518 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.8 Cg_exo -71.41 -22.41 25.01 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.652 1.568 . . . . 0.0 111.153 -178.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.481 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -77.67 -45.34 28.62 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.402 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.233 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 83.7 t -69.01 -22.99 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.635 0 CA-C-O 122.021 0.915 . . . . 0.0 109.848 177.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.36 1.47 7.81 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.361 172.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -125.11 -15.16 6.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.465 174.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 52.7 m-85 -94.1 -30.47 14.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.063 0.458 . . . . 0.0 111.15 177.327 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.651 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.073 -173.502 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.608 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p . . . . . 0 CA--C 1.513 -0.449 0 CA-C-O 121.026 0.441 . . . . 0.0 110.77 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.67 -29.01 67.78 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.405 174.189 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.4 m -91.91 6.5 45.98 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.077 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.487 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.3 mptp? -114.86 7.17 15.65 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.18 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.608 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.1 m -133.61 -37.36 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.986 -176.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.451 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.35 -47.1 70.84 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.476 179.365 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.451 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 4.0 Cg_exo -74.52 -18.96 19.59 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 121.589 1.526 . . . . 0.0 111.654 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.582 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -81.81 -43.99 19.97 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.152 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.495 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.2 t -67.2 -22.63 29.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 CA-C-O 121.932 0.872 . . . . 0.0 109.993 176.35 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.31 -10.8 60.35 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.532 174.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.52 -19.47 13.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.989 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.495 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 53.9 m-85 -90.89 -46.27 8.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.971 178.393 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.69 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.156 178.828 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.583 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.4 p . . . . . 0 CA--C 1.513 -0.469 0 CA-C-O 121.254 0.55 . . . . 0.0 110.332 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.33 68.05 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.973 172.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.7 m -89.31 4.94 47.18 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.401 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 13.9 mptt -112.69 4.02 16.91 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.271 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.612 ' O ' HG22 ' A' ' 24' ' ' VAL . 6.1 m -135.71 -35.82 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.608 -174.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.503 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -71.35 -49.12 12.31 Favored Pre-proline 0 C--N 1.316 -0.863 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.584 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.503 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.3 Cg_exo -71.46 -19.94 27.96 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 121.753 1.635 . . . . 0.0 111.28 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -77.21 -44.44 30.83 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.322 0 C-N-CA 120.406 -0.517 . . . . 0.0 109.875 178.547 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.477 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 99.4 t -68.78 -24.06 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.763 0 CA-C-O 121.851 0.834 . . . . 0.0 110.048 177.242 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -75.18 0.61 15.78 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.432 174.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.54 -21.82 8.99 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.785 172.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.477 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -86.52 -48.07 8.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.522 178.419 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.321 -0.641 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.602 178.087 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.3 p . . . . . 0 CA--C 1.512 -0.485 0 CA-C-O 121.124 0.488 . . . . 0.0 110.302 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.13 -28.03 64.3 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.39 173.68 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 m -93.39 5.87 50.08 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.439 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.0 OUTLIER -114.41 5.05 15.51 Favored 'General case' 0 N--CA 1.44 -0.967 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.229 178.712 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 17' ' ' VAL . 11.5 m -133.44 -32.03 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.063 -174.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.48 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -79.23 -46.39 1.65 Allowed Pre-proline 0 C--N 1.316 -0.871 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.79 -179.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.4 Cg_exo -72.19 -23.25 21.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 121.633 1.555 . . . . 0.0 111.174 179.453 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 21' ' ' VAL . 5.3 m -71.57 -45.06 69.42 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.918 179.088 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.487 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.3 t -68.27 -24.99 30.5 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.7 0.762 . . . . 0.0 109.943 176.596 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.62 -5.72 39.29 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.54 174.499 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.71 -27.25 9.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.94 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.487 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.7 m-85 -81.8 -36.95 27.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.447 179.197 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.318 -0.777 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.095 177.023 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.586 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.511 -0.555 0 CA-C-O 121.185 0.517 . . . . 0.0 110.573 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.24 -23.47 65.66 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.203 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.8 m -94.25 2.51 55.88 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.448 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 14.0 mptt -112.31 7.96 19.48 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.331 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.611 ' O ' HG22 ' A' ' 24' ' ' VAL . 12.6 m -135.37 -37.6 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.09 -175.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.44 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -62.77 -46.67 88.24 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.68 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 3.7 Cg_exo -73.98 -21.55 18.22 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.639 1.56 . . . . 0.0 111.356 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.4 m -80.87 -40.05 18.44 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.302 -179.214 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 21' ' ' VAL . 90.9 t -69.82 -23.12 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 CA-C-O 121.598 0.713 . . . . 0.0 109.84 175.435 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.08 -18.46 63.26 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.154 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -94.42 -20.7 19.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.386 -0.824 . . . . 0.0 109.707 176.106 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.479 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 41.3 m-85 -85.59 -39.9 16.84 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.8 176.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.743 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.329 -177.765 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.61 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.1 p . . . . . 0 CA--C 1.512 -0.489 0 CA-C-O 120.902 0.382 . . . . 0.0 110.779 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 21' ' ' VAL . . . -60.0 -26.26 65.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.36 0.6 . . . . 0.0 110.178 174.279 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.49 1.75 56.91 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.438 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.8 mptp? -113.39 6.55 17.27 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.166 -0.924 . . . . 0.0 109.369 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.61 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.7 m -133.52 -37.51 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.274 -175.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.42 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -64.54 -45.5 76.77 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.696 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.42 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 3.1 Cg_exo -73.92 -20.78 19.21 Favored 'Trans proline' 0 N--CA 1.454 -0.853 0 C-N-CA 121.448 1.432 . . . . 0.0 111.46 179.669 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -82.96 -41.83 17.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.642 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.506 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.1 t -66.31 -24.73 33.96 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 CA-C-O 121.899 0.857 . . . . 0.0 109.814 176.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.03 -7.25 45.04 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.676 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.86 -23.88 10.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.008 174.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.506 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.0 m-85 -83.32 -43.7 15.7 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.256 178.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.32 -0.707 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.951 178.642 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.588 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.509 -0.614 0 CA-C-O 120.911 0.386 . . . . 0.0 110.605 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.76 -32.83 69.64 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.329 0.585 . . . . 0.0 109.818 172.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 66.1 m -86.36 4.44 39.29 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.123 -179.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . 0.447 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 1.2 mptm? -113.76 3.43 15.54 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.223 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 17' ' ' VAL . 5.6 m -134.56 -38.42 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.326 -176.226 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.513 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -67.72 -50.04 36.42 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.397 -178.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.513 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.3 Cg_exo -71.04 -22.62 25.99 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.647 1.565 . . . . 0.0 111.153 -178.038 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.583 HG22 ' O ' ' A' ' 21' ' ' VAL . 2.8 m -78.47 -44.08 26.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.251 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 95.6 t -68.77 -24.2 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.802 0 CA-C-O 121.909 0.861 . . . . 0.0 110.07 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.77 -5.35 33.43 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.445 173.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.76 -19.16 11.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.285 174.301 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.53 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 44.9 m-85 -87.66 -43.06 12.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.602 177.64 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.322 -0.604 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.131 -177.825 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 0.56 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p . . . . . 0 CA--C 1.514 -0.433 0 CA-C-O 121.168 0.508 . . . . 0.0 110.696 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -56.89 -29.06 62.64 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.527 172.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 57.7 m -90.32 4.19 51.49 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -112.24 6.65 19.08 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.128 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' VAL . . . . . 0.62 ' O ' HG22 ' A' ' 24' ' ' VAL . 9.3 m -134.81 -37.01 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.082 -175.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . 0.445 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.23 -46.62 85.68 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.724 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' PRO . . . . . 0.445 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.1 Cg_exo -73.28 -21.55 19.94 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.691 1.594 . . . . 0.0 111.446 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.62 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -82.06 -41.12 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.425 -178.751 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . 0.516 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.8 t -67.86 -24.15 30.22 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 CA-C-O 121.919 0.866 . . . . 0.0 109.646 176.097 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.64 -1.58 14.17 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.761 -1.109 . . . . 0.0 110.566 173.776 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.69 -22.18 8.15 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.208 173.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' PHE . . . . . 0.516 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.0 m-85 -85.68 -35.95 20.57 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-O 121.258 0.551 . . . . 0.0 110.591 178.289 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--N 1.319 -0.721 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.849 177.512 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 21.8 pttp . . . . . 0 N--CA 1.479 1.021 0 CA-C-O 121.164 0.506 . . . . 0.0 110.98 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 65.7 mt -125.32 126.09 70.15 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 CA-C-O 120.988 0.423 . . . . 0.0 110.313 179.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.5 t30 -77.04 117.92 19.1 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.888 -0.596 . . . . 0.0 110.026 178.26 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.61 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 73.2 mmtt -92.43 -16.04 26.41 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.898 -174.022 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . 0.4 ' HA ' ' OE1' ' A' ' 5' ' ' GLN . 7.1 tp60 -68.16 -37.33 80.89 Favored 'General case' 0 C--N 1.322 -0.623 0 N-CA-C 108.659 -0.867 . . . . 0.0 108.659 174.182 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 51.5 tttp -48.92 -43.19 39.23 Favored 'General case' 0 CA--C 1.511 -0.55 0 CA-C-N 114.543 -1.208 . . . . 0.0 111.747 176.625 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.61 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 3.2 mp -60.81 -30.34 47.03 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.931 0 CA-C-N 115.068 -0.969 . . . . 0.0 111.955 -175.982 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 6.5 mptt -81.56 -36.01 29.59 Favored 'General case' 0 CA--C 1.503 -0.832 0 C-N-CA 119.516 -0.874 . . . . 0.0 109.427 173.406 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 20.9 m-80 -55.96 -55.68 29.84 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.076 0.465 . . . . 0.0 110.397 -178.06 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.406 ' O ' ' HB2' ' A' ' 14' ' ' ALA . . . -67.22 -27.5 73.5 Favored Glycine 0 N--CA 1.449 -0.485 0 CA-C-N 115.626 -0.716 . . . . 0.0 112.543 -179.375 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -78.97 -28.6 43.61 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.303 0.573 . . . . 0.0 110.649 178.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 8.8 tmtt? -81.86 -38.82 24.84 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.357 -178.274 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.502 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -84.82 -8.67 58.71 Favored 'General case' 0 C--O 1.201 -1.453 0 N-CA-C 109.527 -0.545 . . . . 0.0 109.527 177.008 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.443 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -65.5 -24.97 67.27 Favored 'General case' 0 C--N 1.316 -0.853 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 172.817 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 10.3 mt -93.62 -33.66 13.61 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 114.317 -1.31 . . . . 0.0 109.39 174.296 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.589 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -69.35 -49.35 39.41 Favored Glycine 0 N--CA 1.445 -0.763 0 CA-C-N 114.937 -1.029 . . . . 0.0 111.14 -179.991 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.528 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.6 p -77.31 -23.84 14.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.734 -0.733 . . . . 0.0 110.529 -177.039 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.443 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -61.89 -26.16 67.99 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.948 172.844 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 21.4 m -91.68 6.65 45.04 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.747 -0.834 . . . . 0.0 108.747 179.01 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.589 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.8 mptt -113.99 9.05 17.31 Favored 'General case' 0 N--CA 1.443 -0.825 0 CA-C-N 114.816 -1.084 . . . . 0.0 109.16 179.005 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.599 ' O ' HG22 ' A' ' 24' ' ' VAL . 8.4 m -140.94 -37.16 0.21 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.347 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.282 -174.258 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.479 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.59 -48.13 65.82 Favored Pre-proline 0 C--N 1.322 -0.606 0 CA-C-N 116.34 -0.391 . . . . 0.0 111.669 179.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.479 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.7 Cg_exo -71.02 -23.59 24.91 Favored 'Trans proline' 0 C--N 1.353 0.768 0 C-N-CA 121.625 1.55 . . . . 0.0 111.358 -178.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.599 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.1 m -78.86 -42.16 24.33 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.3 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.55 -179.346 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.517 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.6 t -69.01 -25.27 29.57 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.883 0 CA-C-O 121.842 0.829 . . . . 0.0 110.059 177.669 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -69.22 -8.74 48.57 Favored 'General case' 0 C--N 1.301 -1.515 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.402 173.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -106.83 -30.28 9.0 Favored 'General case' 0 N--CA 1.451 -0.379 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.068 174.165 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.517 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 41.4 m-85 -77.59 -36.21 52.13 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.758 -0.656 . . . . 0.0 110.425 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.415 ' HB3' ' HD3' ' A' ' 30' ' ' ARG . . . -86.07 -57.53 2.99 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 115.138 -0.937 . . . . 0.0 110.806 -179.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.504 ' HD3' ' N ' ' A' ' 30' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.248 0.99 0 C-N-CA 120.421 -0.511 . . . . 0.0 111.146 -179.033 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 39.6 ttpt . . . . . 0 N--CA 1.477 0.909 0 N-CA-C 110.285 -0.265 . . . . 0.0 110.285 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 11.1 tt -79.3 149.69 5.37 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.799 0 N-CA-C 109.848 -0.427 . . . . 0.0 109.848 175.994 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 35.2 t30 -70.64 122.79 20.44 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 120.771 0.32 . . . . 0.0 110.313 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.609 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 75.1 mmtt -90.66 -24.43 20.48 Favored 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.315 -175.928 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . 0.469 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 52.8 tp60 -61.84 -34.71 76.45 Favored 'General case' 0 C--N 1.326 -0.418 0 N-CA-C 109.131 -0.692 . . . . 0.0 109.131 175.432 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.424 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 59.7 tttt -54.64 -35.85 63.92 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.182 -0.917 . . . . 0.0 111.71 175.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.609 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.4 mp -56.87 -34.32 43.65 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-N 116.545 -0.298 . . . . 0.0 110.939 176.935 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.535 ' HA ' ' HB3' ' A' ' 11' ' ' ALA . 0.0 OUTLIER -87.11 -13.48 44.05 Favored 'General case' 0 CA--C 1.509 -0.606 0 C-N-CA 120.638 -0.425 . . . . 0.0 109.89 178.661 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.478 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 1.0 OUTLIER -62.91 -64.3 0.96 Allowed 'General case' 0 C--N 1.324 -0.521 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 178.955 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.76 -34.36 88.4 Favored Glycine 0 N--CA 1.446 -0.667 0 CA-C-N 115.479 -0.782 . . . . 0.0 111.767 177.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.535 ' HB3' ' HA ' ' A' ' 8' ' ' LYS . . . -65.41 -29.24 69.91 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 121.103 0.477 . . . . 0.0 111.379 179.156 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.431 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 6.6 tmtt? -87.12 -42.33 13.1 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.695 -177.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.605 ' O ' HG12 ' A' ' 17' ' ' VAL . 30.6 pttt -87.01 -1.67 58.05 Favored 'General case' 0 C--O 1.205 -1.252 0 C-N-CA 120.842 -0.343 . . . . 0.0 110.997 -178.449 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -70.12 -15.87 63.03 Favored 'General case' 0 C--N 1.314 -0.973 0 CA-C-O 122.091 0.948 . . . . 0.0 108.476 172.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.6 mt -100.24 -30.27 11.99 Favored 'General case' 0 C--N 1.311 -1.075 0 CA-C-N 113.836 -1.529 . . . . 0.0 109.344 173.469 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.568 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -81.54 -53.96 3.65 Favored Glycine 0 N--CA 1.444 -0.771 0 CA-C-N 115.043 -0.98 . . . . 0.0 111.972 -177.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.605 HG12 ' O ' ' A' ' 13' ' ' LYS . 1.1 p -76.17 -23.15 15.81 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.788 0 CA-C-O 121.06 0.457 . . . . 0.0 110.464 -176.363 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -63.93 -23.61 67.41 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.521 0.677 . . . . 0.0 109.92 171.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 23.5 m -93.23 6.59 47.5 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 178.564 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.568 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.2 mptt -113.04 6.6 17.73 Favored 'General case' 0 N--CA 1.442 -0.847 0 CA-C-N 114.883 -1.053 . . . . 0.0 108.935 178.053 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.588 ' O ' HG22 ' A' ' 24' ' ' VAL . 12.9 m -133.77 -37.81 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.46 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.359 -175.713 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.519 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.16 -48.75 68.97 Favored Pre-proline 0 C--N 1.322 -0.611 0 CA-C-N 116.104 -0.498 . . . . 0.0 111.223 178.622 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.519 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 11.8 Cg_exo -70.24 -24.37 27.54 Favored 'Trans proline' 0 C--N 1.353 0.78 0 C-N-CA 121.637 1.558 . . . . 0.0 111.424 -179.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.588 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.02 -42.0 27.62 Favored 'Isoleucine or valine' 0 C--O 1.22 -0.467 0 C-N-CA 120.38 -0.528 . . . . 0.0 110.437 -179.149 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.491 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.5 t -67.42 -25.57 33.72 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.785 0 CA-C-O 121.755 0.788 . . . . 0.0 109.841 176.58 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.401 ' HB1' ' CZ ' ' A' ' 30' ' ' ARG . . . -70.54 -5.88 32.26 Favored 'General case' 0 C--N 1.301 -1.526 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.668 174.027 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.2 -26.46 9.17 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.03 174.242 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.491 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.5 m-85 -82.29 -33.84 28.92 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.658 -0.701 . . . . 0.0 110.668 179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.83 -62.57 1.47 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.338 -0.846 . . . . 0.0 111.01 -178.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.401 ' CZ ' ' HB1' ' A' ' 26' ' ' ALA . 1.7 ppt_? . . . . . 0 C--O 1.243 0.725 0 C-N-CA 120.023 -0.671 . . . . 0.0 111.638 -179.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 56.3 mtmt . . . . . 0 N--CA 1.48 1.062 0 CA-C-O 120.953 0.406 . . . . 0.0 110.507 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.407 HD12 ' N ' ' A' ' 2' ' ' ILE . 3.2 mp -80.0 133.51 29.49 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.701 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.388 178.242 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 39.0 t30 -59.96 118.86 6.76 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 121.211 0.529 . . . . 0.0 110.977 -177.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.641 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 13.2 mptt -90.8 -20.24 22.57 Favored 'General case' 0 CA--C 1.512 -0.498 0 CA-C-N 115.249 -0.887 . . . . 0.0 110.227 -176.547 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . 0.472 ' HA ' ' OE1' ' A' ' 5' ' ' GLN . 6.1 tp60 -66.42 -37.62 85.62 Favored 'General case' 0 C--N 1.32 -0.694 0 N-CA-C 109.012 -0.736 . . . . 0.0 109.012 177.302 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.426 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 54.6 tttt -54.27 -32.88 57.34 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 114.874 -1.057 . . . . 0.0 112.103 177.004 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.641 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.3 mp -55.35 -38.51 48.51 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.578 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.073 175.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.498 ' O ' ' HB3' ' A' ' 12' ' ' LYS . 6.6 mptt -84.59 -18.37 35.77 Favored 'General case' 0 CA--C 1.505 -0.76 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.738 177.672 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.426 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 0.9 OUTLIER -59.38 -59.92 4.68 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.984 -0.747 . . . . 0.0 108.984 179.704 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.77 -34.23 86.67 Favored Glycine 0 N--CA 1.445 -0.738 0 CA-C-N 115.107 -0.952 . . . . 0.0 111.945 179.49 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.422 ' HB3' ' HA ' ' A' ' 8' ' ' LYS . . . -67.54 -26.62 66.4 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 120.973 0.416 . . . . 0.0 111.315 179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.498 ' HB3' ' O ' ' A' ' 8' ' ' LYS . 0.8 OUTLIER -92.02 -37.52 12.77 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.98 -177.664 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.477 ' O ' HG12 ' A' ' 17' ' ' VAL . 4.9 pttt -84.97 -4.16 59.04 Favored 'General case' 0 C--O 1.202 -1.431 0 N-CA-C 109.945 -0.391 . . . . 0.0 109.945 178.517 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -65.24 -24.12 67.25 Favored 'General case' 0 C--N 1.316 -0.849 0 N-CA-C 108.219 -1.03 . . . . 0.0 108.219 171.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.9 mt -90.94 -33.82 15.43 Favored 'General case' 0 N--CA 1.443 -0.794 0 CA-C-N 113.889 -1.505 . . . . 0.0 109.4 175.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -76.28 -52.3 6.24 Favored Glycine 0 N--CA 1.446 -0.644 0 CA-C-N 115.104 -0.953 . . . . 0.0 111.901 -179.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.619 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.3 p -68.05 -24.3 30.06 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.652 0 CA-C-O 121.311 0.577 . . . . 0.0 110.305 -177.538 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.15 -22.85 65.08 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-N 115.585 -0.734 . . . . 0.0 110.518 173.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.4 m -95.08 3.14 55.14 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.815 -0.809 . . . . 0.0 108.815 177.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.476 ' HB2' ' HA ' ' A' ' 17' ' ' VAL . 5.5 mptp? -113.83 8.34 17.32 Favored 'General case' 0 N--CA 1.444 -0.775 0 CA-C-N 115.031 -0.986 . . . . 0.0 109.438 -179.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.619 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.0 m -135.64 -36.31 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.286 -175.803 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.473 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.73 -47.76 54.78 Favored Pre-proline 0 C--N 1.32 -0.684 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.649 -179.794 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.473 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.8 Cg_exo -72.75 -21.74 21.25 Favored 'Trans proline' 0 C--N 1.353 0.804 0 C-N-CA 121.829 1.686 . . . . 0.0 111.339 -179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.606 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -78.7 -42.4 25.16 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.32 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.275 179.523 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.52 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.3 t -68.37 -24.89 30.17 Favored 'Isoleucine or valine' 0 CA--C 1.502 -0.879 0 CA-C-O 121.858 0.837 . . . . 0.0 109.963 177.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.68 -8.65 53.55 Favored 'General case' 0 C--N 1.3 -1.559 0 CA-C-N 114.821 -1.082 . . . . 0.0 110.475 174.117 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.35 -24.16 11.2 Favored 'General case' 0 N--CA 1.453 -0.323 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.166 175.153 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.52 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 42.3 m-85 -83.08 -40.81 19.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.433 178.699 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -83.36 -49.9 8.88 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.305 179.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.243 0.754 0 CA-C-O 118.585 -0.722 . . . . 0.0 110.205 177.814 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 40.0 ttpt . . . . . 0 N--CA 1.48 1.059 0 CA-C-O 120.699 0.285 . . . . 0.0 110.406 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 72.6 mt -89.47 137.32 21.58 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.758 0 N-CA-C 109.579 -0.526 . . . . 0.0 109.579 176.434 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 36.0 t30 -138.7 125.51 20.98 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 120.953 0.406 . . . . 0.0 110.738 -177.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.62 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 46.4 mmtm -97.31 -17.45 19.76 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.6 -177.659 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -65.74 -36.94 84.99 Favored 'General case' 0 C--N 1.325 -0.477 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 175.942 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 28.8 ttpt -51.18 -35.09 34.5 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 114.949 -1.023 . . . . 0.0 111.571 175.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.62 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.3 mp -57.11 -40.96 76.62 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.47 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.292 177.64 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -76.11 -27.02 56.94 Favored 'General case' 0 CA--C 1.505 -0.783 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 178.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 24.9 m-80 -63.8 -56.07 18.28 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.496 -0.557 . . . . 0.0 109.496 178.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.07 -28.5 72.93 Favored Glycine 0 N--CA 1.445 -0.762 0 CA-C-N 115.394 -0.821 . . . . 0.0 112.321 178.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.59 -32.4 60.31 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.081 0.467 . . . . 0.0 110.561 177.299 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.442 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 0.8 OUTLIER -76.4 -39.21 54.28 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.624 -179.635 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.494 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -85.63 -8.7 58.09 Favored 'General case' 0 C--O 1.2 -1.522 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 178.442 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.422 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -65.65 -25.44 67.36 Favored 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 172.388 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.7 mt -89.34 -36.12 15.71 Favored 'General case' 0 N--CA 1.443 -0.801 0 CA-C-N 114.335 -1.302 . . . . 0.0 109.439 173.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.577 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -70.38 -50.88 24.43 Favored Glycine 0 N--CA 1.447 -0.628 0 CA-C-N 114.892 -1.049 . . . . 0.0 111.813 -178.487 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.533 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p -74.71 -19.91 16.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 114.626 -0.787 . . . . 0.0 110.61 -176.79 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.422 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -59.23 -25.42 64.01 Favored 'General case' 0 C--N 1.315 -0.902 0 CA-C-N 115.456 -0.793 . . . . 0.0 110.443 173.162 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -95.18 7.33 46.48 Favored 'General case' 0 N--CA 1.448 -0.536 0 CA-C-O 121.644 0.735 . . . . 0.0 109.124 178.52 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.577 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.3 mptt -112.36 7.04 19.08 Favored 'General case' 0 N--CA 1.44 -0.934 0 CA-C-N 115.104 -0.953 . . . . 0.0 108.975 179.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.566 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.6 m -133.51 -36.28 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.404 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.272 -175.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.489 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.9 -47.82 52.82 Favored Pre-proline 0 C--N 1.321 -0.643 0 CA-C-N 115.999 -0.546 . . . . 0.0 111.49 178.783 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.489 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 9.3 Cg_exo -71.7 -23.11 23.17 Favored 'Trans proline' 0 C--N 1.353 0.806 0 C-N-CA 121.848 1.698 . . . . 0.0 111.494 179.909 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 21' ' ' VAL . 4.5 m -77.9 -42.22 28.27 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.483 -179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.508 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 87.5 t -68.12 -23.42 28.78 Favored 'Isoleucine or valine' 0 CA--C 1.501 -0.942 0 CA-C-O 121.872 0.844 . . . . 0.0 109.453 174.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.599 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -73.14 -5.74 41.11 Favored 'General case' 0 C--N 1.301 -1.538 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.557 173.566 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -111.11 -21.99 11.67 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.418 -0.81 . . . . 0.0 109.833 173.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.508 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.1 m-85 -86.12 -29.97 22.89 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-O 121.388 0.613 . . . . 0.0 110.01 178.128 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.72 -52.18 5.46 Favored 'General case' 0 N--CA 1.444 -0.766 0 CA-C-N 115.295 -0.866 . . . . 0.0 110.03 176.149 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.599 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 48.5 mtm180 . . . . . 0 C--O 1.25 1.13 0 CA-C-O 118.691 -0.671 . . . . 0.0 110.597 174.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 63.9 pttt . . . . . 0 N--CA 1.481 1.101 0 N-CA-C 110.028 -0.36 . . . . 0.0 110.028 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 73.4 mt -121.19 136.18 58.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.518 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 179.485 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 32.2 t30 -110.65 123.39 49.92 Favored 'General case' 0 C--N 1.321 -0.634 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.602 -177.772 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.645 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 1.1 mptm? -91.45 -15.58 28.63 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.395 -177.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 39.1 tt0 -67.53 -36.6 81.32 Favored 'General case' 0 N--CA 1.445 -0.681 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 174.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 53.4 tttt -54.45 -33.13 59.03 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 115.213 -0.903 . . . . 0.0 111.865 177.249 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.645 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -56.28 -35.33 42.51 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.531 0 CA-C-N 116.519 -0.31 . . . . 0.0 111.02 176.167 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.433 ' O ' ' HB3' ' A' ' 12' ' ' LYS . 0.3 OUTLIER -79.27 -27.48 42.3 Favored 'General case' 0 CA--C 1.507 -0.701 0 C-N-CA 120.551 -0.46 . . . . 0.0 109.789 175.774 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.421 HD22 ' N ' ' A' ' 9' ' ' ASN . 0.8 OUTLIER -59.26 -60.77 3.33 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.023 0.44 . . . . 0.0 109.929 -175.199 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -67.57 -26.46 73.68 Favored Glycine 0 CA--C 1.508 -0.387 0 CA-C-N 115.432 -0.803 . . . . 0.0 112.613 -179.094 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.55 -31.81 60.18 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-O 121.156 0.503 . . . . 0.0 110.636 178.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.433 ' HB3' ' O ' ' A' ' 8' ' ' LYS . 6.1 tmtt? -83.14 -37.81 23.24 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.562 -177.692 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.524 ' O ' HG12 ' A' ' 17' ' ' VAL . 2.7 pttt -84.21 -5.53 59.27 Favored 'General case' 0 C--O 1.201 -1.448 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 177.275 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.452 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -68.41 -22.48 64.62 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.339 -0.985 . . . . 0.0 108.339 170.78 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.3 mt -96.08 -29.19 14.24 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 114.227 -1.352 . . . . 0.0 109.399 173.778 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.555 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -76.33 -48.54 9.29 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.077 -0.965 . . . . 0.0 111.702 -179.625 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.524 HG12 ' O ' ' A' ' 13' ' ' LYS . 1.7 p -76.8 -20.25 14.68 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-O 121.627 0.727 . . . . 0.0 109.86 -178.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.452 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -62.47 -25.71 68.13 Favored 'General case' 0 C--N 1.315 -0.91 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.901 171.039 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.5 m -89.62 5.63 44.84 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 108.729 -0.841 . . . . 0.0 108.729 178.453 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.555 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.1 mptm? -109.4 5.43 23.44 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-N 115.056 -0.975 . . . . 0.0 109.114 179.414 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.629 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.2 m -135.99 -36.76 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.416 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.372 -173.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.441 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.33 -46.1 84.84 Favored Pre-proline 0 C--N 1.321 -0.637 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.818 179.008 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.441 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.6 -22.19 21.23 Favored 'Trans proline' 0 C--N 1.358 1.033 0 C-N-CA 121.795 1.663 . . . . 0.0 111.491 179.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.629 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -81.32 -41.6 19.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.494 -178.834 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 21' ' ' VAL . 89.7 t -67.3 -24.66 32.09 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.714 0 CA-C-O 121.911 0.862 . . . . 0.0 109.704 176.461 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.21 -3.45 20.3 Favored 'General case' 0 C--N 1.303 -1.446 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.646 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.24 -17.91 10.67 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.49 -0.777 . . . . 0.0 110.188 174.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.8 m-85 -90.11 -42.82 10.87 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.828 178.151 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 -52.62 6.03 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.926 -176.788 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.246 0.869 0 C-N-CA 120.782 -0.367 . . . . 0.0 111.526 -179.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 26.7 mtpp . . . . . 0 N--CA 1.479 1.007 0 CA-C-O 120.984 0.421 . . . . 0.0 110.838 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 89.1 mt -110.25 134.51 52.21 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.607 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.027 178.697 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 35.8 t30 -159.1 106.85 1.81 Allowed 'General case' 0 C--N 1.322 -0.597 0 CA-C-O 121.336 0.589 . . . . 0.0 110.174 178.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.62 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 74.9 mmtt -88.76 -20.1 25.18 Favored 'General case' 0 C--N 1.315 -0.929 0 CA-C-N 114.896 -1.047 . . . . 0.0 110.291 -174.555 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 8.6 tp-100 -64.1 -32.85 74.56 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 175.884 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.474 ' HA ' ' HB2' ' A' ' 9' ' ' ASN . 4.0 ttpm? -59.01 -35.08 72.66 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.471 -0.786 . . . . 0.0 111.278 176.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.62 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.8 mp -58.54 -32.16 45.23 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.539 0 C-N-CA 121.029 -0.268 . . . . 0.0 111.368 178.326 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.434 ' HD3' ' HA ' ' A' ' 5' ' ' GLN . 0.4 OUTLIER -85.72 -37.25 19.57 Favored 'General case' 0 CA--C 1.503 -0.851 0 N-CA-C 109.13 -0.693 . . . . 0.0 109.13 176.545 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.474 ' HB2' ' HA ' ' A' ' 6' ' ' LYS . 12.8 m-20 -65.6 -45.96 81.2 Favored 'General case' 0 C--N 1.322 -0.607 0 CA-C-N 115.686 -0.688 . . . . 0.0 111.304 -176.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.47 -25.88 72.7 Favored Glycine 0 CA--C 1.506 -0.485 0 N-CA-C 111.358 -0.697 . . . . 0.0 111.358 176.47 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -80.93 -25.16 37.66 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.268 0.556 . . . . 0.0 110.145 174.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.69 -34.12 27.46 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.447 -179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.541 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -87.15 -7.95 57.46 Favored 'General case' 0 C--O 1.199 -1.571 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 174.103 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.447 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -66.3 -23.33 66.36 Favored 'General case' 0 C--N 1.316 -0.858 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 170.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.9 mt -94.57 -33.59 12.97 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 114.06 -1.427 . . . . 0.0 109.446 173.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.577 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -71.12 -46.81 41.03 Favored Glycine 0 N--CA 1.446 -0.647 0 CA-C-N 115.212 -0.904 . . . . 0.0 111.401 -179.84 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.541 HG12 ' O ' ' A' ' 13' ' ' LYS . 2.5 p -76.15 -24.6 16.41 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.726 0 CA-C-O 121.35 0.595 . . . . 0.0 110.037 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.447 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -62.21 -25.4 67.78 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 115.436 -0.802 . . . . 0.0 109.51 171.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 22.1 t -90.41 3.4 53.91 Favored 'General case' 0 N--CA 1.444 -0.725 0 N-CA-C 108.362 -0.977 . . . . 0.0 108.362 179.429 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.577 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.6 mptt -111.44 7.05 20.66 Favored 'General case' 0 N--CA 1.443 -0.795 0 CA-C-N 115.01 -0.995 . . . . 0.0 109.166 179.344 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.612 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.4 m -135.21 -37.83 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.401 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.341 -175.55 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.501 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.59 -48.78 80.06 Favored Pre-proline 0 C--N 1.324 -0.53 0 CA-C-N 116.319 -0.401 . . . . 0.0 111.392 179.169 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.501 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.2 Cg_exo -71.71 -23.47 22.72 Favored 'Trans proline' 0 C--N 1.353 0.778 0 C-N-CA 121.61 1.54 . . . . 0.0 111.379 -179.183 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -78.65 -41.81 24.98 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.305 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.272 -179.132 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.509 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 88.4 t -67.34 -24.57 31.87 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.712 0 CA-C-O 121.923 0.868 . . . . 0.0 109.798 176.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -72.48 0.78 9.41 Favored 'General case' 0 C--N 1.303 -1.415 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.52 174.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -119.73 -22.48 6.84 Favored 'General case' 0 N--CA 1.451 -0.387 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.209 173.031 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.509 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 48.9 m-85 -86.82 -34.87 19.39 Favored 'General case' 0 CA--C 1.519 -0.233 0 CA-C-O 121.223 0.535 . . . . 0.0 110.956 178.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -88.92 -61.41 1.71 Allowed 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.251 179.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.247 0.94 0 CA-C-O 119.272 -0.394 . . . . 0.0 111.515 -178.529 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 64.8 pttt . . . . . 0 N--CA 1.48 1.053 0 N-CA-C 110.151 -0.314 . . . . 0.0 110.151 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 39.6 mm -104.41 131.97 52.08 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 CA-C-N 116.503 -0.317 . . . . 0.0 110.277 179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 55.4 t-20 -114.34 122.49 46.86 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.158 177.505 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.612 ' HA ' HD13 ' A' ' 7' ' ' ILE . 34.4 mmtp -124.6 -17.39 5.99 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-N 115.419 -0.809 . . . . 0.0 109.974 172.308 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 24.4 tp60 -61.0 -37.17 81.59 Favored 'General case' 0 N--CA 1.452 -0.345 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.149 178.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 68.5 tttt -64.5 -41.77 96.23 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.658 176.986 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.612 HD13 ' HA ' ' A' ' 4' ' ' LYS . 3.8 mp -60.31 -41.96 88.96 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 177.157 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.476 ' HA ' ' HD2' ' A' ' 8' ' ' LYS . 37.9 tptt -64.63 -42.83 95.21 Favored 'General case' 0 N--CA 1.444 -0.759 0 CA-C-N 115.618 -0.719 . . . . 0.0 110.272 175.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.649 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 75.8 m-20 -68.96 -44.48 72.88 Favored 'General case' 0 C--N 1.322 -0.619 0 CA-C-N 115.967 -0.56 . . . . 0.0 111.748 -175.775 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.47 ' O ' ' HB2' ' A' ' 14' ' ' ALA . . . -64.21 -22.21 66.93 Favored Glycine 0 N--CA 1.451 -0.365 0 C-N-CA 120.479 -0.867 . . . . 0.0 111.391 177.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -88.8 -28.02 20.72 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.043 0.449 . . . . 0.0 110.572 176.286 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.457 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 3.2 tmtm? -85.32 -49.53 8.08 Favored 'General case' 0 N--CA 1.454 -0.268 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.959 -178.281 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.649 ' HG2' ' O ' ' A' ' 9' ' ' ASN . 50.4 pttt -81.47 -7.05 59.53 Favored 'General case' 0 C--O 1.205 -1.244 0 CA-C-O 120.726 0.298 . . . . 0.0 110.259 -175.494 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.488 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -66.18 -12.52 56.46 Favored 'General case' 0 C--N 1.314 -0.966 0 O-C-N 121.161 -0.962 . . . . 0.0 108.956 175.529 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.4 mt -102.75 -33.01 9.56 Favored 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 113.689 -1.596 . . . . 0.0 110.129 172.424 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.475 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -82.91 -53.96 3.36 Favored Glycine 0 N--CA 1.448 -0.501 0 CA-C-N 115.573 -0.739 . . . . 0.0 112.122 -177.944 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.604 HG12 ' O ' ' A' ' 13' ' ' LYS . 1.1 p -76.74 -18.36 14.75 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.802 0 CA-C-O 121.242 0.544 . . . . 0.0 110.049 -177.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.488 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -61.56 -24.29 66.55 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.641 -0.709 . . . . 0.0 109.784 170.617 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 24.7 m -93.27 8.29 40.91 Favored 'General case' 0 N--CA 1.446 -0.648 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.276 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.475 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.8 mptt -114.91 7.52 15.68 Favored 'General case' 0 N--CA 1.443 -0.822 0 CA-C-N 114.771 -1.104 . . . . 0.0 108.888 178.279 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.623 ' O ' HG22 ' A' ' 24' ' ' VAL . 10.6 m -136.71 -35.48 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.388 0 CA-C-N 114.626 -1.17 . . . . 0.0 109.788 -175.878 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.467 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -64.11 -47.16 79.97 Favored Pre-proline 0 C--N 1.323 -0.57 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.732 177.881 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.467 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.25 -22.81 21.67 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.633 1.555 . . . . 0.0 111.325 -179.753 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.7 m -78.98 -40.29 22.44 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.332 0 C-N-CA 120.4 -0.52 . . . . 0.0 110.204 -179.381 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.502 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.7 t -68.9 -25.25 29.74 Favored 'Isoleucine or valine' 0 CA--C 1.5 -0.947 0 CA-C-O 121.676 0.75 . . . . 0.0 109.566 174.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.502 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -72.03 -3.39 22.62 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.519 173.419 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.83 -28.57 8.71 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.701 172.526 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.502 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.5 m-85 -80.99 -31.05 34.89 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.454 -0.793 . . . . 0.0 110.661 179.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.3 -50.66 6.43 Favored 'General case' 0 C--N 1.318 -0.769 0 CA-C-N 115.305 -0.861 . . . . 0.0 109.972 177.3 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.502 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 79.1 mtm180 . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.629 -0.701 . . . . 0.0 110.341 175.422 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 51.7 mtmt . . . . . 0 N--CA 1.481 1.079 0 CA-C-O 120.846 0.355 . . . . 0.0 110.396 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 11.6 tt -78.22 155.06 5.12 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.721 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.211 179.163 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 26.7 t30 -74.48 115.33 13.9 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-O 121.001 0.429 . . . . 0.0 109.948 176.802 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.627 ' HA ' HD13 ' A' ' 7' ' ' ILE . 34.4 mmtp -85.89 -19.92 29.83 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-N 115.68 -0.691 . . . . 0.0 110.289 -172.904 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 51.3 tp60 -65.24 -37.5 87.43 Favored 'General case' 0 N--CA 1.446 -0.651 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.448 177.903 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 63.0 tttt -58.55 -40.86 84.22 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.944 175.342 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.627 HD13 ' HA ' ' A' ' 4' ' ' LYS . 1.7 mp -53.45 -41.19 44.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.276 178.069 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.505 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 2.9 mptt -77.83 -38.14 46.92 Favored 'General case' 0 CA--C 1.507 -0.688 0 C-N-CA 119.861 -0.736 . . . . 0.0 109.998 178.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 15.7 m-80 -62.49 -49.14 76.54 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.847 -176.808 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.8 -29.41 75.03 Favored Glycine 0 N--CA 1.446 -0.665 0 C-N-CA 120.842 -0.694 . . . . 0.0 111.945 178.011 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.45 -30.23 59.92 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-O 121.107 0.479 . . . . 0.0 110.301 176.568 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.449 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 9.9 tmtt? -77.68 -40.14 42.52 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.301 179.908 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.493 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -82.02 -11.05 59.03 Favored 'General case' 0 C--O 1.2 -1.522 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 177.86 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.9 -23.15 67.14 Favored 'General case' 0 C--N 1.312 -1.056 0 CA-C-O 121.868 0.842 . . . . 0.0 108.782 173.127 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.9 mt -90.75 -38.76 12.82 Favored 'General case' 0 C--N 1.317 -0.831 0 CA-C-N 114.302 -1.317 . . . . 0.0 109.121 172.843 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.707 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -69.42 -54.89 11.24 Favored Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.694 -1.139 . . . . 0.0 111.585 -177.249 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.582 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.5 p -68.7 -28.06 38.5 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.934 0 CA-C-N 114.817 -0.691 . . . . 0.0 111.017 -175.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -62.27 -22.34 65.93 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.447 174.343 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 32.4 m -100.03 9.15 43.34 Favored 'General case' 0 N--CA 1.447 -0.59 0 CA-C-N 115.384 -0.825 . . . . 0.0 109.139 178.212 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.707 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.4 mptm? -114.48 9.06 16.66 Favored 'General case' 0 N--CA 1.448 -0.533 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.122 178.161 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 17' ' ' VAL . 14.1 m -131.99 -35.93 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.323 -0.566 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.113 -175.818 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.485 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -70.13 -47.84 20.79 Favored Pre-proline 0 C--N 1.318 -0.767 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.351 179.808 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.485 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 5.0 Cg_exo -73.73 -20.05 20.51 Favored 'Trans proline' 0 C--N 1.352 0.759 0 C-N-CA 121.868 1.712 . . . . 0.0 111.596 -179.631 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.528 HG22 ' O ' ' A' ' 21' ' ' VAL . 4.4 m -78.73 -42.86 25.32 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.383 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.185 178.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.49 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.4 t -66.93 -24.3 32.25 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.596 0 CA-C-O 121.972 0.891 . . . . 0.0 109.691 175.414 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.485 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -73.07 -0.62 14.52 Favored 'General case' 0 C--N 1.304 -1.398 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.504 174.2 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.68 -22.17 8.17 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.102 -0.954 . . . . 0.0 109.948 173.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.49 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.2 m-85 -87.38 -40.99 13.93 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 116.092 -0.503 . . . . 0.0 110.889 179.488 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.35 -46.41 9.69 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.744 179.38 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.485 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 8.7 mtm180 . . . . . 0 C--O 1.249 1.048 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.769 176.689 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.48 1.057 0 CA-C-O 120.798 0.332 . . . . 0.0 110.439 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 34.7 mm -107.01 123.58 62.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.467 0 CA-C-N 116.019 -0.537 . . . . 0.0 109.927 178.231 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 51.0 t30 -85.14 115.17 22.79 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.991 0.425 . . . . 0.0 111.041 -177.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.668 ' HA ' HD13 ' A' ' 7' ' ' ILE . 34.0 mmtp -109.51 -5.08 15.86 Favored 'General case' 0 C--N 1.317 -0.822 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.109 175.239 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 6.5 tp-100 -59.86 -51.26 70.48 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.058 -0.519 . . . . 0.0 109.638 179.448 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 57.8 tttt -58.19 -37.44 74.77 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 115.832 -0.622 . . . . 0.0 111.3 177.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.668 HD13 ' HA ' ' A' ' 4' ' ' LYS . 3.1 mp -61.33 -40.39 85.99 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.442 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 176.255 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.437 ' HA ' ' HD2' ' A' ' 8' ' ' LYS . 17.3 tptm -64.82 -41.28 95.89 Favored 'General case' 0 N--CA 1.442 -0.858 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.734 174.252 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 20.9 m-80 -55.09 -57.03 13.38 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 178.146 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.31 -36.71 92.88 Favored Glycine 0 N--CA 1.446 -0.688 0 CA-C-N 115.634 -0.712 . . . . 0.0 112.537 -179.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.8 -34.79 72.11 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.032 0.444 . . . . 0.0 111.148 179.787 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -81.86 -36.17 28.53 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.686 -176.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.49 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -83.54 -11.17 57.73 Favored 'General case' 0 C--O 1.202 -1.406 0 N-CA-C 109.727 -0.471 . . . . 0.0 109.727 177.376 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.411 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -62.21 -23.85 66.88 Favored 'General case' 0 C--N 1.312 -1.048 0 N-CA-C 108.42 -0.956 . . . . 0.0 108.42 172.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 9.2 mt -90.81 -38.3 13.06 Favored 'General case' 0 N--CA 1.444 -0.753 0 CA-C-N 114.229 -1.351 . . . . 0.0 109.756 174.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.533 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -70.21 -50.75 26.0 Favored Glycine 0 N--CA 1.447 -0.62 0 CA-C-N 115.119 -0.946 . . . . 0.0 111.775 -178.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.503 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p -71.72 -24.46 23.26 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 114.899 -0.65 . . . . 0.0 110.442 -177.793 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.411 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -64.53 -18.67 65.04 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.229 172.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 9.5 t -99.84 7.85 44.63 Favored 'General case' 0 N--CA 1.444 -0.747 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 177.077 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.533 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 4.9 mptp? -114.08 11.59 17.69 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.089 -0.96 . . . . 0.0 108.97 178.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.609 ' O ' HG22 ' A' ' 24' ' ' VAL . 13.5 m -138.03 -37.37 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 114.713 -1.131 . . . . 0.0 109.969 -175.434 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.487 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.87 -48.08 52.49 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.551 178.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.487 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 12.0 Cg_exo -70.51 -24.25 26.47 Favored 'Trans proline' 0 C--N 1.353 0.798 0 C-N-CA 121.627 1.551 . . . . 0.0 111.412 -179.209 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.609 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.8 m -75.85 -43.22 39.89 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 C-N-CA 120.316 -0.554 . . . . 0.0 110.199 -179.676 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 21' ' ' VAL . 94.8 t -69.2 -25.88 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.498 -1.03 0 CA-C-O 121.477 0.656 . . . . 0.0 110.282 176.642 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -67.28 -16.57 64.35 Favored 'General case' 0 C--N 1.298 -1.638 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.279 173.731 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -98.46 -27.5 14.04 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.069 176.292 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.475 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 51.1 m-85 -83.24 -26.14 31.03 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.533 -0.758 . . . . 0.0 111.018 178.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -90.91 -64.84 1.07 Allowed 'General case' 0 C--N 1.321 -0.66 0 CA-C-N 115.704 -0.68 . . . . 0.0 110.542 179.339 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.25 1.111 0 C-N-CA 120.242 -0.583 . . . . 0.0 110.863 179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 63.1 tttm . . . . . 0 N--CA 1.479 0.994 0 CA-C-O 121.038 0.447 . . . . 0.0 110.332 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 79.0 mt -106.62 125.95 62.47 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.559 0 N-CA-C 109.651 -0.5 . . . . 0.0 109.651 178.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 40.0 t30 -67.67 112.8 4.99 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-O 121.286 0.565 . . . . 0.0 110.371 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.62 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 34.8 mmtp -95.35 -17.69 21.39 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.008 -176.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -61.4 -40.07 93.03 Favored 'General case' 0 C--N 1.325 -0.483 0 N-CA-C 109.002 -0.74 . . . . 0.0 109.002 175.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.42 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 4.5 ttpm? -55.38 -33.44 63.45 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.207 -0.906 . . . . 0.0 111.83 178.063 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.62 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -56.91 -40.79 74.32 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.511 0 C-N-CA 120.832 -0.347 . . . . 0.0 111.085 176.646 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.37 -32.45 60.84 Favored 'General case' 0 CA--C 1.5 -0.952 0 C-N-CA 120.176 -0.609 . . . . 0.0 109.384 177.305 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.491 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 17.0 m-80 -55.9 -57.39 12.27 Favored 'General case' 0 C--N 1.324 -0.541 0 O-C-N 123.526 0.516 . . . . 0.0 109.643 178.234 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -64.81 -36.37 93.02 Favored Glycine 0 N--CA 1.444 -0.768 0 CA-C-N 115.289 -0.869 . . . . 0.0 112.143 179.962 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -68.35 -27.45 66.27 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.016 0.436 . . . . 0.0 111.066 177.995 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.434 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 9.1 tmtt? -82.81 -43.31 16.83 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.759 -178.96 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.589 ' O ' HG12 ' A' ' 17' ' ' VAL . 25.0 pttt -86.75 -3.6 59.07 Favored 'General case' 0 C--O 1.202 -1.396 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.857 -179.18 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.48 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -68.87 -17.09 63.93 Favored 'General case' 0 C--N 1.314 -0.952 0 O-C-N 121.24 -0.913 . . . . 0.0 108.56 173.145 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.1 mt -98.61 -32.98 11.15 Favored 'General case' 0 C--N 1.313 -0.996 0 CA-C-N 113.754 -1.567 . . . . 0.0 109.403 172.939 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.489 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -77.89 -52.22 5.48 Favored Glycine 0 N--CA 1.447 -0.622 0 CA-C-N 115.12 -0.946 . . . . 0.0 112.062 -177.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.589 HG12 ' O ' ' A' ' 13' ' ' LYS . 1.2 p -76.13 -21.65 15.53 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.77 0 CA-C-O 121.258 0.551 . . . . 0.0 110.127 -177.702 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.48 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -61.02 -27.78 68.57 Favored 'General case' 0 C--N 1.316 -0.855 0 CA-C-N 115.576 -0.738 . . . . 0.0 109.914 170.847 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 17.3 m -89.69 6.02 43.28 Favored 'General case' 0 N--CA 1.446 -0.674 0 N-CA-C 108.474 -0.935 . . . . 0.0 108.474 179.937 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.489 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -111.89 5.89 19.19 Favored 'General case' 0 N--CA 1.441 -0.921 0 CA-C-N 114.809 -1.087 . . . . 0.0 108.854 178.349 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.604 ' O ' HG22 ' A' ' 24' ' ' VAL . 7.5 m -135.98 -37.76 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.382 0 CA-C-N 114.832 -1.076 . . . . 0.0 110.38 -175.352 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.494 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.2 -48.61 68.82 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.337 -0.392 . . . . 0.0 111.707 179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.494 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.7 Cg_exo -72.01 -22.09 23.4 Favored 'Trans proline' 0 C--N 1.352 0.736 0 C-N-CA 121.554 1.503 . . . . 0.0 111.371 -179.023 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.604 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.2 m -79.57 -41.42 22.17 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.381 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.279 -179.751 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 92.5 t -67.51 -24.11 30.86 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.779 0 CA-C-O 121.846 0.831 . . . . 0.0 109.674 176.558 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -74.57 2.6 9.36 Favored 'General case' 0 C--N 1.303 -1.443 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.519 174.705 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -120.98 -22.64 6.1 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.081 172.516 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -84.98 -41.6 15.7 Favored 'General case' 0 CA--C 1.517 -0.324 0 CA-C-O 121.297 0.57 . . . . 0.0 110.361 178.494 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.07 -51.46 7.99 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-N 115.445 -0.798 . . . . 0.0 109.357 177.584 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 44.7 mtm180 . . . . . 0 C--O 1.247 0.953 0 CA-C-O 118.479 -0.772 . . . . 0.0 111.125 175.605 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 96.8 mttt . . . . . 0 N--CA 1.476 0.868 0 N-CA-C 110.055 -0.35 . . . . 0.0 110.055 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 48.2 mm -79.09 147.05 7.03 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.637 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.604 -176.028 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 54.1 t30 78.34 104.41 0.07 Allowed 'General case' 0 CA--C 1.51 -0.578 0 O-C-N 124.327 1.017 . . . . 0.0 110.773 -179.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.605 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 75.2 mmtt -94.18 -12.7 27.76 Favored 'General case' 0 C--N 1.311 -1.098 0 CA-C-N 114.421 -1.263 . . . . 0.0 110.195 -178.486 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . 0.436 ' HA ' ' CD ' ' A' ' 8' ' ' LYS . 49.8 tp60 -65.15 -33.78 76.83 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 109.514 -0.55 . . . . 0.0 109.514 174.471 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -55.47 -42.12 73.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.92 174.972 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.605 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 3.6 mp -58.18 -39.06 71.66 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.5 0 CA-C-N 116.027 -0.533 . . . . 0.0 111.555 179.535 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.493 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 2.8 mptt -79.51 -26.95 41.43 Favored 'General case' 0 CA--C 1.506 -0.714 0 C-N-CA 119.592 -0.843 . . . . 0.0 109.853 177.858 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 41.0 m-20 -72.03 -46.14 58.19 Favored 'General case' 0 C--N 1.319 -0.759 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.709 -177.791 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -63.84 -31.1 79.66 Favored Glycine 0 N--CA 1.446 -0.673 0 N-CA-C 111.035 -0.826 . . . . 0.0 111.035 174.157 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -75.85 -27.3 57.77 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-O 120.966 0.413 . . . . 0.0 110.697 176.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.483 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 0.9 OUTLIER -78.87 -42.04 28.36 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.143 -179.905 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.494 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -83.38 -10.13 58.62 Favored 'General case' 0 C--O 1.199 -1.57 0 N-CA-C 109.619 -0.511 . . . . 0.0 109.619 178.346 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.12 -24.89 67.86 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 108.292 -1.003 . . . . 0.0 108.292 172.611 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 7.7 mt -87.24 -40.69 14.31 Favored 'General case' 0 N--CA 1.445 -0.702 0 CA-C-N 114.149 -1.387 . . . . 0.0 109.333 172.907 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.594 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -68.77 -52.38 25.07 Favored Glycine 0 N--CA 1.446 -0.653 0 CA-C-N 115.098 -0.955 . . . . 0.0 111.89 -177.342 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.556 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.6 p -71.03 -22.92 23.06 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-N 114.743 -0.729 . . . . 0.0 110.721 -176.175 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.12 -31.15 68.68 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.549 -0.75 . . . . 0.0 110.121 172.763 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 20.1 m -90.61 8.54 33.68 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.594 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.1 mptm? -112.42 5.19 17.96 Favored 'General case' 0 N--CA 1.437 -1.076 0 CA-C-N 115.03 -0.986 . . . . 0.0 108.854 178.046 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.658 ' O ' HG22 ' A' ' 24' ' ' VAL . 5.8 m -136.3 -36.96 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.596 -174.678 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.516 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -69.8 -47.79 23.35 Favored Pre-proline 0 C--N 1.319 -0.728 0 CA-C-N 116.28 -0.418 . . . . 0.0 111.684 179.567 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.516 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 11.0 Cg_exo -70.14 -22.22 30.63 Favored 'Trans proline' 0 C--N 1.351 0.675 0 C-N-CA 121.797 1.665 . . . . 0.0 111.419 -179.512 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.658 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.5 m -76.79 -42.42 33.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 C-N-CA 120.328 -0.549 . . . . 0.0 110.137 179.76 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.479 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 93.1 t -68.13 -25.14 31.14 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.715 0 CA-C-O 121.833 0.825 . . . . 0.0 109.682 176.031 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -73.05 0.51 11.22 Favored 'General case' 0 C--N 1.303 -1.442 0 CA-C-N 114.78 -1.1 . . . . 0.0 110.664 174.057 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.63 -22.32 8.13 Favored 'General case' 0 N--CA 1.45 -0.444 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.037 172.764 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.479 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.4 m-85 -85.95 -41.61 14.76 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.846 178.618 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.56 -56.5 3.83 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.803 -178.695 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.241 0.626 0 C-N-CA 120.868 -0.333 . . . . 0.0 111.454 179.937 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 67.1 mttm . . . . . 0 N--CA 1.477 0.924 0 CA-C-O 120.745 0.307 . . . . 0.0 110.386 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 72.4 mt -117.39 132.59 66.74 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-N 115.947 -0.569 . . . . 0.0 109.869 179.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.4 t30 -68.18 109.0 3.36 Favored 'General case' 0 C--N 1.324 -0.519 0 CA-C-O 121.029 0.442 . . . . 0.0 110.296 177.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.637 ' HA ' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -96.94 -7.94 31.91 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-N 115.645 -0.707 . . . . 0.0 110.018 -176.233 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 5.9 tp-100 -64.74 -43.65 92.66 Favored 'General case' 0 N--CA 1.449 -0.478 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 176.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 16.4 ttpp -56.97 -35.38 69.08 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.539 173.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.637 HD13 ' HA ' ' A' ' 4' ' ' LYS . 1.8 mp -64.07 -42.82 96.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.8 0 N-CA-C 109.53 -0.544 . . . . 0.0 109.53 177.038 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.471 ' HA ' ' HD2' ' A' ' 8' ' ' LYS . 22.5 tptp -58.54 -42.01 86.85 Favored 'General case' 0 CA--C 1.51 -0.586 0 CA-C-N 115.837 -0.62 . . . . 0.0 110.908 172.993 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 24.2 m-80 -55.83 -57.52 11.7 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.474 179.666 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.77 -20.8 70.67 Favored Glycine 0 N--CA 1.45 -0.381 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.606 -179.819 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -84.08 -25.94 29.39 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-O 121.223 0.535 . . . . 0.0 110.672 177.551 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 2.1 tmtm? -88.25 -40.19 13.84 Favored 'General case' 0 N--CA 1.448 -0.574 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.382 -178.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.477 ' O ' HG12 ' A' ' 17' ' ' VAL . 3.5 pttt -80.82 -6.65 58.83 Favored 'General case' 0 C--O 1.202 -1.395 0 N-CA-C 109.857 -0.423 . . . . 0.0 109.857 177.016 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -66.2 -21.27 66.3 Favored 'General case' 0 C--N 1.316 -0.882 0 CA-C-O 121.945 0.879 . . . . 0.0 108.7 172.721 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 8.1 mt -93.26 -35.87 12.87 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 114.038 -1.437 . . . . 0.0 109.532 173.48 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.631 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -72.83 -52.25 9.75 Favored Glycine 0 CA--C 1.502 -0.745 0 CA-C-N 115.008 -0.996 . . . . 0.0 111.797 -178.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.581 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.8 p -69.37 -25.11 28.48 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 114.999 -0.6 . . . . 0.0 110.423 -176.574 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.67 -28.13 67.0 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.458 -0.792 . . . . 0.0 110.433 173.524 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 15.6 m -93.08 5.96 49.65 Favored 'General case' 0 C--N 1.326 -0.437 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.287 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.631 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 0.9 OUTLIER -111.48 8.02 20.95 Favored 'General case' 0 N--CA 1.439 -0.992 0 CA-C-N 115.093 -0.958 . . . . 0.0 108.849 179.507 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.621 ' O ' HG22 ' A' ' 24' ' ' VAL . 5.4 m -136.56 -39.93 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.452 -0.374 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.435 -175.966 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.52 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -66.1 -49.05 58.18 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.284 -0.416 . . . . 0.0 111.74 -178.435 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.52 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.9 Cg_exo -72.28 -21.32 23.41 Favored 'Trans proline' 0 N--CA 1.454 -0.82 0 C-N-CA 121.65 1.566 . . . . 0.0 111.396 -178.806 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.0 m -78.73 -43.19 25.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 C-N-CA 120.374 -0.531 . . . . 0.0 110.027 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.6 t -68.34 -23.85 28.91 Favored 'Isoleucine or valine' 0 CA--C 1.506 -0.721 0 CA-C-O 121.922 0.868 . . . . 0.0 109.975 176.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.88 -5.15 28.45 Favored 'General case' 0 C--N 1.305 -1.358 0 CA-C-N 114.861 -1.063 . . . . 0.0 110.205 174.39 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.18 -25.11 9.05 Favored 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 115.083 -0.962 . . . . 0.0 110.349 174.28 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.9 m-85 -85.39 -31.93 22.66 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.019 -0.537 . . . . 0.0 110.968 -179.342 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -96.26 -55.39 2.96 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.486 -0.779 . . . . 0.0 110.489 -179.504 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.969 0 CA-C-O 118.46 -0.781 . . . . 0.0 110.158 -179.019 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 46.7 mmtm . . . . . 0 N--CA 1.481 1.103 0 CA-C-O 120.774 0.321 . . . . 0.0 110.192 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.423 ' N ' HD12 ' A' ' 2' ' ' ILE . 3.1 mp -92.75 125.94 45.27 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.651 0 CA-C-N 116.164 -0.471 . . . . 0.0 109.959 -178.852 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 40.4 t30 -121.9 106.45 11.25 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 121.423 0.63 . . . . 0.0 110.485 177.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.619 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 34.6 mmtp -88.37 -17.44 30.54 Favored 'General case' 0 C--N 1.315 -0.926 0 CA-C-N 114.843 -1.071 . . . . 0.0 109.723 -177.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . 0.442 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 54.9 tp60 -64.29 -37.56 87.92 Favored 'General case' 0 N--CA 1.448 -0.571 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 174.732 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 5.0 ttpm? -50.01 -37.48 32.99 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-N 115.593 -0.73 . . . . 0.0 111.301 175.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.619 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -56.66 -39.95 66.44 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.428 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.222 178.373 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.442 ' HD3' ' HA ' ' A' ' 5' ' ' GLN . 0.0 OUTLIER -80.96 -22.59 39.43 Favored 'General case' 0 CA--C 1.508 -0.664 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.855 179.746 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 25.7 m-80 -64.42 -57.57 8.91 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 177.77 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -60.66 -39.4 96.53 Favored Glycine 0 N--CA 1.444 -0.784 0 CA-C-N 115.396 -0.82 . . . . 0.0 111.633 177.45 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -65.36 -29.38 70.1 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.817 0.341 . . . . 0.0 111.423 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.405 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 1.0 OUTLIER -83.6 -43.14 15.96 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-O 121.041 0.448 . . . . 0.0 110.763 -177.936 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.536 ' O ' HG12 ' A' ' 17' ' ' VAL . 2.6 pttm -88.42 -3.16 58.88 Favored 'General case' 0 C--O 1.202 -1.442 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.748 -177.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -68.31 -22.18 64.72 Favored 'General case' 0 C--N 1.313 -0.998 0 N-CA-C 108.131 -1.063 . . . . 0.0 108.131 171.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.8 mt -94.54 -29.88 14.67 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 114.059 -1.428 . . . . 0.0 109.454 174.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.591 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -79.27 -53.23 4.51 Favored Glycine 0 N--CA 1.444 -0.824 0 CA-C-N 114.977 -1.011 . . . . 0.0 111.98 -179.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.612 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.4 p -72.6 -25.59 22.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.757 0 CA-C-N 115.317 -0.442 . . . . 0.0 110.617 -175.716 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -59.99 -28.99 68.15 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 121.267 0.556 . . . . 0.0 109.916 173.008 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 41.5 m -89.34 3.88 50.71 Favored 'General case' 0 N--CA 1.446 -0.649 0 N-CA-C 108.915 -0.772 . . . . 0.0 108.915 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.591 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.5 mptm? -112.29 4.58 17.8 Favored 'General case' 0 N--CA 1.441 -0.903 0 CA-C-N 115.242 -0.89 . . . . 0.0 109.078 179.292 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.612 HG13 ' O ' ' A' ' 17' ' ' VAL . 7.2 m -134.35 -36.13 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.481 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.754 -175.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.518 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -71.25 -49.92 11.75 Favored Pre-proline 0 C--N 1.318 -0.764 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.406 -179.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.518 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.8 Cg_exo -71.41 -22.41 25.01 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.652 1.568 . . . . 0.0 111.153 -178.261 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.481 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -77.67 -45.34 28.62 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.402 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.233 -179.807 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 83.7 t -69.01 -22.99 26.71 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.635 0 CA-C-O 122.021 0.915 . . . . 0.0 109.848 177.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.417 ' HA ' ' HD2' ' A' ' 30' ' ' ARG . . . -72.36 1.47 7.81 Favored 'General case' 0 C--N 1.303 -1.43 0 CA-C-N 114.605 -1.18 . . . . 0.0 110.361 172.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -125.11 -15.16 6.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.465 174.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.504 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 52.7 m-85 -94.1 -30.47 14.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 121.063 0.458 . . . . 0.0 111.15 177.327 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -112.78 -47.1 3.08 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.879 -0.6 . . . . 0.0 112.073 -173.502 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.417 ' HD2' ' HA ' ' A' ' 26' ' ' ALA . 0.6 OUTLIER . . . . . 0 C--O 1.246 0.909 0 CA-C-O 119.075 -0.488 . . . . 0.0 112.073 -174.569 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt . . . . . 0 N--CA 1.484 1.235 0 CA-C-O 120.652 0.263 . . . . 0.0 111.045 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 81.2 mt -98.17 129.28 48.64 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.573 0 CA-C-O 120.94 0.4 . . . . 0.0 110.505 -178.624 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 54.3 t-20 -113.68 131.74 56.04 Favored 'General case' 0 C--N 1.319 -0.754 0 N-CA-C 109.373 -0.603 . . . . 0.0 109.373 176.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.596 ' O ' ' HB ' ' A' ' 7' ' ' ILE . 32.7 mmtp -112.37 -33.35 6.22 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.032 177.078 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 24.5 tp60 -59.49 -45.93 90.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 120.957 0.408 . . . . 0.0 110.667 -178.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 55.8 tttt -53.2 -34.16 55.82 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-O 121.832 0.825 . . . . 0.0 110.832 178.502 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.596 ' HB ' ' O ' ' A' ' 4' ' ' LYS . 1.2 mp -62.27 -31.17 50.72 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 114.363 -1.289 . . . . 0.0 111.423 -176.598 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.476 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 0.0 OUTLIER -87.71 -25.08 23.64 Favored 'General case' 0 CA--C 1.504 -0.79 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 177.076 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 21.6 m-80 -60.81 -59.06 5.98 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 178.585 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.455 ' O ' ' HB2' ' A' ' 14' ' ' ALA . . . -65.81 -26.14 72.06 Favored Glycine 0 N--CA 1.443 -0.866 0 CA-C-N 115.157 -0.929 . . . . 0.0 112.229 179.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -76.77 -27.79 55.44 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.08 0.467 . . . . 0.0 110.653 177.437 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -83.91 -40.44 18.57 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.677 -178.205 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.509 ' O ' HG12 ' A' ' 17' ' ' VAL . 10.2 pttt -85.57 -4.03 59.04 Favored 'General case' 0 C--O 1.201 -1.492 0 N-CA-C 109.699 -0.482 . . . . 0.0 109.699 177.215 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.455 ' HB2' ' O ' ' A' ' 10' ' ' GLY . . . -66.16 -21.81 66.35 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 108.423 -0.954 . . . . 0.0 108.423 171.766 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 4.9 mt -91.42 -34.82 14.69 Favored 'General case' 0 C--N 1.318 -0.779 0 CA-C-N 113.978 -1.464 . . . . 0.0 109.475 175.03 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.511 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -75.84 -54.45 5.35 Favored Glycine 0 N--CA 1.446 -0.699 0 CA-C-N 115.122 -0.945 . . . . 0.0 111.93 -179.262 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.608 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.7 p -70.01 -24.11 26.06 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.772 0 CA-C-N 115.052 -0.574 . . . . 0.0 110.77 -175.827 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.406 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -59.67 -29.01 67.78 Favored 'General case' 0 C--N 1.318 -0.771 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.405 174.189 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 19.4 m -91.91 6.5 45.98 Favored 'General case' 0 N--CA 1.446 -0.626 0 N-CA-C 108.798 -0.816 . . . . 0.0 108.798 179.077 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.511 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 5.3 mptp? -114.86 7.17 15.65 Favored 'General case' 0 N--CA 1.441 -0.907 0 CA-C-N 115.211 -0.904 . . . . 0.0 109.18 179.193 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.608 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.1 m -133.61 -37.36 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.599 0 CA-C-N 114.83 -1.077 . . . . 0.0 109.986 -176.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.451 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -65.35 -47.1 70.84 Favored Pre-proline 0 C--N 1.322 -0.601 0 CA-C-N 116.049 -0.523 . . . . 0.0 111.476 179.365 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.451 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 4.0 Cg_exo -74.52 -18.96 19.59 Favored 'Trans proline' 0 N--CA 1.453 -0.858 0 C-N-CA 121.589 1.526 . . . . 0.0 111.654 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.582 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -81.81 -43.99 19.97 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.301 0 C-N-CA 120.358 -0.537 . . . . 0.0 110.152 179.518 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.495 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 89.2 t -67.2 -22.63 29.39 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.807 0 CA-C-O 121.932 0.872 . . . . 0.0 109.993 176.35 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.31 -10.8 60.35 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.075 -0.966 . . . . 0.0 110.532 174.25 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -107.52 -19.47 13.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.266 -0.879 . . . . 0.0 109.989 175.554 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.495 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 53.9 m-85 -90.89 -46.27 8.29 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.971 178.393 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -75.37 -48.97 20.51 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.156 178.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.421 HH11 ' HD2' ' A' ' 30' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.95 0 CA-C-O 118.204 -0.903 . . . . 0.0 110.227 178.084 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 71.2 mmtt . . . . . 0 N--CA 1.48 1.041 0 CA-C-O 121.006 0.432 . . . . 0.0 111.127 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 82.3 mt -135.24 119.11 25.29 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.557 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.267 177.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 27.7 t30 -164.47 119.29 1.43 Allowed 'General case' 0 C--N 1.323 -0.544 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.434 178.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.615 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 47.9 mmtm -93.3 -17.64 23.37 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.884 -175.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 46.9 tp60 -61.99 -42.74 99.48 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 109.654 -0.498 . . . . 0.0 109.654 176.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 29.2 ttpt -51.8 -35.5 44.39 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-N 115.395 -0.82 . . . . 0.0 111.767 176.711 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.615 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.5 mp -57.32 -38.05 60.19 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.431 0 CA-C-N 116.552 -0.295 . . . . 0.0 111.495 177.873 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -75.92 -32.82 59.77 Favored 'General case' 0 CA--C 1.501 -0.935 0 N-CA-C 108.957 -0.757 . . . . 0.0 108.957 178.764 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . . . . . . . . . 25.8 m-80 -59.52 -56.34 23.25 Favored 'General case' 0 N--CA 1.447 -0.579 0 CA-C-N 115.776 -0.647 . . . . 0.0 109.719 179.638 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -62.78 -36.68 93.68 Favored Glycine 0 N--CA 1.445 -0.752 0 CA-C-N 115.19 -0.914 . . . . 0.0 112.275 179.751 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -70.72 -30.73 67.35 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.876 0.37 . . . . 0.0 111.203 179.123 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 8.8 tmtt? -80.5 -38.45 29.81 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.004 0.43 . . . . 0.0 110.967 -178.793 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.465 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -87.3 -7.04 58.27 Favored 'General case' 0 C--O 1.2 -1.54 0 N-CA-C 109.832 -0.433 . . . . 0.0 109.832 178.576 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.92 -22.61 67.03 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 172.042 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 mt -91.79 -35.21 14.24 Favored 'General case' 0 C--N 1.319 -0.737 0 CA-C-N 114.024 -1.444 . . . . 0.0 109.553 174.186 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.532 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -75.65 -51.57 7.11 Favored Glycine 0 N--CA 1.448 -0.537 0 CA-C-N 115.105 -0.952 . . . . 0.0 112.468 -178.485 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.583 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.4 p -71.39 -23.27 22.76 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.723 0 CA-C-O 121.254 0.55 . . . . 0.0 110.332 -177.06 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -60.33 -28.33 68.05 Favored 'General case' 0 C--N 1.318 -0.792 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.973 172.85 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 10.7 m -89.31 4.94 47.18 Favored 'General case' 0 N--CA 1.447 -0.578 0 N-CA-C 108.789 -0.819 . . . . 0.0 108.789 178.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.532 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 13.9 mptt -112.69 4.02 16.91 Favored 'General case' 0 N--CA 1.437 -1.117 0 CA-C-N 115.151 -0.931 . . . . 0.0 109.271 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.612 ' O ' HG22 ' A' ' 24' ' ' VAL . 6.1 m -135.71 -35.82 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.36 -0.836 . . . . 0.0 110.608 -174.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.503 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -71.35 -49.12 12.31 Favored Pre-proline 0 C--N 1.316 -0.863 0 CA-C-N 116.088 -0.505 . . . . 0.0 111.584 -179.509 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.503 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 7.3 Cg_exo -71.46 -19.94 27.96 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 121.753 1.635 . . . . 0.0 111.28 -178.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -77.21 -44.44 30.83 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.322 0 C-N-CA 120.406 -0.517 . . . . 0.0 109.875 178.547 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.477 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 99.4 t -68.78 -24.06 28.34 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.763 0 CA-C-O 121.851 0.834 . . . . 0.0 110.048 177.242 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.413 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -75.18 0.61 15.78 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.432 174.694 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -116.54 -21.82 8.99 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.144 -0.935 . . . . 0.0 109.785 172.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.477 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.8 m-85 -86.52 -48.07 8.7 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.735 -0.666 . . . . 0.0 110.522 178.419 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -75.14 -48.23 24.71 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.602 178.087 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.413 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 34.2 mtm180 . . . . . 0 C--O 1.248 1.002 0 CA-C-O 118.502 -0.761 . . . . 0.0 111.016 176.041 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 14.6 mmmm . . . . . 0 N--CA 1.479 1.0 0 CA-C-O 120.825 0.345 . . . . 0.0 110.975 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 80.4 mt -122.74 129.82 74.91 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.596 0 N-CA-C 109.958 -0.386 . . . . 0.0 109.958 178.998 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 40.2 t30 -119.43 119.01 32.66 Favored 'General case' 0 C--N 1.321 -0.637 0 CA-C-O 121.067 0.461 . . . . 0.0 110.585 177.279 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.568 ' HA ' HD13 ' A' ' 7' ' ' ILE . 33.7 mmtp -100.81 -20.75 15.39 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.663 179.616 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . 0.526 ' HG3' ' ND2' ' A' ' 9' ' ' ASN . 24.5 tp60 -60.03 -38.18 81.95 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.928 -179.665 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 44.4 tttp -56.91 -42.31 79.7 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.399 -0.819 . . . . 0.0 111.421 176.452 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.568 HD13 ' HA ' ' A' ' 4' ' ' LYS . 2.9 mp -54.69 -38.42 43.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.15 -179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.484 ' HD3' ' NE2' ' A' ' 5' ' ' GLN . 0.0 OUTLIER -81.99 -35.94 28.39 Favored 'General case' 0 CA--C 1.507 -0.7 0 C-N-CA 119.43 -0.908 . . . . 0.0 109.578 178.532 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.526 ' ND2' ' HG3' ' A' ' 5' ' ' GLN . 12.6 m-80 -60.77 -51.15 70.55 Favored 'General case' 0 C--N 1.325 -0.476 0 C-N-CA 120.659 -0.416 . . . . 0.0 111.177 -176.715 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.44 -30.41 77.5 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.078 179.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -79.69 -22.84 42.9 Favored 'General case' 0 C--N 1.323 -0.569 0 CA-C-O 121.16 0.505 . . . . 0.0 110.833 178.437 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.481 ' C ' ' HD3' ' A' ' 12' ' ' LYS . 4.8 tmtm? -88.5 -43.44 11.43 Favored 'General case' 0 N--CA 1.448 -0.554 0 CA-C-N 115.825 -0.625 . . . . 0.0 110.102 -178.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.503 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -77.32 -11.26 59.81 Favored 'General case' 0 C--O 1.199 -1.564 0 N-CA-C 109.644 -0.502 . . . . 0.0 109.644 178.584 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.437 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -63.89 -22.11 66.77 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 172.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 6.9 mt -97.12 -32.16 12.1 Favored 'General case' 0 C--N 1.318 -0.783 0 CA-C-N 114.36 -1.291 . . . . 0.0 109.631 174.348 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.555 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -72.97 -52.29 9.3 Favored Glycine 0 N--CA 1.447 -0.617 0 CA-C-N 115.034 -0.985 . . . . 0.0 111.664 179.695 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.643 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.3 p -72.82 -24.12 21.05 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.87 0 CA-C-N 114.909 -0.646 . . . . 0.0 110.302 -177.329 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.437 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -58.13 -28.03 64.3 Favored 'General case' 0 C--N 1.317 -0.821 0 CA-C-N 115.609 -0.723 . . . . 0.0 110.39 173.68 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.7 m -93.39 5.87 50.08 Favored 'General case' 0 N--CA 1.446 -0.664 0 N-CA-C 108.803 -0.814 . . . . 0.0 108.803 179.739 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.555 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.0 OUTLIER -114.41 5.05 15.51 Favored 'General case' 0 N--CA 1.44 -0.967 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.229 178.712 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 17' ' ' VAL . 11.5 m -133.44 -32.03 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.299 0 CA-C-N 115.703 -0.681 . . . . 0.0 111.063 -174.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.48 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -79.23 -46.39 1.65 Allowed Pre-proline 0 C--N 1.316 -0.871 0 CA-C-N 115.986 -0.552 . . . . 0.0 111.79 -179.626 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.48 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.4 Cg_exo -72.19 -23.25 21.35 Favored 'Trans proline' 0 N--CA 1.453 -0.854 0 C-N-CA 121.633 1.555 . . . . 0.0 111.174 179.453 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.48 HG22 ' O ' ' A' ' 21' ' ' VAL . 5.3 m -71.57 -45.06 69.42 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.321 0 C-N-CA 120.303 -0.559 . . . . 0.0 109.918 179.088 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.487 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.3 t -68.27 -24.99 30.5 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.788 0 CA-C-O 121.7 0.762 . . . . 0.0 109.943 176.596 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.45 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -72.62 -5.72 39.29 Favored 'General case' 0 C--N 1.301 -1.543 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.54 174.499 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -109.71 -27.25 9.44 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.184 -0.916 . . . . 0.0 109.94 173.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.487 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 47.7 m-85 -81.8 -36.95 27.84 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.447 179.197 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -82.48 -49.49 9.87 Favored 'General case' 0 C--N 1.318 -0.777 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.095 177.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.45 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.972 0 CA-C-O 118.814 -0.612 . . . . 0.0 110.648 177.275 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 30.5 ttpt . . . . . 0 N--CA 1.48 1.037 0 CA-C-O 121.119 0.485 . . . . 0.0 110.263 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 41.0 mm -128.83 133.51 66.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.451 -178.737 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 42.3 t30 -146.44 112.84 5.9 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-O 121.227 0.536 . . . . 0.0 109.732 173.97 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.609 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 74.5 mmtt -86.28 -22.63 26.69 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.222 -174.487 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 24.7 tp60 -60.86 -38.61 86.17 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.264 -0.643 . . . . 0.0 109.264 174.369 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.416 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 36.7 tttp -52.9 -37.51 60.72 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.372 -0.831 . . . . 0.0 111.734 177.164 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.609 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 3.1 mp -57.78 -35.51 51.45 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.481 0 CA-C-N 116.491 -0.322 . . . . 0.0 111.317 178.813 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.4 mptt -82.95 -23.42 33.45 Favored 'General case' 0 CA--C 1.504 -0.806 0 C-N-CA 120.081 -0.648 . . . . 0.0 109.578 176.57 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.416 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 11.7 m-80 -60.92 -59.99 4.5 Favored 'General case' 0 C--N 1.321 -0.637 0 C-N-CA 120.375 -0.53 . . . . 0.0 109.726 -178.219 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -65.29 -26.36 71.61 Favored Glycine 0 N--CA 1.45 -0.406 0 CA-C-N 115.576 -0.738 . . . . 0.0 112.29 179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -77.06 -29.17 54.96 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-O 121.196 0.522 . . . . 0.0 110.855 178.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.464 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 7.1 tmtt? -85.3 -41.82 15.18 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.891 -0.595 . . . . 0.0 110.82 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.51 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.1 OUTLIER -80.63 -9.88 59.76 Favored 'General case' 0 C--O 1.203 -1.392 0 CA-C-N 116.388 -0.369 . . . . 0.0 110.628 -177.817 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -67.44 -20.84 65.55 Favored 'General case' 0 C--N 1.31 -1.133 0 C-N-CA 119.323 -0.951 . . . . 0.0 108.762 173.93 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 3.8 mt -97.71 -32.02 11.96 Favored 'General case' 0 C--N 1.316 -0.878 0 CA-C-N 114.104 -1.407 . . . . 0.0 109.073 172.785 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.61 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -74.38 -55.23 5.71 Favored Glycine 0 N--CA 1.443 -0.881 0 CA-C-N 114.608 -1.178 . . . . 0.0 111.797 -177.687 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.586 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p -71.22 -25.93 26.21 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.824 0 CA-C-N 114.983 -0.609 . . . . 0.0 110.573 -175.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -61.24 -23.47 65.66 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.203 173.8 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 14.8 m -94.25 2.51 55.88 Favored 'General case' 0 N--CA 1.448 -0.551 0 N-CA-C 108.964 -0.754 . . . . 0.0 108.964 178.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.61 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 14.0 mptt -112.31 7.96 19.48 Favored 'General case' 0 N--CA 1.446 -0.669 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.331 -179.677 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.611 ' O ' HG22 ' A' ' 24' ' ' VAL . 12.6 m -135.37 -37.6 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.4 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.09 -175.092 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.44 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -62.77 -46.67 88.24 Favored Pre-proline 0 C--N 1.323 -0.576 0 CA-C-N 116.097 -0.501 . . . . 0.0 111.68 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.44 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 3.7 Cg_exo -73.98 -21.55 18.22 Favored 'Trans proline' 0 C--N 1.353 0.772 0 C-N-CA 121.639 1.56 . . . . 0.0 111.356 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.4 m -80.87 -40.05 18.44 Favored 'Isoleucine or valine' 0 C--O 1.221 -0.42 0 C-N-CA 120.584 -0.446 . . . . 0.0 110.302 -179.214 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 21' ' ' VAL . 90.9 t -69.82 -23.12 25.39 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.149 0 CA-C-O 121.598 0.713 . . . . 0.0 109.84 175.435 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -70.08 -18.46 63.26 Favored 'General case' 0 C--N 1.295 -1.766 0 CA-C-N 115.317 -0.856 . . . . 0.0 110.154 172.944 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -94.42 -20.7 19.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.386 -0.824 . . . . 0.0 109.707 176.106 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.479 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 41.3 m-85 -85.59 -39.9 16.84 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.8 176.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.02 -59.74 2.56 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 114.963 -1.017 . . . . 0.0 111.329 -177.765 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.248 1.001 0 CA-C-O 117.996 -1.002 . . . . 0.0 110.596 176.012 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 10.1 ptpp? . . . . . 0 N--CA 1.48 1.03 0 CA-C-O 120.806 0.336 . . . . 0.0 110.569 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 4.5 mp -117.85 125.84 74.42 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 CA-C-N 116.449 -0.342 . . . . 0.0 110.18 179.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 28.6 t30 -150.01 116.71 5.85 Favored 'General case' 0 C--N 1.319 -0.722 0 CA-C-N 116.12 -0.491 . . . . 0.0 109.845 177.722 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.628 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 5.0 mptp? -88.15 -24.65 23.29 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.932 -174.852 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . 0.434 ' HA ' ' HD3' ' A' ' 8' ' ' LYS . 8.5 tp-100 -61.04 -36.96 80.97 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.229 -0.656 . . . . 0.0 109.229 174.581 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.413 ' O ' ' HB2' ' A' ' 9' ' ' ASN . 37.2 tttp -52.58 -35.74 54.61 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.278 -0.874 . . . . 0.0 111.791 176.43 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.628 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.4 mp -56.44 -37.9 53.49 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.577 0 CA-C-N 116.396 -0.365 . . . . 0.0 110.733 176.908 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.434 ' HD3' ' HA ' ' A' ' 5' ' ' GLN . 7.9 mptt -79.04 -22.66 45.08 Favored 'General case' 0 CA--C 1.504 -0.793 0 N-CA-C 109.66 -0.496 . . . . 0.0 109.66 177.269 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.413 ' HB2' ' O ' ' A' ' 6' ' ' LYS . 0.8 OUTLIER -60.6 -57.15 13.92 Favored 'General case' 0 N--CA 1.448 -0.57 0 N-CA-C 108.662 -0.866 . . . . 0.0 108.662 -179.949 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -66.16 -35.78 90.93 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-N 114.775 -1.102 . . . . 0.0 112.058 178.238 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . 0.427 ' HB3' ' HA ' ' A' ' 8' ' ' LYS . . . -65.22 -35.42 81.0 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-O 121.07 0.462 . . . . 0.0 111.077 179.5 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -80.06 -38.48 31.76 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.947 -0.57 . . . . 0.0 111.034 -178.341 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.508 ' O ' HG12 ' A' ' 17' ' ' VAL . 0.0 OUTLIER -81.32 -11.02 59.45 Favored 'General case' 0 C--O 1.2 -1.502 0 N-CA-C 109.808 -0.441 . . . . 0.0 109.808 178.706 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -64.56 -22.56 67.0 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.915 0.864 . . . . 0.0 108.713 172.775 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 mt -92.76 -36.37 12.93 Favored 'General case' 0 N--CA 1.444 -0.73 0 CA-C-N 114.07 -1.423 . . . . 0.0 109.246 173.479 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.555 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -70.08 -53.66 13.87 Favored Glycine 0 N--CA 1.447 -0.624 0 CA-C-N 115.116 -0.947 . . . . 0.0 111.484 -178.888 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.61 ' O ' HG13 ' A' ' 21' ' ' VAL . 2.1 p -68.93 -28.48 39.75 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.905 0 CA-C-N 114.908 -0.646 . . . . 0.0 110.779 -178.01 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.449 ' HA ' HG22 ' A' ' 21' ' ' VAL . . . -60.0 -26.26 65.92 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-O 121.36 0.6 . . . . 0.0 110.178 174.279 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 13.7 m -91.49 1.75 56.91 Favored 'General case' 0 N--CA 1.445 -0.693 0 N-CA-C 108.792 -0.818 . . . . 0.0 108.792 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.555 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 5.8 mptp? -113.39 6.55 17.27 Favored 'General case' 0 N--CA 1.442 -0.845 0 CA-C-N 115.166 -0.924 . . . . 0.0 109.369 -179.738 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.61 HG13 ' O ' ' A' ' 17' ' ' VAL . 12.7 m -133.52 -37.51 0.48 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.492 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.274 -175.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.42 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -64.54 -45.5 76.77 Favored Pre-proline 0 C--N 1.321 -0.647 0 CA-C-N 116.298 -0.41 . . . . 0.0 111.696 -179.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.42 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 3.1 Cg_exo -73.92 -20.78 19.21 Favored 'Trans proline' 0 N--CA 1.454 -0.853 0 C-N-CA 121.448 1.432 . . . . 0.0 111.46 179.669 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.6 m -82.96 -41.83 17.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.642 -178.437 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.506 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 94.1 t -66.31 -24.73 33.96 Favored 'Isoleucine or valine' 0 CA--C 1.503 -0.831 0 CA-C-O 121.899 0.857 . . . . 0.0 109.814 176.308 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.03 -7.25 45.04 Favored 'General case' 0 C--N 1.302 -1.484 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.676 174.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -110.86 -23.88 10.75 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.32 -0.854 . . . . 0.0 110.008 174.952 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.506 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 44.0 m-85 -83.32 -43.7 15.7 Favored 'General case' 0 CA--C 1.517 -0.299 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.256 178.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.36 -50.76 10.35 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-N 115.455 -0.793 . . . . 0.0 109.951 178.642 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.247 0.97 0 CA-C-O 118.458 -0.782 . . . . 0.0 110.129 178.004 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 49.1 mmtm . . . . . 0 N--CA 1.48 1.039 0 N-CA-C 110.185 -0.302 . . . . 0.0 110.185 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 2.1 mp -82.61 125.55 39.94 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-O 121.095 0.474 . . . . 0.0 110.962 -177.509 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 28.7 t30 -169.17 125.36 0.91 Allowed 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.618 178.782 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.627 ' HA ' ' CD1' ' A' ' 7' ' ' ILE . 47.6 mmtm -92.2 -21.8 20.17 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-O 120.894 0.378 . . . . 0.0 110.394 -175.299 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . 0.463 ' C ' HD22 ' A' ' 9' ' ' ASN . 52.6 tt0 -65.74 -35.11 79.81 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 174.363 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.484 ' HA ' ' HB2' ' A' ' 9' ' ' ASN . 29.6 ttpt -51.11 -35.75 36.95 Favored 'General case' 0 CA--C 1.52 -0.18 0 CA-C-N 115.357 -0.838 . . . . 0.0 111.646 176.37 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.627 ' CD1' ' HA ' ' A' ' 4' ' ' LYS . 2.4 mp -55.28 -40.76 58.01 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.329 177.209 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . . . . . . . . . 8.0 mptt -80.32 -29.7 38.08 Favored 'General case' 0 CA--C 1.499 -1.0 0 N-CA-C 109.117 -0.697 . . . . 0.0 109.117 177.487 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.499 ' O ' ' HG2' ' A' ' 13' ' ' LYS . 24.0 m-80 -58.94 -57.79 11.53 Favored 'General case' 0 N--CA 1.444 -0.729 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 179.649 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -61.82 -34.59 89.26 Favored Glycine 0 N--CA 1.446 -0.697 0 CA-C-N 115.702 -0.681 . . . . 0.0 111.846 178.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -71.53 -22.69 61.74 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.097 0.475 . . . . 0.0 110.739 178.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.434 ' HD3' ' N ' ' A' ' 13' ' ' LYS . 1.0 OUTLIER -90.75 -45.4 8.86 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.753 178.701 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.575 ' O ' HG12 ' A' ' 17' ' ' VAL . 24.0 pttt -81.06 -2.9 49.99 Favored 'General case' 0 C--O 1.206 -1.232 0 CA-C-N 116.656 -0.247 . . . . 0.0 110.996 -177.534 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . . . . . . . . . . . -71.06 -17.85 62.58 Favored 'General case' 0 C--N 1.312 -1.04 0 O-C-N 121.043 -1.035 . . . . 0.0 108.506 173.034 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 2.3 mt -101.85 -24.92 13.97 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-N 113.874 -1.512 . . . . 0.0 109.264 173.837 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.596 ' O ' ' HD3' ' A' ' 20' ' ' LYS . . . -82.83 -55.42 2.98 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 115.06 -0.973 . . . . 0.0 111.722 -179.968 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.588 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p -75.03 -24.37 17.8 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.773 0 CA-C-N 115.27 -0.465 . . . . 0.0 110.605 -175.251 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . . . . . . . . . . . -58.76 -32.83 69.64 Favored 'General case' 0 C--N 1.319 -0.745 0 CA-C-O 121.329 0.585 . . . . 0.0 109.818 172.999 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 66.1 m -86.36 4.44 39.29 Favored 'General case' 0 N--CA 1.446 -0.668 0 CA-C-N 115.538 -0.755 . . . . 0.0 109.123 -179.383 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . 0.596 ' HD3' ' O ' ' A' ' 16' ' ' GLY . 1.2 mptm? -113.76 3.43 15.54 Favored 'General case' 0 N--CA 1.435 -1.198 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.223 -179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.588 HG13 ' O ' ' A' ' 17' ' ' VAL . 5.6 m -134.56 -38.42 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.476 0 CA-C-N 115.184 -0.916 . . . . 0.0 110.326 -176.226 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.513 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -67.72 -50.04 36.42 Favored Pre-proline 0 C--N 1.32 -0.687 0 CA-C-N 116.23 -0.441 . . . . 0.0 111.397 -178.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.513 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 8.3 Cg_exo -71.04 -22.62 25.99 Favored 'Trans proline' 0 C--N 1.353 0.766 0 C-N-CA 121.647 1.565 . . . . 0.0 111.153 -178.038 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.583 HG22 ' O ' ' A' ' 21' ' ' VAL . 2.8 m -78.47 -44.08 26.42 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.355 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.251 -179.552 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.504 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 95.6 t -68.77 -24.2 28.52 Favored 'Isoleucine or valine' 0 CA--C 1.504 -0.802 0 CA-C-O 121.909 0.861 . . . . 0.0 110.07 177.786 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . . . . . . . . . . . -71.77 -5.35 33.43 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.445 173.969 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -113.76 -19.16 11.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.285 174.301 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.53 ' HD1' ' O ' ' A' ' 24' ' ' VAL . 44.9 m-85 -87.66 -43.06 12.22 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.602 177.64 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.31 -55.5 4.68 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.131 -177.825 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.454 ' HD3' ' N ' ' A' ' 30' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--O 1.249 1.038 0 CA-C-O 117.98 -1.009 . . . . 0.0 110.946 -178.614 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' LYS . . . . . . . . . . . . . 45.0 mmtm . . . . . 0 N--CA 1.481 1.086 0 CA-C-O 120.957 0.408 . . . . 0.0 110.794 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 41.1 mm -95.37 132.14 40.23 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.659 0 CA-C-N 116.06 -0.518 . . . . 0.0 109.92 177.736 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ASN . . . . . . . . . . . . . 20.5 t30 -162.92 117.17 1.7 Allowed 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.821 -0.627 . . . . 0.0 109.41 -179.297 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' LYS . . . . . 0.591 ' HA ' HD13 ' A' ' 7' ' ' ILE . 34.7 mmtp -79.69 -22.14 43.81 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.458 -171.193 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' GLN . . . . . . . . . . . . . 26.2 tp60 -64.6 -39.68 94.16 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 173.903 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.747 ' HA ' ' OD1' ' A' ' 9' ' ' ASN . 29.6 ttpt -61.09 -32.67 72.33 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 115.153 -0.931 . . . . 0.0 111.853 179.234 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.591 HD13 ' HA ' ' A' ' 4' ' ' LYS . 1.7 mp -55.25 -35.6 36.86 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.506 0 C-N-CA 120.492 -0.483 . . . . 0.0 110.586 175.372 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' LYS . . . . . 0.447 ' HD2' ' O ' ' A' ' 4' ' ' LYS . 0.1 OUTLIER -82.45 -22.85 35.06 Favored 'General case' 0 CA--C 1.511 -0.525 0 C-N-CA 119.942 -0.703 . . . . 0.0 110.204 177.035 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ASN . . . . . 0.747 ' OD1' ' HA ' ' A' ' 6' ' ' LYS . 4.6 m120 -62.49 -56.06 21.67 Favored 'General case' 0 CA--C 1.514 -0.412 0 N-CA-C 107.938 -1.134 . . . . 0.0 107.938 178.149 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.426 ' HA2' ' HE3' ' A' ' 13' ' ' LYS . . . -67.84 -28.23 73.5 Favored Glycine 0 N--CA 1.443 -0.892 0 CA-C-N 114.653 -1.158 . . . . 0.0 112.385 -179.468 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ALA . . . . . . . . . . . . . . . -73.46 -30.23 63.04 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-O 121.013 0.435 . . . . 0.0 110.778 178.556 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -83.27 -37.58 23.31 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.935 -178.509 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.493 ' O ' HG12 ' A' ' 17' ' ' VAL . 12.3 pttt -87.78 -3.99 58.91 Favored 'General case' 0 C--O 1.2 -1.502 0 N-CA-C 109.893 -0.41 . . . . 0.0 109.893 177.378 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' ALA . . . . . 0.511 ' O ' ' HB2' ' A' ' 18' ' ' ALA . . . -64.55 -21.34 66.66 Favored 'General case' 0 C--N 1.318 -0.795 0 N-CA-C 108.246 -1.02 . . . . 0.0 108.246 172.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' LEU . . . . . . . . . . . . . 5.3 mt -90.77 -37.41 13.68 Favored 'General case' 0 C--N 1.318 -0.803 0 CA-C-N 113.694 -1.594 . . . . 0.0 109.673 175.317 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -75.71 -53.91 5.67 Favored Glycine 0 CA--C 1.509 -0.338 0 CA-C-N 115.425 -0.807 . . . . 0.0 112.298 -179.528 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 0.56 ' O ' HG13 ' A' ' 21' ' ' VAL . 1.1 p -70.83 -16.97 20.02 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.776 0 CA-C-N 115.118 -0.541 . . . . 0.0 110.696 -176.886 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ALA . . . . . 0.511 ' HB2' ' O ' ' A' ' 14' ' ' ALA . . . -56.89 -29.06 62.64 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.527 172.717 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' SER . . . . . . . . . . . . . 57.7 m -90.32 4.19 51.49 Favored 'General case' 0 N--CA 1.45 -0.458 0 N-CA-C 109.156 -0.683 . . . . 0.0 109.156 178.794 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' LYS . . . . . . . . . . . . . 5.0 mptp? -112.24 6.65 19.08 Favored 'General case' 0 N--CA 1.441 -0.894 0 CA-C-N 115.213 -0.903 . . . . 0.0 109.128 -179.033 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' VAL . . . . . 0.62 ' O ' HG22 ' A' ' 24' ' ' VAL . 9.3 m -134.81 -37.01 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.527 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.082 -175.653 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . 0.445 ' HB3' ' HD3' ' A' ' 23' ' ' PRO . . . -63.23 -46.62 85.68 Favored Pre-proline 0 C--N 1.323 -0.545 0 CA-C-N 116.102 -0.499 . . . . 0.0 111.724 179.419 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' PRO . . . . . 0.445 ' HD3' ' HB3' ' A' ' 22' ' ' ALA . 6.1 Cg_exo -73.28 -21.55 19.94 Favored 'Trans proline' 0 C--N 1.354 0.818 0 C-N-CA 121.691 1.594 . . . . 0.0 111.446 -179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.62 HG22 ' O ' ' A' ' 21' ' ' VAL . 3.3 m -82.06 -41.12 17.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.425 -178.751 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . 0.516 ' HA ' ' HB2' ' A' ' 28' ' ' PHE . 96.8 t -67.86 -24.15 30.22 Favored 'Isoleucine or valine' 0 CA--C 1.505 -0.783 0 CA-C-O 121.919 0.866 . . . . 0.0 109.646 176.097 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' ALA . . . . . 0.499 ' O ' ' HB2' ' A' ' 30' ' ' ARG . . . -71.64 -1.58 14.17 Favored 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.761 -1.109 . . . . 0.0 110.566 173.776 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ALA . . . . . . . . . . . . . . . -117.69 -22.18 8.15 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.224 -0.898 . . . . 0.0 110.208 173.833 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' PHE . . . . . 0.516 ' HB2' ' HA ' ' A' ' 25' ' ' VAL . 46.0 m-85 -85.68 -35.95 20.57 Favored 'General case' 0 CA--C 1.518 -0.28 0 CA-C-O 121.258 0.551 . . . . 0.0 110.591 178.289 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -87.79 -50.62 6.35 Favored 'General case' 0 C--N 1.319 -0.721 0 CA-C-N 115.361 -0.836 . . . . 0.0 109.849 177.512 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' ARG . . . . . 0.499 ' HB2' ' O ' ' A' ' 26' ' ' ALA . 42.9 mtm180 . . . . . 0 C--O 1.248 0.991 0 CA-C-O 118.886 -0.578 . . . . 0.0 111.491 177.651 . . . . . . . . 1 1 . 1 stop_ save_